Endocrine Involvement in Developmental Syndromes
This book has been printed with financial support from Pfizer Italia
Endocrine Development Vol. 14
Series Editor
P.-E. Mullis
Bern
Workshop, April 21–22, 2008, Rome
Endocrine Involvement in Developmental Syndromes Volume Editors
Marco Cappa Rome Mohamad Maghnie Genova Sandro Loche Cagliari Gian Franco Bottazzo Rome 26 figures, 2 in color, and 15 tables, 2009
Basel · Freiburg · Paris · London · New York · Bangalore · Bangkok · Shanghai · Singapore · Tokyo · Sydney
Endocrine Development Founded 1999 by Martin O. Savage, London
Marco Cappa
Mohamad Maghnie
Department of Pediatrics Pediatric Hospital Bambino Gesù Rome, Italy
Department of Pediatrics IRCCS G. Gaslini University of Genova Genova, Italy
Sandro Loche
Gian Franco Bottazzo
Regional Hospital for Microcytaemia Cagliari, Italy
Department of Pediatrics Pediatric Hospital Bambino Gesù Rome, Italy
Library of Congress Cataloging-in-Publication Data Workshop on Endocrine Involvement in Developmental Syndromes (2008 : Rome, Italy) Endocrine involvement in developmental syndromes / Workshop on Endocrine Involvement in Developmental Syndromes, April 21-22, 2008, Rome ; volume editors, Marco Cappa ... [et al.]. p. ; cm. -- (Endocrine development, ISSN 1421-7082 ; v. 14) Includes bibliographical references and indexes. ISBN 978-3-8055-9041-9 (hard cover : alk. paper) 1. Pediatric endocrinology--Congresses. 2. Growth disorders--Endocrine aspects--Congresses. 3. Developmental disabilities--Endocrine aspects--Congresses. I. Cappa, Marco. II. Title. III. Series: Endocrine development ; v. 14. [DNLM: 1. Endocrine System Diseases--etiology--Congresses. 2. Congenital Abnormalities--Congresses. 3. Genetic Diseases, Inborn--complications--Congresses. W1 EN3635 v.14 2009 / WK 140 W926e 2009] RJ482.G76.W67 2009 618.92'4--dc22 2008052202 Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. © Copyright 2009 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck, Basel ISSN 1421–7082 ISBN 978–3–8055–9041–9
Contents
VII Preface Cappa, M.; Bottazzo, G.F. (Rome) 1
10 20 29
38 53
61 67
83 95
Inherited and Sporadic Epimutations at the IGF2-H19 Locus in BeckwithWiedemann Syndrome and Wilms’ Tumor Riccio, A. (Caserta/Naples); Sparago, A.; Verde, G. (Naples); De Crescenzo, A. (Caserta); Citro, V.; Cubellis, M.V. (Naples); Ferrero, G.B.; Silengo, M.C. (Torino); Russo, S.; Larizza, L. (Milan); Cerrato, F. (Caserta) Epigenetic Regulation of Growth: Lessons from Silver-Russell Syndrome Eggermann, T. (Aachen) Genetic Imprinting: The Paradigm of Prader-Willi and Angelman Syndromes Gurrieri, F.; Accadia, M. (Rome) Muscle Involvement and IGF-1 Signaling in Genetic Disorders: New Therapeutic Approaches Barberi, L.; Dobrowolny, G.; Pelosi, L.; Giacinti, C.; Musarò, A. (Rome) Mitochondrial Encephalomyopathies and Related Syndromes: Brief Review Bertini, E.; D’Amico A. (Rome) Overgrowth Syndromes: A Classification Neri, G.; Moscarda, M. (Rome) C-Type Natriuretic Peptide and Overgrowth Bocciardi, R.; Ravazzolo, R. (Genova) Role of Transcription Factors in Midline Central Nervous System and Pituitary Defects Kelberman, D.; Dattani, M.T. (London) Developmental Abnormalities of the Posterior Pituitary Gland di Iorgi, N.; Secco, A.; Napoli, F.; Calandra, E.; Rossi, A.; Maghnie, M. (Genova) Hyperinsulinism in Developmental Syndromes Kapoor, R.R.; James, C.; Hussain, K. (London)
114
135 143
151 167
174
181 182
VI
Developmental Syndromes: Growth Hormone Deficiency and Treatment Mazzanti, L.; Tamburrino, F.; Bergamaschi, R.; Scarano, E.; Montanari, F.; Torella, M.; Ballarini, E.; Cicognani, A. (Bologna) Growth Hormone-Resistant Syndromes: Long-Term Follow-Up Chernausek, S.D. (Oklahoma City, Okla.) Phenotypic Aspects of Growth Hormone- and IGF-I-Resistant Syndromes Savage, M.O.; David, A.; Camacho-Hübner, C.; Metherell, L.A.; Clark, A.J.L. (London/Stockholm) Double Diabetes: A Mixture of Type 1 and Type 2 Diabetes in Youth Pozzilli, P.; Guglielmi, C. (Rome) Cryptorchidism as Part of the Testicular Dysgenesis Syndrome: The Environmental Connection Main, K.M.; Skakkebæk, N.E. (Copenhagen); Toppari, J. (Turku) Disorders of Sex Development in Developmental Syndromes Hiort, O.; Gillessen-Kaesbach, G. (Lübeck) Author Index Subject Index
Contents
Preface
Recent years have seen a significant improvement in the knowledge of genetics and developmental syndromes. In this scenario, the study of endocrinological aspects in patients with genetic syndromes acquires increasing interest and significance. The workshop on “Endocrine Involvement in Developmental Syndromes”, held in Rome on April 21–22, 2008, represented a precious opportunity to provide an updated global view of this important field of medical sciences. The scientific program of the workshop included the most recent advances in the study of developmental syndromes and epigenetics, with world-wide experts focusing their contributions on modern concepts of basic and clinical science in order to clarify genetic, clinical and biological aspects of these syndromes. This book is the result of this fruitful exchange of experience and knowledge, and it provides a thorough elucidation of endocrine involvement and epigenetic aspects of various developmental syndromes, opening new ways to manage the complexity of such a topic. We are confident that the state-of-art information provided by this book will be of great interest for endocrinologists, pediatricians, and genetists involved in the study and treatment of developmental syndromes. Marco Cappa Gian Franco Bottazzo Rome
Endocrine Involvement in Developmental Syndromes
This book has been printed with financial support from Pfizer Italia
Endocrine Development Vol. 14
Series Editor
P.-E. Mullis
Bern
Workshop, April 21–22, 2008, Rome
Endocrine Involvement in Developmental Syndromes Volume Editors
Marco Cappa Rome Mohamad Maghnie Genova Sandro Loche Cagliari Gian Franco Bottazzo Rome 26 figures, 2 in color, and 15 tables, 2009
Basel · Freiburg · Paris · London · New York · Bangalore · Bangkok · Shanghai · Singapore · Tokyo · Sydney
Endocrine Development Founded 1999 by Martin O. Savage, London
Marco Cappa
Mohamad Maghnie
Department of Pediatrics Pediatric Hospital Bambino Gesù Rome, Italy
Department of Pediatrics IRCCS G. Gaslini University of Genova Genova, Italy
Sandro Loche
Gian Franco Bottazzo
Regional Hospital for Microcytaemia Cagliari, Italy
Department of Pediatrics Pediatric Hospital Bambino Gesù Rome, Italy
Library of Congress Cataloging-in-Publication Data Workshop on Endocrine Involvement in Developmental Syndromes (2008 : Rome, Italy) Endocrine involvement in developmental syndromes / Workshop on Endocrine Involvement in Developmental Syndromes, April 21-22, 2008, Rome ; volume editors, Marco Cappa ... [et al.]. p. ; cm. -- (Endocrine development, ISSN 1421-7082 ; v. 14) Includes bibliographical references and indexes. ISBN 978-3-8055-9041-9 (hard cover : alk. paper) 1. Pediatric endocrinology--Congresses. 2. Growth disorders--Endocrine aspects--Congresses. 3. Developmental disabilities--Endocrine aspects--Congresses. I. Cappa, Marco. II. Title. III. Series: Endocrine development ; v. 14. [DNLM: 1. Endocrine System Diseases--etiology--Congresses. 2. Congenital Abnormalities--Congresses. 3. Genetic Diseases, Inborn--complications--Congresses. W1 EN3635 v.14 2009 / WK 140 W926e 2009] RJ482.G76.W67 2009 618.92'4--dc22 2008052202 Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. © Copyright 2009 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck, Basel ISSN 1421–7082 ISBN 978–3–8055–9041–9
Contents
VII Preface Cappa, M.; Bottazzo, G.F. (Rome) 1
10 20 29
38 53
61 67
83 95
Inherited and Sporadic Epimutations at the IGF2-H19 Locus in BeckwithWiedemann Syndrome and Wilms’ Tumor Riccio, A. (Caserta/Naples); Sparago, A.; Verde, G. (Naples); De Crescenzo, A. (Caserta); Citro, V.; Cubellis, M.V. (Naples); Ferrero, G.B.; Silengo, M.C. (Torino); Russo, S.; Larizza, L. (Milan); Cerrato, F. (Caserta) Epigenetic Regulation of Growth: Lessons from Silver-Russell Syndrome Eggermann, T. (Aachen) Genetic Imprinting: The Paradigm of Prader-Willi and Angelman Syndromes Gurrieri, F.; Accadia, M. (Rome) Muscle Involvement and IGF-1 Signaling in Genetic Disorders: New Therapeutic Approaches Barberi, L.; Dobrowolny, G.; Pelosi, L.; Giacinti, C.; Musarò, A. (Rome) Mitochondrial Encephalomyopathies and Related Syndromes: Brief Review Bertini, E.; D’Amico A. (Rome) Overgrowth Syndromes: A Classification Neri, G.; Moscarda, M. (Rome) C-Type Natriuretic Peptide and Overgrowth Bocciardi, R.; Ravazzolo, R. (Genova) Role of Transcription Factors in Midline Central Nervous System and Pituitary Defects Kelberman, D.; Dattani, M.T. (London) Developmental Abnormalities of the Posterior Pituitary Gland di Iorgi, N.; Secco, A.; Napoli, F.; Calandra, E.; Rossi, A.; Maghnie, M. (Genova) Hyperinsulinism in Developmental Syndromes Kapoor, R.R.; James, C.; Hussain, K. (London)
114
135 143
151 167
174
181 182
VI
Developmental Syndromes: Growth Hormone Deficiency and Treatment Mazzanti, L.; Tamburrino, F.; Bergamaschi, R.; Scarano, E.; Montanari, F.; Torella, M.; Ballarini, E.; Cicognani, A. (Bologna) Growth Hormone-Resistant Syndromes: Long-Term Follow-Up Chernausek, S.D. (Oklahoma City, Okla.) Phenotypic Aspects of Growth Hormone- and IGF-I-Resistant Syndromes Savage, M.O.; David, A.; Camacho-Hübner, C.; Metherell, L.A.; Clark, A.J.L. (London/Stockholm) Double Diabetes: A Mixture of Type 1 and Type 2 Diabetes in Youth Pozzilli, P.; Guglielmi, C. (Rome) Cryptorchidism as Part of the Testicular Dysgenesis Syndrome: The Environmental Connection Main, K.M.; Skakkebæk, N.E. (Copenhagen); Toppari, J. (Turku) Disorders of Sex Development in Developmental Syndromes Hiort, O.; Gillessen-Kaesbach, G. (Lübeck) Author Index Subject Index
Contents
Preface
Recent years have seen a significant improvement in the knowledge of genetics and developmental syndromes. In this scenario, the study of endocrinological aspects in patients with genetic syndromes acquires increasing interest and significance. The workshop on “Endocrine Involvement in Developmental Syndromes”, held in Rome on April 21–22, 2008, represented a precious opportunity to provide an updated global view of this important field of medical sciences. The scientific program of the workshop included the most recent advances in the study of developmental syndromes and epigenetics, with world-wide experts focusing their contributions on modern concepts of basic and clinical science in order to clarify genetic, clinical and biological aspects of these syndromes. This book is the result of this fruitful exchange of experience and knowledge, and it provides a thorough elucidation of endocrine involvement and epigenetic aspects of various developmental syndromes, opening new ways to manage the complexity of such a topic. We are confident that the state-of-art information provided by this book will be of great interest for endocrinologists, pediatricians, and genetists involved in the study and treatment of developmental syndromes. Marco Cappa Gian Franco Bottazzo Rome
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 1–9
Inherited and Sporadic Epimutations at the IGF2-H19 Locus in Beckwith-Wiedemann Syndrome and Wilms’ Tumor Andrea Riccioa,b ⭈ Angela Sparagob ⭈ Gaetano Verdeb ⭈ Agostina De Crescenzoa ⭈ Valentina Citroc ⭈ Maria Vittoria Cubellisc ⭈ Giovanni Battista Ferrerod ⭈ Margherita Cirillo Silengod ⭈ Silvia Russoe ⭈ Lidia Larizzae,f ⭈ Flavia Cerratoa a
Dipartimento di Scienze Ambientali, Seconda Università di Napoli, Caserta; bIstituto di Genetica e Biofisica ‘A. Buzzati Traverso’, CNR, and cDipartimento di Biologia Strutturale e Funzionale, Università di Napoli ‘Federico II’, Naples; dDipartimento di Scienze Pediatriche e dell’Adolescenza, Università di Torino, Torino, and eLaboratorio di Citogenetica e Genetica Molecolare, Istituto Auxologico Italiano, Milano, fDivision of Medical Genetics, San Paolo School of Medicine, University of Milan, Milan, Italy
Abstract The parent-of-origin-dependent expression of IGF2 and H19 is controlled by the imprinting center 1 (IC1) consisting of a methylation-sensitive chromatin insulator. IC1 is normally methylated on the paternal chromosome and nonmethylated on the maternal chromosome. We found that 22 cases in a large cohort of patients affected by Beckwith-Wiedemann syndrome (BWS) had IC1 methylated on both parental chromosomes, resulting in biallelic activation of IGF2 and biallelic silencing of H19. These individuals had marked macrosomia and high incidence of Wilms’ tumor. A subset of these patients had 1.4- to 1.8-kb deletions with hypermethylation of the remaining IC1 region and fully penetrant BWS phenotype when transmitted maternally. Another subset of individuals with IC1 hypermethylation had a similar clinical phenotype but no mutation in the local vicinity. All these cases were sporadic and in at least two families affected and unaffected members shared the same maternal IC1 allele but not the abnormal maternal epigenotype. Similarly, no IC1 deletion was detected in 10 nonsyndromic Wilms’ tumors with IC1 hypermethylation. In conclusion, methylation defects at the IGF2-H19 locus can result from inherited mutations of the imprinting center and have high recurrence risk or arise independently from the sequence context and not transmitted to the Copyright © 2009 S. Karger AG, Basel progeny.
There is increasing evidence that aberrant chromatin states leading to aberrant gene expression patterns (epimutations) have important roles in human disease [1]. However, the causes, heritability and relationship with phenotype of many of these
lesions are still undefined. For instance, although it is generally accepted that epigenetic marks are cleared between generations, there is a number of cases in which this seems not to be the case. The human disorders caused by defects of genomic imprinting provide a paradigm for studying these issues.
Genomic Imprinting
Genomic imprinting is an epigenetic mechanism causing the expression of a minority of genes to be monoallelic and dependent on their gametic origin [2]. Correct imprinting is required for normal development, while defective imprinting is associated with human disease [3]. A 1-Mb cluster of imprinted genes is present at chromosome 11p15.5 (fig. 1). The cluster is functionally divided into two domains that are autonomously controlled by separate imprinting control regions or imprinting centers (IC1 and IC2 [4, 5]). These are CpG-rich regions that work by different mechanisms, but share as a common feature to be differentially methylated on the maternally and paternally derived chromosomes (differentially methylated regions, DMRs). Two genes, insulin-like growth factor 2 (IGF2) and H19, are located in domain 1 of the 11p15.5 imprinted gene cluster. IGF2 is a paternally expressed fetal growth factor gene with an important role in cancer development [6]. H19 is a maternally expressed noncoding RNA with possible tumor-suppressor functions [7]. The reciprocal imprinting of IGF2 and H19 is controlled by IC1 in the majority of tissues. The function of this control element has been extensively studied in the mouse. IC1 (also known as H19 DMR) is a methylation-sensitive chromatin insulator located between IGF2 and H19 [8]. Its nonmethylated maternal allele interacts with the multi-zinc finger protein CTCF. This binding is required on the maternal chromosome for maintaining the nonmethylated status of the region and preventing the activation of the IGF2 promoter by downstream enhancers that activate the H19 gene instead. On the paternal chromosome, conversely, DNA methylation prevents CTCF binding at IC1 and allows the enhancer-mediated activation of IGF2 while the H19 promoter is hypermethylated and silenced. Recent evidences indicate that the methylationsensitive binding of CTCF at IC1 mediates higher-order chromatin conformations in a parent of origin-specific manner [9]. In particular, the two parental IC1 alleles interact with two different DMRs of Igf2 on the maternal and paternal chromosomes [10]. This may partition the maternal and paternal Igf2 alleles into inactive and active chromatin domains, respectively.
Beckwith-Wiedemann Syndrome
The Beckwith-Wiedemann syndrome (BWS, MIM 130650) is a developmental disorder characterized by variable clinical features, including overgrowth, macroglossia,
2
Riccio · Sparago · Verde · De Crescenzo · Citro · Cubellis · Ferrero · Silengo · Russo · Larizza · Cerrato
d H19
d INS d IGF2
d TH
d ASCL2
LTRPC5 TSSC4 CD81 TSSC6 d D D D
D KCNQ1
d KCNQ1OT1/LIT1
CARS NAP1L4 TSSC3 TSSC5 CDKN1C d d d D d
Domain 2
IC1
tel IC2
cen
Domain 1
Expressed from the paternal chromosome Expressed from the maternal chromosome Biallelic expression Imprinted expression not well defined DMR methylated on the paternal chromosome DMR methylated on the maternal chromosome
Fig. 1. The 11p15.5 imprinted gene cluster.
abdominal wall defects and increased incidence of embryonal tumors that is caused by defective expression of imprinted genes located on chromosome 11p15.5 [11]. The majority of the BWS cases are sporadic. The rare familial cases show a predominantly autosomal-dominant inheritance and preferential expression following maternal transmission. Heterogeneous molecular defects are found in BWS. Only 5% of the cases (40% of the familial ones) have typical single-gene defects, consisting in lossof-function mutations of CDKN1C. About 20% of the cases have uniparental paternal disomy (UPD) of 11p15.5 loci, indicating that BWS is caused by excess of imprinted genes expressed from the paternal chromosome and/or defect of imprinted genes expressed from the maternal chromosome. The majority of the other cases show DNA methylation defects at either IC1 or IC2. Similarly to BWS, patients with nonsyndromic Wilms’ tumor also have IC1 hypermethylation, but this is restricted to cancer tissues in these cases [12]. In this chapter, we review the clinical characteristics and molecular features of the cases of BWS and Wilms’ tumor with hypermethylation at IC1.
IC1 Microdeletions
Gain of methylation at IC1 is usually found in only 5–10% of the BWS cases [11, 13]. However, the high incidence of Wilms’ tumor-associated with these molecular abnormalities makes them particularly important to study. We found 1.4- to
Epimutations at the IGF2-H19 Locus in BWS and Wilms’ Tumor
3
1.8-kb deletions of the IC1 region in 9 BWS patients with IC1 hypermethylation [14–16]. These cases were part of dominant inheritance pedigrees with maternal transmission and characterized by high recurrence risk. The deletions remove 1–2 target sequences for CTCF (CTS) resulting in hypermethylation of the residual CTSs and cosegregate with the BWS phenotype with full penetrance if maternally inherited. In 2005, Prawitt et al. [17] described a further BWS family with a 2.2-kb deletion eliminating 3 CTSs from IC1. However, maternal transmission of this deletion was not necessarily associated with the BWS phenotype. Indeed, an additional mutation consisting in duplication of the 11p15 region was present in the affected children. Interestingly, this deletion did not alter the methylation of the flanking sequences, suggesting that the hypermethylation of the imprinting center significantly contribute to the BWS pathogenesis. We also observed that the mutant alleles with gain of methylation had abnormally spaced CTSs and proposed that the 1.4- to 1.8-kb deletions resulted in lowering the affinity of IC1 for CTCF [15].
IC1 Hypermethylation without Microdeletion
Neither deletion nor any other point mutation of the IC1 region was demonstrated in 13 patients of our cohort with IC1 hypermethylation [18, and data not shown]. These were all sporadic cases and in 2 of them, the maternal IC1 allele of the index patient segregated in 1 of his healthy relatives. A detailed methylation analysis showed that the hypermethylation was extended over the entire or only 3⬘ half of the IC1 region, did not affect other imprinted loci, generally occurred in the mosaic form and was never present in the unaffected relatives. The chromosome carrying the imprinting abnormality derived from either the maternal grandfather or maternal grandmother. These results indicate that, in the absence of deletions, IC1 hypermethylation generally occurs as sporadic epimutation and is associated with low recurrence risk.
Clinical Phenotype
The clinical features of the patients carrying IC1 deletions and those with IC1 hypermethylation without accompanying deletion are very similar. However, they differ significantly from the phenotypes of the BWS patients with other molecular defects [18]. Table 1 is a summary of the characteristics of a cohort of 132 individuals with clinical diagnosis of BWS [19], subdivided into 4 classes according to the molecular defect found [20]. Features, such as pronounced macrosomia, mild or absent defects of the abdominal wall and elevated incidence of Wilms’ tumor are evident among the individuals with IC1 hypermethylation.
4
Riccio · Sparago · Verde · De Crescenzo · Citro · Cubellis · Ferrero · Silengo · Russo · Larizza · Cerrato
Table 1. Clinical features of 132 BWS patients investigated for methylation defects at chromosome 11p15.5 Clinical features
IC1 hypermethylation IC2 11p15.5 Pat with and without hypomethylation UPD (n = 22) microdeletion (n = 43) (n = 20)
Normal methylation (n = 47)
Macrosomia (weight >90th centile) Polydramnios Macroglossia Rectum diastasis Umbilical hernia Exomphalos Inguinal hernia Hemihypertrophy Facial Asymmetry Hepato-/spleno-megaly Neonatal Hypoglycemia Ear pits/creases Facial dysmorphisms Naevus flammeous Renal abnormalities Wilms’ tumor Hepatoblastoma Other tumors Ureteral abnormalities VSD/ASD/PDA shunt Convulsions Mental retardation
16 (80)
17 (39)
8 (36)
22 (47)
5 (25) 17 (85) 12 (60) 10 (50) 0 (0) 1 (5) 7 (35) 4 (20) 12 (60) 8 (40) 7 (35) 7 (35) 5 (25) 11 (55) 5 (25) 0 (0) 0 (0) 3 (15) 1 (5) 1 (5) 1 (5)
8 (19) 42 (98) 20 (46) 17 (39) 14 (33) 4 (9) 14 (33) 8 (19) 12 (28) 18 (42) 30 (70) 20 (46) 27 (63) 7 (16) 0 (0) 0 (0) 1*(2) 2 (4) 2 (4) 5 (12) 6 (14)
6 (27) 19 (86) 9 (41) 7 (32) 1 (4) 0 (0) 16 (73) 1 (4) 9 (41) 10 (45) 7 (32) 6 (27) 8 (36) 9 (41) 1 (4) 2 (9) 0 (0) 2 (9) 0 (0) 0 (0) 3 (14)
3 (6) 38 (81) 28 (60) 17 (36) 4 (8) 3 (6) 14 (30) 6 (13) 6 (13) 8 (17) 26 (55) 18 (38) 14 (30) 10 (21) 1 (2) 0 (0) 0 (0) 2 (4) 2 (4) 2 (4) 8 (17)
Numbers in parentheses denote percent values. Percentages that significantly differ in one molecular subgroup of patients from the others are indicated in bold. * Neuroblastoma.
Epigenetic Mosaicism
We observed that all IC1 CTSs are completely and exclusively methylated on the paternal chromosome in normal leukocyte DNA while incomplete hypermethylation of the maternal allele is present in the BWS patients with the 1.4- to 1.8kb IC1 deletions and the majority of patients without deletions suggesting that this imprinting defect is generally present in the mosaic form [16, 18]. We did not observe a clear relationship between the extent of hypermethylation at the IGF2-H19 locus and the severity of the BWS phenotype. However, it is possible that
Epimutations at the IGF2-H19 Locus in BWS and Wilms’ Tumor
5
the degree of methylation of leukocyte DNA is insufficient to predict the extent of mosaicism in the whole body and tissues, which is more important as the BWS phenotype should be examined. The high incidence of hemihyperthrophy (table 1) suggests that at least some of the clinical features of the patients with IC1 deletion are influenced by mosaicism. Mosaicism can also explain the high variability of the clinical phenotype that is characteristic of this disorder. In addition, diagnostic problems may be encountered with individuals who may not have abnormal methylation in their leukocyte DNA. To avoid these problems, it may be useful in the future to analyze DNAs derived from more than one tissue (e.g. blood leukocytes and buccal mucosa).
Loss of IGF2-H19 Imprinting
It has been shown in the mouse that the CTSs within the IC1 element are required for its insulator function [21]. Furthermore, CTCF binding controls the interaction between IC1 and the Igf2 DMRs that are required to partition the Igf2 and H19 genes into transcriptionally active and inactive chromatin loops [9, 10]. We observed a gain of methylation at the IGF2 DMR0 and DMR2 in the majority of the patients with IC1 hypermethylation (with or without microdeletions) [16, 22, and data not shown]. In addition, biallelic activation of IGF2 and biallelic silencing of H19 could be demonstrated in many of these patients. It is therefore likely that the epigenetic alterations resulting from the microdeletions or sporadic epimutations of IC1 lead the maternal 11p15.5 locus to acquire high-order chromatin structures that are typical of the paternal chromosome and associated with IGF2 activation and H19 silencing (fig. 2).
Origin of the Imprinting Defects
In principle, imprinting defects at ICs can derive from failure of erasure, establishment or maintenance of the imprint [2]. The incomplete hypermethylation of the CTSs found in the BWS patients with 1.4- to 1.8-kb deletions indicates mosaicism for the imprinting defect and suggests that the methylation is acquired postzygotically and results from insufficient protection from de novo methylation of the mutated maternal IC1. In the BWS patients without microdeletions the chromosome with abnormal IC1 methylation derived from either the maternal grandfather or maternal grandmother. Since the majority of these cases also showed mosaic hypermethylation, it is likely that also in these cases the methylation defect is acquired at a postzygotic stage. However, an incomplete imprint erasure resulting in an unstable methylation cannot be excluded. Knocking-down of CTCF in mouse oocytes and in cultured cells results in gain of methylation of IC1 [23]. We ruled out the presence of a mutation of CTCF gene in
6
Riccio · Sparago · Verde · De Crescenzo · Citro · Cubellis · Ferrero · Silengo · Russo · Larizza · Cerrato
IGF2
H19 Normal
IGF2
H19
BWS with IC1 microdeletions
IGF2
DMR0
H19
DMR2
IC1
BWS without IC1 microdeletions
Fig. 2. Loss of IGF2-H19 imprinting as consequence of sporadic and inherited epimutations. The diagram shows the expression of the maternal and paternal IGF2 and H19 alleles in normal individuals and BWS patients with maternally inherited IC1 microdeletions or sporadic IC1 hypermethylation. The methylated or nonmethylated status of the IGF2 DMR0, IGF2 DMR2, seven IC1 CTSs and H19 promoter is indicated by filled and open lollipops, respectively. The enhancers are indicated by ovals.
the patients without IC1 deletions. It cannot be excluded, however, that a mutation is present in other modifier genes. Considering the sporadic nature of these cases, the possibility that IC1 hypermethylation occurs as consequence of stochastic events or environmental influence should also be envisaged [24].
Absence of IC1 Microdeletions in Non-Syndromic Wilms’ Tumor
The 11p15.5 imprinted gene cluster is frequently affected in Wilms’ tumors [12]. Either maternal deletion/paternal duplication (LOH) or IC1 hypermethylation coupled to H19 silencing and IGF2 activation (LOI) can be found in a high proportion of tumors. In addition, the individuals who have somawide IC1 hypermethylation or 11p15.5 paternal UPD represent the molecular subgroup of BWS patients showing the highest risk of developing Wilms’ tumor [13]. Consistent with these observations, we found that 5/20 BWS patients with IC1 hypermethylation in our cohort had developed this neoplasm. Two of these had IC1 microdeletions [18]. However, no
Epimutations at the IGF2-H19 Locus in BWS and Wilms’ Tumor
7
IC1 deletion was found in 40 sporadic non-syndromic Wilms’ tumors. A previous American study demonstrated the absence of point mutations in the IC1 sequence of a series of sporadic Wilms’ tumors [25]. Overall, these data suggest that IC1 imprinting defects are generally not associated with a mutation in cis in non-syndromic Wilms’ tumor, as well as sporadic BWS. We recently demonstrated the presence of different methylation abnormalities at IGF2 in Wilms’ tumors and BWS, suggesting that sporadic imprinting defects arise through different mechanisms in neoplastic and non-neoplastic cells [22]
Conclusion
Although the common hallmark and probably the ultimate cause of the imprinting defects at the IGF2/H19 locus is represented by hypermethylation of IC1, our studies demonstrate that this epigenetic abnormality can result from more than one mechanism in BWS and Wilms’ tumor. In a first group of patients, we found that the epimutation is a direct consequence of a mutation in cis, consisting of a deletion of 1–2 CTSs. In these cases, the methylation defect and disease phenotype are reproduced whenever the mutation is transmitted through the maternal germline. In another group of patients, who carry no IC1 deletion, the epimutation is independent of the local DNA sequence and generally not transmitted to the progeny. Sporadic BWS and non-syndromic Wilms’ tumor belong to the second group of cases. Despite these differences, the IC1 epimutation is generally present in the patients in the mosaic form and probably acquired by postzygotic de novo methylation, providing an example of how intricate the relationship between genotype and epigenotype can be.
Acknowledgments This work was supported by grants from MIUR PRIN 2005, Istituto Superiore di Sanità, Associazione Italiana Ricerca sul Cancro, Telethon-Italia Grant No. GGP07086. F.C. was recipient of a fellowship from Società Italiana di Cancerologia and Fondazione Pezcoller.
References 1 2
3
8
Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433–440. Reik W, Walter J: Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001;2:21– 32. Arnaud P, Feil R: Epigenetic deregulation of genomic imprinting in human disorders and following assisted reproduction. Birth Defects Res [C] 2005; 75:81–97.
4
5
Ainscough JFX, Koide T, Tada M, Barton S, Surani MA: Imprinting of Igf2 and H19 from a 130 kb YAC transgene. Development 1997;124:3621–3632. Cerrato F, Sparago A, Di Matteo I, Zou X, Dean W, Sasaki H, Smith P, Genesio R, Bruggemann M, Reik W, Riccio A: The two-domain hypothesis in BeckwithWiedemann syndrome: autonomous imprinting of the telomeric domain of the distal chromosome 7 cluster. Hum Mol Genet 2005;14: 503–511.
Riccio · Sparago · Verde · De Crescenzo · Citro · Cubellis · Ferrero · Silengo · Russo · Larizza · Cerrato
6 LeRoith D, Roberts, CTJr: The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127– 137. 7 Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumour-suppressor activity of H19 RNA. Nature 1993;365:764–767. 8 Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405:486–489. 9 Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, Zhao Z, Lobanenkov V, Reik, W, Ohlsson R: CTCF binding at the H19 imprinting control region mediates maternally inherited higherorder chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci USA 2006; 103:10684–10689. 10 Murrell A, Heeson S, Reik W: Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nat Genet 2004;36:889–893. 11 Weksberg R, Shuman C, Smith AC: BeckwithWiedemann syndrome. Am J Med Genet [C] 2005; 137:12–23. 12 Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 2002; 12:389–398. 13 Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Bliek J, Schofield PN, Reik W, Macdonald F, Maher ER: Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005;13:1025–1032. 14 Sparago A, Cerrato F, Vernucci M, Ferrero GB, Cirillo Silengo M, Riccio A: Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann. Nat Genet 2004;36:958– 960. 15 Cerrato F, Sparago A, Farina L, Ferrero GB, Cirillo Silengo M, Riccio A: Reply to Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilm’s tumor. Nat Genet 2005;37:786–787. 16 Sparago A, Russo S, Cerrato F, Ferraiuolo S, Castorina P, Selicorni A, Schwienbacher C, Negrini M, Ferrero GB, Silengo MC, Anichini C, Larizza L, Riccio A: Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms’ tumour. Hum Mol Genet 2007;16; 254–264.
17 Prawitt D, Enklaar T, Gartner-Rupprecht B, Spangenberg C, Oswald M, Lausch E, Schmidtke P, Reutzel D, Fees S, Lucito R, Korzon M, Brozek I, Limon J, Housman DE, Pelletier J, Zabel B: Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms’ tumor. Proc Natl Acad Sci USA 2005;102:4085–4090. 18 Cerrato F, Sparago A, Verde G, De Crescenzo A, Citro V, Cubellis MV, Rinaldi MM, Boccuto L, Neri G, Magnani C, D’Angelo P, Collini P, Perotti D, Sebastio G, Maher ER, Riccio A: Different mechanisms cause imprinting defects at the IGF2/H19 locus in BeckwithWiedemann syndrome and Wilms’ tumour. Hum Mol Genet 2008;17:1427–1435. 19 DeBaun MR, Tucker MA: Risk of cancer during the first four years of life in children from The BeckwithWiedemann Syndrome Registry. J Pediatr 1998;132: 398–400. 20 Priolo M, Sparago A, Mammì C, Cerrato F, Laganà C, Riccio A: MS-MLPA is a specific and sensitive technique for detecting all chromosome 11p15.5 imprinting defects of BWS and SRS in a single-tube experiment. Eur J Hum Genet 2008;16:565–571. 21 Schoenherr CJ, Levorse JM, Tilghman SM: CTCF maintains differential methylation at the Igf2/H19 locus. Nat Genet 2002;33:66–69. 22 Murrell A, Ito Y, Verde G, Huddleson J, Woodfinel K, Cirillo Silengo M, Spreafico F, Perotti D, De Crescenzo A, Sparago S, Cerrato F, Riccio A: Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PloS ONE 2008;3:e1849. 23 Fedoriw AM, Stein P, Svoboda P, Schultz RM, Bartolomei MS: Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science 2004;303:238–240. 24 Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(suppl): 245–254. 25 Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenkov VV , Feinberg AP: Loss of imprinting of insulin-like growth factor-II in Wilms’ tumour commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 2001;61:4947–4950.
Andrea Riccio Dipartimento di Scienze Ambientali Seconda Università di Napoli, Via Vivaldi, 43 IT–81100 Caserta (Italy) Tel. +39 0823 274 599, Fax +39 082 274 605, E-Mail
[email protected]
Epimutations at the IGF2-H19 Locus in BWS and Wilms’ Tumor
9
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 10–19
Epigenetic Regulation of Growth: Lessons from Silver-Russell Syndrome Thomas Eggermann Institute of Human Genetics, University Hospital, RWTH Aachen, Germany
Abstract Human growth is a complex process and requires the appropriate interaction of many members. Central members in the growth axes are regulated epigenetically and thereby reflect the profound significance of imprinting for correct mammalian ontogenesis. A prominent imprinting disorder, Silver-Russell syndrome (SRS), is a congenital disease characterized by intrauterine and postnatal growth retardation and other features. SRS represents the first human disorder with imprinting disturbances affecting two different chromosomes: nearly one tenth of patients carry a maternal uniparental disomy of chromosome 7 and more than 38% show a hypomethylation in the imprinting control region 1 in 11p15. Interestingly, hypermethylation of the same region is associated with the overgrowth disease Beckwith-Wiedemann syndrome (BWS), thus SRS and BWS can be regarded as genetically (and clinically) opposite diseases. Because of the different imprinting regions involved, SRS is a suitable model to decipher the role of imprinting in growth and the functional interaction Copyright © 2009 S. Karger AG, Basel between imprinted genes in different genomic regions.
Growth is a complex process with both genetics and environment contributing in equally parts. Among the involved genes is a substantial number of so-called imprinted factors, e.g. these genes are expressed only from one chromosome from one parent. Generally, paternally expressed imprinted genes enhance fetal growth, whereas maternally expressed ones suppress it. Based on this observation, the genetic conflict theory has been hypothesized: it explains the evolution of imprinted genes by paternally derived genes that aim at extracting more resources from the mother whereas maternally derived genes have to balance the nutrient provision to the current fetus with that to future fetuses of the same mother [1]. With the identification of human diseases caused by epigenetic mutations, the significance of a balanced expression of imprinted genes became obvious. In addition to the profound role of imprinted genes in congenital disorders, there is evidence for epigenetic inheritance in humans which might explain the transgenerational effects of grandparental nutrition on health in next generations [2].
The close relationship between imprinting and (fetal) growth is illustrated by the recent identification of specific genetic and epigenetic alterations in Silver-Russell syndrome (SRS)(OMIM 180860). SRS is a congenital disorder mainly characterized by pre- and postnatal growth restriction. The children are relatively macrocephalic and their face is triangular-shaped with a broad forehead and a pointed, small chin. In many cases, asymmetry of limbs and body and clinodactyly of the fifth digit is present. Growth failure is often accompanied by severe failure to thrive, and feeding difficulties are frequently reported. The latter is the main clinical concern and much effort is expended in encouraging adequate feeding. For those children without catch-up growth by the age of 2, growth hormone therapy is encouraged.
Genetics of SRS
The observation of ‘classical’ genetic findings in SRS patients such as families with several affected members and cytogenetic aberrations indicated the influence of genetic factors in the etiology of SRS. Among the rare SRS families, autosomalrecessive as well as dominant inheritance have been reported. This genetic heterogeneity has also been confirmed by the observation of different chromosomal disturbances (fig. 1). Whereas in other genetic diseases these findings help to identify the specific genes, in SRS the majority of the putative genetic observations did not enlighten the molecular basis of the disorder but indeed led to more confusion. This confusion was increased by the finding that the majority of monozygotic twins are discordant (for review, see ref. [3]). In circumstances in which genetic information is incomplete, twin studies are often helpful in establishing genetic causes. In SRS, these discordant monozygotic twins were misleading for a long time but can now be explained by the data from Gicquel et al. [4] who reported on discordant monozygotic twins carrying the same 11p15 epimutation but with mosaic distribution in different tissues. Despite the heterogeneous cytogenetic findings, aberrations of four chromosomal regions have been described for several times and these regions were therefore considered to harbor SRS relevant genes.
Chromosomes 15 and 17
The identification of deletions in 15q26qter in patients with SRS features led to the assumption that an imbalanced expression of the insulin-like growth factor 1 receptor gene (IGF1R) might cause SRS. Nevertheless, pathogenic mutations in IGF1R were not found in SRS patients [5]. Based on balanced translocations in 2 patients involving 17q24-q25, a central role of this chromosomal region in SRS etiology had been long discussed. However,
(Epi)Genetics of Silver-Russell Syndrome
11
3 1
5
4
2 …
6
7
…
…
13
14
19
20
Deletion
15
…
8
9
…
11
10
16
17
21
22
UPD
12
X
18
Y
Isochromosome/marker chromosome
Duplication/trisomy Translocation breakpoint
Ring chromosome
… more than two cases
Fig. 1. Chromosomal aberrations in SRS: Review on types, frequencies and affected genomic regions. A complete list of the literature describing chromosomal aberrations in SRS is available on request.
characterization of the 17q breakpoints in both patients showed that they were not identical [6]. Furthermore, the previously reported heterozygous deletions in the growth hormone (GH) gene cluster in 17q are now regarded as apathogenic polymorphisms [7].
Chromosome 7
Cytogenetic aberrations of chromosome 7 including duplications of 7p11.2p13 and small marker chromosomes have been identified in several SRS individuals (for review, see ref. [8]) and lead to the assumption that a ‘SRS gene’ should be localized in
12
Eggermann
the short arm of chromosome 7 (see below). However, the most spectacular finding was that of maternal uniparental disomy of chromosome 7 (UPD(7)mat) in 7–10% of SRS individuals [9]. Uniparental disomy (UPD) is the inheritance of two homologous chromosomes or chromosomal fragments (partial UPD) from only one parent in an euploid offspring. Whole chromosome UPD can be the result of meiotic as well as mitotic non-disjunction errors, but the most frequent mode of formation is via trisomic rescue: 10–15% of all recognized human conceptions are trisomic and most of them are lethal. For many chromosomes, the only way that the trisomic conception survives is that one of the three chromosomes is lost. In one third of these cases a random chromosome loss might lead to UPD. If the UPD results from a postzygotic mitotic error, it might be associated with chromosomal mosaicism. Identification of UPD is extremely helpful because it helps deciphering imprinted regions and genes. UPD has meanwhile been described for the majority of chromosomes but only chromosomes 6, 7, 11, 14 and 15 show a specific phenotype on the basis of imprinting disturbances. So far, research on chromosome 7 encoded factors has focused on two chromosomal segments. For the candidate region in 7p11.2-p13 SRS patients with duplications have been reported (for review, see ref. [10]). The region harbors an imprinted gene (growth factor receptor bound protein 10/GRB10, see below) and several factors involved in human growth and development (fig. 2). Pathogenic mutations in these genes have not yet been described in SRS (for review, see ref. [8]). The most prominent candidate in 7p is GRB10 which encodes a cytoplasmic adaptor protein and interacts with tyrosine kinase receptors. The gene shows a complex expression in mammalian tissues with various isoforms expressed either from the maternal or from the paternal copy. In mice, Grb10 is mainly expressed from the maternal allele; the loss of maternal Grb10 results in both fetal and placental overgrowth [11, 12] demonstrating its role as a growth suppressor. By contrast, Grb10 overexpression in mice causes postnatal growth retardation and insulin resistance [13]. Grb10 serves a negative regulator of insulin signaling and action in vivo [12, 13] but a role in a fetal growth pathway independent of Igf2 has also been postulated [11]. To summarize, Grb10/GRB10 plays an essential role in growth and is therefore still a good candidate for SRS. Nevertheless, neither point mutations in the coding region nor aberrant methylation of GRB10 have been detected in SRS patients despite extensive screening studies (for review, see ref. [8]). There is additional evidence that the chromosomal region 7q31 is also involved in the etiology of SRS: meanwhile four growth-restricted patients have been described with segmental maternal UPD of the long arm of chromosome 7, three of which with SRS features (fig. 2). In 7q31, three imprinted genes (MEST/PEG1; CPA4; COPG2) and two imprinted noncoding RNAs (MESTIT1, CIT1/COPG2IT1) are localized but screening studies did not detect any pathogenic variants.
(Epi)Genetics of Silver-Russell Syndrome
13
22
Candidate genes
21
p
15 14 13
Fig. 2. SRS candidate genes on chromosomes 7 and review on the extents of segmental UPD(7)mat and maternal duplications in 7p12 reported so far (* imprinted genes). IGFBP1, IGFBP3 insulin-like growth factor-binding proteins 1 and 3; PHKG1 = Phosphorylase kinase 1; EGFR = epidermal growth factor receptor; GHRHR = growth hormone-releasing hormone receptor; MEST/PEG1 = mesoderm-specific transcript; CPA4 = carboxypeptidase A4; COPG2 = coatomer protein complex subunit gamma 2; MESTIT MEST = intronic transcript; CIT1/COPG2IT1 COPG2 = intronic transcript; PAX4 = paired box gene 4.
12 11.2 11.1 11.1
Duplications Segmental UPD(7)mat
GHRHR IGFBP1 IGFBP3 GRB10*
EGFR PHKG1 c7orf10
11.2
21
q
22
31
32 33 34 35 36
MEST* MESTIT1*
CIT1* COPG2*
PAX4 CPA4
Chromosome 7
Chromosome 11
Recent exciting findings indicate an important role of the region 11p15 in the etiology of SRS (fig. 3). The first hint was the identification of maternal 11p15 duplications in growth retarded patients and more or less striking SRS features (for review: [14]). Interestingly, the opposite disturbance – duplication of paternal 11p15 – is associated with the overgrowth disease Beckwith-Wiedemann syndrome (BWS, OMIM 130650). Numerous genetic and epigenetic alterations can be detected in BWS patients (table 1; fig. 3) (for review, see ref. [15]) but in more than 50% aberrant methylation patterns in 11p15 are involved. The search for epimutations in 11p15 in SRS patients was therefore consequent and indeed, hypomethylation at the telomeric imprinting control region 1 (ICR1) in 11p15 regulating H19 and IGF2 expression could be identified in more than 38% of cases (table 1; fig. 3). A comparison of the 11p15 disturbances in BWS and SRS reveals many similarities in the molecular biology of the two disorders.
14
Eggermann
Table 1. 11p15 (epi)mutations in SRS and BWS and their frequencies: modified from Eggermann et al. [8] Type of mutation
SRS
Frequencies
BWS
Frequencies
In ICR1
hypomethylation
>38%
hypermethylation
2–8%
In ICR2
mutations in CKDN1C
–
mutations in CDKN1C
5–10% sporadic 40% autosomal dominant traits
hypermethylation
–
hypomethylation
50–60%
maternal duplication
1 case
11p structural rearrangements
maternal duplications
4 cases
paternal duplications
1–2%
UPD of 11p15
maternal
?
paternal UPD
10–20%
Others
maternal UPD7/7p 10% duplications >40% unknown
unknown
10–20%
First of all, epimutations affect the ICR1 in both entities. In BWS, hypermethylation of the ICR1 leads to biallelic expression of IGF2, potentially doubling the IGF2 dose in specific organs. By contrast, the ICR1 hypomethylation observed in SRS should result in a suppressed IGF2 expression in the target tissues. As a result of its central role in human growth (and tumorigenesis), IGF2 is the perfect candidate for both diseases, and indeed IGF2 is highly expressed in tissues which are affected in BWS. In vitro, IGF2 expression is altered in both syndromes: in tissue samples from BWS patients IGF2 is overexpressed at the mRNA level (for review, see ref. [15]), in fibroblasts of SRS individuals IGF2 mRNA is reduced [4]. However, IGF2 serum levels in both BWS patients and SRS patients with H19 hypomethylation are normal [16, 17] but we have to consider that the liver as the major organ of postnatal IGF2 secretion expresses the factor from a nonimprinted promoter. Due to the negative findings in serum it has been concluded that ICR1 demethylation does not directly influence IGF2 secretion in SRS children but an altered IGF2 production probably leads to a diminished autoparacrine action in the fetus. The recent identification of a SRS patient with a duplication restricted to the centromeric imprinting control region 2 (ICR2) [18] which regulates the expression of CDKN1C, KCNQ1 and further genes suggests that both ICRs on 11p15 are involved in the aetiology of the disease, like in BWS where epi/mutations in the ICR2 account for more than 50% of cases (table 1). This finding and further data obtained from BWS patients and mice models suggest that ICR1 and ICR2 interact (for review, see ref. [8]).
(Epi)Genetics of Silver-Russell Syndrome
15
11pter
11cen CDKN1C
KCNQ1
IGF2
M
H19
CTCF
KCNQ1OT1 CH3
CH3
CH3 CH3
CDKN1C
KCNQ1
IGF2
H19
P KCNQ1OT1
BWS
ICR2
SRS
ICR1
Chromosomal rearrangements (duplications) CDKN1C
M
KCNQ1
IGF2
H19
IGF2
H19
IGF2
H19
M
KCNQ1OT1
CDKN1C
P
KCNQ1
M
KCNQ1OT1
CDKN1C
P
KCNQ1
P
KCNQ1OT1
CDKN1C
KCNQ1
IGF2
H19
IGF2
H19
IGF2
H19
IGF2
H19
IGF2
H19
KCNQ1OT1
CDKN1C
KCNQ1 KCNQ1OT1
CDKN1C
KCNQ1 KCNQ1OT1
Uniparental disomy (UPD) CDKN1C
KCNQ1
P
IGF2
H19
IGF2
H19
KCNQ1OT1
CDKN1C
P
KCNQ1 KCNQ1OT1
Altered Methylation of ICR1
M P
CDKN1C
KCNQ1
CDKN1C
KCNQ1
IGF2
H19
IGF2
H19
M
CDKN1C
P
KCNQ1OT1
KCNQ1 KCNQ1OT1
KCNQ1OT1
CDKN1C
KCNQ1 KCNQ1OT1
Duplication of ICR2
(Epi)mutations of/in ICR2 Hypomethylation of ICR2 M
CDKN1C
P
CDKN1C
KCNQ1
IGF2
H19
IGF2
H19
KCNQ1OT1
KCNQ1
M
CDKN1C
KCNQ1
CDKN1C
KCNQ1
KCNQ1OT1
P
CDKN1C
M P
CDKN1C
KCNQ1
CDKN1C
KCNQ1
IGF2
H19
IGF2
H19
H19
KCNQ1
IGF2
H19
KCNQ1OT1
KCNQ1OT1
Pointmutations in CDKN1C
IGF2
KCNQ1OT1
Expressed
Silenced
IGF2
IGF2
CDKN1C
CDKN1C
KCNQ1OT1 KCNQ1OT1
Fig. 3. Epigenetic regulation of the two imprinting center regions (ICR) in 11p15 and the different (epi)mutations affecting 11p15 in BWS and SRS. CDKN1C = Cyclin-dependent kinase inhibitor/p57KIP2; KCNQ1 = potassium channel KQT-family member 1; KCNQ1OT1 KCNQ1 = intronic transcript 1; IGF2 = insulin-like growth factor 2.
Do Different Mutations in Functional Networks Explain the Heterogeneity of SRS?
When looking at the major chromosomal regions involved in rearrangements in SRS we see that three of them, i.e. chromosomes 7, 11 and 15, harbor members of the IGF system, a mediator of pre- and postnatal growth. SRS might therefore represent a common phenotype caused by alterations in members of this axis such as the ligand IGF2, its receptor IGF1R and the IGF signaling modulator GRB10. The effects of IGF2 on fetal growth are mainly mediated through the IGF1R. Mice knockout models indicate that loss of the paternal IGF2 causes IUGR with reduction in 40% of the body weight in newborn mice [19] whereas experimental overexpression of the same allele results in hypertrophic mice [20].
16
Eggermann
Another axis – an ‘imprinted gene network’ – has recently been hypothesized by Arima et al. [21]. They observed that in vitro the imprinted gene PLAGL1/ZAC (pleomorphic adenoma gene-like 1) in 6q24 drives the expression of KCNQ1OT1 noncoding RNA in 11p15. PLAGL1/ZAC might affect imprinted expression along the ICR2 domain in 11p15, including CDKN1C. This would put PLAGL1/ZAC, KCNQ1OT1 and CDKN1C in a common regulatory mechanism that influences intrauterine growth. According to Arima et al. [21], the assumed regulation of CDKN1C by PLAGL1/ZAC indicates a potential role of this gene in BWS but they did not detect aberrant methylation at the PLAGL1/ZAC DMR in a small number of BWS patients. Indeed they observed changes in the methylation of the ICR2 in two patients with transient neonatal diabetes mellitus (TNDM) and 6q24 disturbances.
Genotype-Phenotype Correlation in SRS?
With the identification of the ICR1 hypomethylation in 11p15 and UPD(7)mat the molecular confirmation of the clinical diagnosis of SRS is now possible in ~50% of patients (table 1). However, we have to bear in mind that routine diagnostics is based on lymphocytes and that nearly all SRS patients with ICR1 hypomethylation are mosaics. Thus, we hypothesize that a subgroup of patients escapes molecular diagnosis because their mosaicism affects other tissues than blood cells. In these cases, the mosaic distribution of the epimutation probably influences the phenotype. This assumption is supported by the findings of several groups [4, 22, 23] who reported on a correlation between the degree of methylation at the ICR1 locus and the severity of the phenotype. The finding of different epigenetic and genetic alterations in SRS patients should enable us to delineate a genotype-phenotype correlation. Indeed, the SRS phenotype of carriers of the 11p15 epimutation is generally more severe and typical than that of UPD(7)mat carriers or those SRS without known mutation [16, 24] but exceptions exist [23]. Additionally, in single cases chromosomal anomalies might also influence the phenotype depending on the chromosomal regions involved. In total, the phenotypic transition is fluent and therefore carriers of 11p15 epimutations and UPD(7) mat can not be discriminated solely by clinical findings. We therefore suggest to test all patients with intrauterine and severe postnatal growth retardation and only slight signs reminiscent for SRS for the known mutations. Screening of larger groups of growth-retarded patients will help to establish the frequency of 11p15 epimutation and UPD(7)mat in this heterogeneous cohort. Based on the current data it can be hypothesized that the frequency of SRS is underestimated because of the difficult and often subjective clinical diagnosis which depends on the experience of the clinical investigator. As aforementioned, IGF2 serum levels are within the normal range in SRS patients possibly due to a biallelic expression in the liver whereas its predominantly paternal
(Epi)Genetics of Silver-Russell Syndrome
17
expression in the fetus makes functional consequences of an aberrant methylation possible. Recently, Binder et al. [24] demonstrated that IGF1 serum levels in 11p15 epimutation carriers are inadequately high in comparison to non-syndromic short children. Moreover, IGFB3 levels were increased in the 11p15 patients while UPD(7) mat patients showed regular IGF1 and IGFB3 serum levels. It was therefore concluded that heterogeneity of SRS does not only include the genetic and clinical level but also hormone regulation.
Conclusion
In the highly developed countries ~3% of children are born too small and 20% of them do not show catch-up growth, patients with SRS belonging to the latter group. The functional cause for the persisting growth retardation is currently unknown in the majority of cases, and the only pharmacological option available is treatment with hGH. Since the response is highly variable even in a defined cohort like SRS patients, a more specific classification of the patients based on genetic methods might help to understand this variable response and allow to specifically adapt the treatment. Thus, SRS can be regarded as a model to decipher the functional link between the different genetic and epigenetic factors identified in growth retarded individuals; future studies will further enlighten the complex interactions between growth factors and contribute to a better directed therapy.
References 1
2
3
4
5
18
Moore T, Haig D: Genomic imprinting in mammalian development: a parent tug-of-war. Trends Genet 1991;7:45–49. Pembrey ME, Bygren LO, Kaati G, Edvinsson S, Northstone K, Sjöström M, Golding J, ALSPAC Study Team: Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet 2006; 14: 159–166. Bailey W, Popovich B, Jones KL: Monozygotic twins discordant for the Russell-Silver syndrome. Am J Med Genet 1995;58:101–105. Gicquel C, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, Danton F, Thibaud N, Le Merrer M, Burglen L, Bertrand AM, Netchine I, Le Bouc Y: Epimutation of the telomeric imprinting center region on chromosome 11p15 in SilverRussell syndrome. Nat Genet 2005;37:1003–1007. Binder G, Mavridou K, Wollmann HA, Eggermann T: Screening for insulin-like growth factor-I receptor mutations in patients with Silver-Russell syndrome. J Pediatr Endocrinol Metab 2002;15; 1167–1171.
6
7
8
9
Dörr S, Midro AT, Farber C, Giannakudis J, Hansmann I: Construction of a detailed physical and transcript map of the candidate region for Russell- Silver syndrome on chromosome 17q23q24. Genomics 2001;71:174–181. Eggermann T, Schoenherr N, Eggermann K, Wollmann HA: Hypomethylation in the 11p15 telomeric imprinting domain in a Silver-Russell patient with a CSH1 deletion (17q24) renders a functional role of this alteration unlikely. J Med Genet 2007; 44:e77. Eggermann T, Eggermann K, Schönherr N: Growth retardation versus overgrowth: Silver-Russell syndrome is genetically opposite to BeckwithWiedemann syndrome. Trends Genet 2008;24: 195–204. Kotzot D, Schmitt S, Bernasconi F, et al: Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation. Hum Mol Genet 1995;4:583– 587.
Eggermann
10 Monk D, Bentley L, Hitchins M, Myler RA, ClaytonSmith J, Ismail S, Price SM, Preece MA, Moore GE: Chromosome 7p disruptions in Silver-Russell syndrome: delineating an imprinted candidate gene region. Hum Genet 2002;111:376–387. 11 Charalambous M, Smith FM, Bennett WR, Crewe TE, MacKenzie F, Ward A: Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. PNAS 2003;100:8292–8297. 12 Wang L, Balas B, Christ-Roberts CY, Kim RY, Ramos FJ, Kikov CK, Li C, Deng C: Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. Mol Cell Biol 2007;27:6497– 6505. 13 Shiura H, Reyna S, Muri N, Dony LQ, De Fronzo RA, Liu F: Meg1/Grb10 overexpression causes postnatal growth retardation and insulin resistance via negative modulation of the IGF1R and IR cascades. BBRC 2005;329; 909–916. 14 Eggermann T, Meyer E, Obermann C, Heil I, Schuler H, Ranke MB, Eggermann K, Wollmann HA: Is maternal duplication 11p15 associated with Silver-Russell syndrome? J Med Genet 2005;42:e26. 15 Weksberg K, Smith AC, Squire J, Sadowski P: Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003;12:R61–R68. 16 Netchine I, Rossignol S, Dufourg MN, Azzi S, Rousseau A, Perin L, Houang M, Seunou V, Esteva B, Thibaud N, Demay M-CR, Danton F, Petricko E, Bertrand A-M, Heirnichs C, Carel J-C, Loeuille G-A, Pinto G, Jaquemont M-L, Gicquel C, Cabrol S, Le Bouc Y: 11p15 ICR1 loss of methylation is a common and specific cause of typical Russell-Silver syndrome: clinical scoring system and epigeneticphenotypic correlations. J Clin Endocrinol Metabol 2007;92: 3148–4154.
17 Schneid H, Vazquez MP, Vachev P, Gournelen M, Cabrol S, Le Bouc Y: The Beckwith-Wiedemann syndrome phenotype and the risk of cancer. Med Pediatr Oncol 1997;28; 411–415. 18 Schönherr N, Meyer E, Schmidt A, Wollmann HA, Eggermann T: The centromeric 11p15 imprinting center is also involved in Silver-Russell syndrome. J Med Genet 2007;44:59–63. 19 DeChiara TM, Efstratiadis A, Robertson EJ: A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990;345:78–80. 20 Sun F-L, Dean WC, Kelsey G, Allen ND, Reik W: Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 1997;389: 809–815. 21 Arima T, Kamikara T, Hayashita T, Kato K, Inoue T, Shirayashi Y, Oskimura M, Soejima H, Makai T, Wake N: ZAC, Lit1 (KCNQ1OT1) and p57KIP2 (CKDN1C) are in an imprinted gene network that might play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res 2005;33:2650–2660. 22 Bliek J, Terhal P, van den Bogaard M-J, Maas S, Hamel B, Salieb-Beugelaar G, Simon M, Letteboer T, van der Smagt J, Kroes H, Mannens M: Hypomethylation of the H19 gene causes not only Silver-Russell syndrome (SRS) but also isolated asymmetry or an SRS-like phenotype. Am J Hum Genet 2006;78:604–614. 23 Zeschnigk M, Albrecht B, Buiting K, Kanber D, Eggermann T, Binder G, Gromoll J, Prott E-C, Seland S, Horsthemke B: IGF2/H19 hypomethylation in Silver-Russell syndrome and isolated hemihypoplasia. Eur J Hum Genet 2008;16:328–334. 24 Binder G, Seidel A-K, Martin DD, Schweizer R, Schwarze P, Wollmann HA, Eggermann T, Ranke MB: The endocrine phenotype in Silver-Russell syndrome is defined by the underlying epigenetic alteration. J Clin Endocrinol Metab 2008;93:1402– 1407.
Thomas Eggermann, PhD Institute of Human Genetics University Hospital, RWTH Aachen Pauwelsstrasse 30, DE–52074 Aachen (Germany) Tel. +49 241 808 8008, Fax +49 241 808 2394, E-Mail
[email protected]
(Epi)Genetics of Silver-Russell Syndrome
19
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 20–28
Genetic Imprinting: The Paradigm of Prader-Willi and Angelman Syndromes Fiorella Gurrieri ⭈ Maria Accadia Institute of Medical Genetics, Catholic University, Rome, Italy
Abstract Imprinted genes are expressed from only one of the two parental alleles. A consequence of genomic imprinting is that viable embryos must receive two haploid genome complements from parents of opposite sex. The parental-specific expression is obtained through epigenetic modifications (DNA methylation, histone tail modifications) which alter the conformation of chromatin fiber and therefore regulate the expression of the underlying genes. Deletions, duplication, mutations or alterations of imprinting of the only active allele, as well as uniparental disomy or loss of imprinting of the inactive allele lead to an unbalance (loss of function or gain of function) in the dosage of the gene product and may have phenotypic consequences. Two such examples in human pathology are represented by the Prader-Willi and Angelman syndromes, whose phenotypes result from loss of paternal or maternal contribution of the 15q11-q13 genomic region, respectively. Prader-Willi syndrome is characterized by pre- and postnatal hypotonia, feeding difficulties in early life and subsequent hyperphagia with obsessive/compulsive food searching, obesity, short stature, hypogonadism and acromicria. Psychomotor development is mildly affected and behavioral problems are more relevant. Patients with Angelman syndrome show a completely different phenotype characterized by severe mental retardation, absent speech, autistic-like behavior, severe epilepsy and postnatal Copyright © 2009 S. Karger AG, Basel microcephaly.
The term ‘genomic imprinting’ refers to the different expression of an allele depending on its parent-specific origin, so that only the paternal or the maternal allele is expressed in certain tissues or developmental stages. A direct consequence of this process is a physiologic functional haploidy of imprinted genes, which makes them more likely to be associated with disease. Normal development in mammals requires genes to be inherited from both parents. The functional differences between the maternal and paternal genomes are clearly recognized in two human tumors: the ovarian teratoma, arising from ovarian germ cells, and the hydatidiform mole, arising from cytotrophoblast. The ovarian teratoma has a gynogenetic origin and contains elements derived from all three germinal layers (ectoderm, mesoderm, endoderm)
[1], whereas the hydatidiform mole has an androgenetic origin and is composed by extra-embryonic trophoblast elements [2]. Nuclear transplantation experiments in mouse provided further evidence of the different developmental program of the maternal and paternal genome in embryo. Mouse eggs manipulated to contain two maternal pronuclei (gynogenotes) showed better formation of the embryo, but very poor development of extraembryonic tissues. In contrast, in mouse eggs with two paternal pronuclei (androgenotes), an exuberant trophoblast growth and failure of embryonic development was noted. These experiments pointed out that the maternal and paternal contributions to the embryonic genome in mammals were not equivalent and the correct development of the embryo required both of them [3]. It was also noted that this parental effect did not involve the whole genome, but was limited to specific chromosomal regions containing clusters of imprinted genes, which were differentially marked in the maternal and paternal germ lines [4].
Meaning of Epigenetic Reprogramming
Genomic imprinting is an epigenetic process. But what does ‘epigenetic’ mean? Actually, this term has been reinvented twice in the history of biology and development. The term epigenetic was first introduced in 1942 by Conrad Hal Waddington to describe biological differences between tissues that result from the process of development. He used the metaphor ‘genetic landscape’, suggesting that cell fates were established in development in a way similar to a marble rolling down to the lowest point of a ground in which ridges and furrows delineate the path and make it irreversible. Therefore, such a path depends not only on the intrinsic nature of the marble, but also on the conditioning through external forces [5]. Today, the term epigenetic refers to the modification of a given DNA trait, not changing its sequence, but rather its function through DNA methylation and histone tail modifications. Such modifications alter the conformation of the chromatin fiber, interfering with the transcriptional machinery and with DNA-binding proteins thus regulating the expression of the underlying genes [6]. This process is very important during the development of a multicellular organism, in which different cells and tissues acquire different programs of gene expression. From this point of view, genomic imprinting is a particular type of epigenetic regulation in which the activity of a gene is modified depending on the sex of the transmitting parent. Imprinting requires three main steps: gamete DNA marking, maintenance of the marking in embryo and adult somatic tissues, and resetting of marking at the beginning of gametogenesis [7]. In mammalian embryos there are two major cycles of epigenetic reprogramming of the genome: during preimplantation and during germ cell differentiation. These events have been widely studied in mouse embryos. After fertilization, the paternal and maternal genomes undergo a genomewide demethylation, followed by de novo methylation around the time of implantation. Imprinted alleles are protected from this wave of demethylation and
Prader-Willi and Angelman Syndromes
21
remethylation to maintain their proper dosage effects. The second step in epigenetic reprogramming is necessary to reset imprinting in germ cells. This process takes place in primordial germ cells and consists of DNA demethylation, involving also imprinted genes, and subsequent remethylation according to the sex, so that in ovocytes all imprinted genes will have a maternal mark and in sperm cells a paternal one [8]. Occasionally, epigenetic information appears to be inherited through the germ line, and this is likely to be a result of incomplete erasure in the germ line (or after fertilization) [9].
Paradigm of Prader-Willi and Angelman Syndromes: Imprinting Regulation and Evolutionary Aspects
Deletions, duplication, mutations or alterations of imprinting of the only active allele, as well as uniparental disomy or loss of imprinting of the inactive allele lead to an unbalance (loss of function or gain of function) in the dosage of the gene product and may have phenotypic consequences. The first clinical syndromes recognized in humans as a result of anomalies at imprinted loci were Prader-Willi (PWS) and Angelman syndromes (AS) in 1989 [10]. PWS and AS result from loss of paternal or maternal contribution of the same genetic region at 15q11.q13 (PWS-AS imprinting domain). The PWS-AS imprinting domain has a bipartite structure, revealed by the smallest region of overlap in AS and PWS patients due to an imprinting center deletion. The PWS imprinting center (PWS-IC) is located in exon 1 of SNRPN and is defined by a cluster of CpG sites that are not methylated on the paternal allele and methylated on the maternal allele. The AS imprinting center (AS-IC) resides 35–40 kb upstream of SNRPN exon 1 and its proposed function is to promote the methylation of the adjacent PWS-IC in the maternal germline. This IC regulates the expression of several paternally expressed genes (among those SNRPN, MAGEL2, MKRN3, NDN and more than seventy snoRNAs) and two maternally expressed genes (UBE3A and ATP10C) (fig. 1) [11]. Proximal to this region the non-imprinted P gene is also mapped, encoding a tyrosine transporter whose deficiency contributes to the skin and ocular hypopigmentation that occurs in PWS and AS patients with deletion [12].The AS phenotype is caused by several genetic mechanisms leading to loss of function of the UBE3A gene, which encodes for an ubiquitin protein ligase, E6-AP, and is expressed only by the maternal allele in certain brain regions [13]. For PWS, instead, the phenotype seems to result from loss of function of a number of paternally expressed genes on chromosome 15q11-q13 [14]. In an evolutionary perspective, the PWS-AS domain was constructed relatively recently, between 180 and 105 million years ago. In marsupials, in which the first evidence of imprinting was found, the PWS-AS domain is absent, SNRPN and UBE3A are not on the same chromosome and a completely different gene, CNGA3 (now located on human chromosome 2) is situated in place of SNRPN, ~60 kb distant from UBE3A. The construction of the
22
Gurrieri · Accadia
P1 0 AT
UB E
3A
26.1 26.2 26.3
25
24
15 21.1 21.2 21.3 22.1 22.2 22.3 23
11.2 11.1 11.1 11.2 12 13 14
13 12
Chromosome 15
M
Mat
SN RP N
ND N
M
AG E
L2
AS-IC PWS-IC
Pat AS-IC PWS-IC
Fig. 1. The PWS-AS imprinting domain. The imprinting center (IC) has bipartite structure: PWS-IC and AS-IC. On the maternal allele AS-IC confers methylation (M) of PWS-IC. As a result, all paternally expressed genes are silenced (empty boxes) and UBE3A and ATP10 are active (full boxes, arrows indicate transcription sense). On the paternal allele, PWS-IC remains unmethylated and activates all paternally expressed genes (e.g. MAGEL2, NDN, SNRPN).
PWS-AS domain was reached in eutherian through translocation of SNRPN beside UBE3A and insertion of miRNAs, snoRNAs and retroposed genes from all over the genome. Imprinting arose during or after this complex rearrangement (fig. 2) [15].
Prader-Willi Syndrome
This syndrome was clinically described by Prader and colleagues in 1956, but only in 1989 were the molecular bases of PWS and AS unraveled and related to an imprinting disorder [10]. A recent epidemiological study in the United Kingdom estimates an incidence of ~1 in 25,000 births and a prevalence of ~1 in 50,000 [16]. PWS is characterized by pre- and postnatal hypotonia, with a history of decreased fetal movements, poor suck and early failure to thrive. The fetus is usually podalic and delivery is commonly after term and requires cesarean section. Polyhydramnios is highly frequent. The hypotonia is most severe in early infancy, but improves somewhat over time. In the neonatal period feeble reflexes, lethargy and weak cry are often present. Feeding is usually an issue in the first few months of life and gavage is frequently required. Minor anomalies are often described and the typical facial appearance shows almond-shaped palpebral fissures, narrow bifrontal diameter, narrow nasal
Prader-Willi and Angelman Syndromes
23
Eutheria 180 MYA
Mouse
210 MYA
No evidence of imprinting
Monotremes
Avians Oviparous
450 MYA
Imprinting
Marsupials 310 MYA
350 MYA
Evolution of euhterianspecific imprinting
Human
105 MYA Lactation
Viviparity and placentation
Mammals
Reptiles
No evidence of imprinting
Amphibians
Fish
Non-mammals
Fig. 2. Evolution of imprinting in mammals. Imprinting is not present in non-mammals nor in monotremes, the most primitive mammals, which are capable of lactation but are still oviparous. The first evidence of imprinting has been found in marsupials. Modified from Hore et al. [15].
bridge and downturned mouth with thin upper lip, but not everyone has these features. Most patients have strabismus early in life. Frequently noted is also acromicria of the hands and feet with tapering fingers. Obesity is a hallmark of this syndrome, it occurs between the ages of 1 and 6 years and is due to hyperphagia. It is the major cause of morbidity and mortality in PWS and medical problems related to obesity are cardiopulmonary issues, increased risk for type II diabetes, obstructive sleep apnea and gastrointestinal complications [17, 18]. Hypoplastic genitalia, with cryptorchidism, scrotal hypoplasia and small penis in males and hypoplastic labia minora and clitoris in females are related to hypothalamic hypogonadism. An incomplete pubertal development is usually present, menarche may occur late and some female may have oligoamenorrhea or amenorrhea. Short stature is common and growth hormone (GH) deficiency has been demonstrated in most patients. Therapy with GH results in significant improvement of height and body composition (decreased fat mass and increased lean body mass) [17]. However, a significant number of deaths in children treated with GH has been reported, raising some concern about the safety of GH treatment in this population. A recent study shows that the major cause of death in children with PWS, who received GH treatment or did not, is a respiratory disease and no difference is found between the two groups. Nevertheless, since most deaths
24
Gurrieri · Accadia
Clinical features and genetic mechanisms AS Loss of maternal contribution
PWS Loss of paternal contribution
• Mild- to moderate mental retardation • Hypotonia • Obesity • Hypogonadism • Short stature
• Severe mental retardation • Seizures • Ataxic movements • Absent speech • Inappropriate laughter
70%
Deletion
70%
25% maternal
Uniparental disomy
3–5% paternal
2–5%
Imprinting defect
2–5%
?
Single gene mutation
10–15% UBE3A
⬍1%
Chromosomal rearrangement
⬍1%
Unknown (all diagnostic test negative)
10%
Fig. 3. Clinical features and genetic mechanisms of PWS and AS. Modified from Cassidy et al. [14]. Pictures of PWS and AS patients: courtesy of Prof. Giovanni Neri.
occurred in the first 9 months of therapy, a possible aggravating role of GH at the start of treatment cannot be excluded [18]. The incidence of spinal deformity in PWS is high: scoliosis can occur at any age and kyphosis usually develops in early adulthood. Psychomotor development is mildly affected: walking is achieved at around 24 months and language development at 3–4 years. Mental retardation is in the mildto-moderate range and most patients have an IQ ranging from 60 to 70. Many show an unusual skill in doing jigsaw puzzles, suggesting a particular attention to visual details. Behavioral problems are frequent and include not only food-related problems (excessive appetite, absent sense of satisfaction, obsession with eating), but also temper tantrums, impulsivity, sleep disturbance, skin picking, obsessive-compulsive symptoms and anxiety [14, 17]. The genetic abnormality of PWS is the lack of expression of paternally inherited genes in chromosome 15q11-q13. Approximately 70% of affected individuals have a cytogenetically small deletion of chromosome segment 15q11-q13. Maternal uniparental disomy (UPD) accounts for 25%, imprinting defect (small deletion or mutation) for 2–5% and the remaining <1% is due to chromosomal rearrangement involving proximal 15q (fig. 3). Patients with UPD or imprinting defect generally have a milder phenotype than those with deletions [14]. The differential diagnosis for PWS in infancy includes many causes of neonatal hypotonia,
Prader-Willi and Angelman Syndromes
25
particularly neuromuscular disorders. In childhood, syndromes presenting with mental retardation and obesity should be taken into account (Bardet-Biedl syndrome, Cohen syndrome and Albright hereditary osteodystrophy) [19].
Angelman Syndrome
The disorder, first described in 1965 by Angelman, has an estimated incidence between 1 in 10,000 and 1 in 40,000. The main clinical features are learning disability, ataxic and jerky movements, seizures, absent speech and happy, sociable disposition. Severe developmental delay and absent speech (fewer than 6 words) are seen in almost all patients. Most individuals are able to walk independently at between 2.5 and 5 years, with a characteristic jerky, stiff gait with upraised arms resembling a puppet-like gait; however, few patients remain nonambulatory. In spite of the severe speech impairment, many can communicate in other ways, such as sign language [20]. Birth growth parameters are normal, but frequently there is a slow down in growth of head circumference, usually resulting in microcephaly by age of 2 years. Facial dysmorphisms include deep-set eyes, large mouth with protruding tongue, widely spaced teeth and prominent chin. Skin hypopigmentation may be present. Seizures, varying from major motor to akinetic, usually begin before 3 years of age and can be severe, but many patients show improvement with age. Typical electroencephalographic patterns are described in AS and may suggest this diagnosis. Behavioral features of patients are sociable attitude, frequent laughter, hyperactivity, stereotypies such as hand flapping or twirling, attraction to water and fascination for shiny objects (mirror or plastic). In infancy, feeding problems are reported. Patients may have sleep disturbance with decreased need for sleep. In adult life, obesity and scoliosis develop frequently [20, 21]. AS is caused by a variety of genetic mechanisms (fig. 3) affecting the chromosome region 15q11-q13 [14] and classification by molecular defect shows some correlation to the clinical phenotype [22]. Patients with maternal deletion (70%) generally have a more severe phenotype including microcephaly, seizures, motor difficulties and language impairment. Physical features are clearly recognized and hypopigmentation of skin and eyes is common. Patients with paternal UPD (3–5%) show a milder phenotype: they have better physical growth, ataxia is less frequent and seizures have a lower prevalence. Facial features are more subtle and communication skills are better than in the deletion group. Patients with imprinting defect (2–5%) rarely have microcephaly and seizures are less frequent. They have a relatively better developmental and language ability, especially those who are mosaic for the imprinting defect. Patients with UBE3A mutation show generally some typical facial features and a smaller head size. Seizures are present in 50% of the patients. Compared to the deletion group, ataxia is less frequent, and development and language ability can be better. The differential diagnoses for AS include other genetic syndromes with mental retardation, absence of speech and seizures: Rett syndrome, 22q13.3 terminal deletion,
26
Gurrieri · Accadia
Mowat-Wilson syndrome, alpha-thalassemia X-linked mental retardation (ATR-X) syndrome, Pitt-Hopkins syndrome and X-linked AS-like [23–25].
Genetic Counseling
It is currently crucial to identify the specific genetic mechanism that leads to PWS or AS in a given patient. This is not in the interest of phenotype-genotype correlation, but rather for the sake of counseling the parents about risk of recurrence. In fact, whereas deletions and uniparental disomies are sporadic events and therefore imply a low recurrence risk, imprinting defects and maternally inherited UBE3A mutation on the other hand have a 50% recurrence risk [14].
References 1 Linder D, McCaw BK, Hecht F: Parthenogenic origin of benign ovarian teratomas. N Engl J Med 1975; 292:63–66. 2 Kajii T, Ohama K: Androgenetic origin of hydatidiform mole. Nature 1977;268:633–634. 3 McGrath J, Solter D: Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 1984;37:179–183. 4 Cattanach BM, Kirk M: Differential activity of maternally and paternally derived chromosome regions in mice. Nature 1985;315:496–498. 5 Slack JM: Conrad Hal Waddington: the last Renaissance biologist? Nat Rev Genet 2002;3:889– 895. 6 Holliday R: Epigenetics: a historical overview. Epigenetics 2006;1:76–80. 7 Hall JG: Genomic imprinting: review and relevance to human diseases. Am J Hum Genet 1990;46:857– 873. 8 Reik W, Dean W, Walter J : Epigenetic reprogramming in mammalian development. Science 2001; 293:1089–1093. 9 Morgan HD, Sutherland HG, Martin DI, Whitelaw E: Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999;23:314–318. 10 Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M : Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 1989;342:281–285. 11 Shemer R, Hershko AY, Perk J, Mostoslavsky R, Tsuberi B, Cedar H, Buiting K, Razin A: The imprinting box of the Prader-Willi/Angelman syndrome domain. Nat Genet 2000;26:440–443.
Prader-Willi and Angelman Syndromes
12 King RA, Wiesner GL, Townsend D, White JG: Hypopigmentation in Angelman syndrome. Am J Med Genet 1993;46:40–44. 13 Kishino T, Lalande M, Wagstaff J: UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997;15:70–73. Erratum in: Nat Genet 1997;15:411. 14 Cassidy SB, Dykens E, Williams CA: Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet 2000;97:136–146. 15 Hore TA, Rapkins RW, Graves JA: Construction and evolution of imprinted loci in mammals. Trends Genet 2007;23:440–448. 16 Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H: Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792–798. 17 Cassidy SB: Prader-Willi syndrome. J Med Genet 1997;34:917–923. 18 Tauber M, Diene G, Molinas C, Hébert M: Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet 2008;146A:881– 887. 19 Gunay-Aygun M, Cassidy SB, Nicholls RD: PraderWilli and other syndromes associated with obesity and mental retardation. Behav Genet 1997;27:307– 324. 20 Clayton-Smith J, Laan L: Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87–95. 21 Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, Magenis RE, Moncla A, Schinzel AA, Summers JA, Wagstaff J: Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet 2006;140A:413–418.
27
22 Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, Theriaque D, Hutson A, Nicholls RD, Zori RT, Williams CA, Driscoll DJ: Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet 2001;38:834–845. 23 Williams CA, Lossie A, Driscoll D : Angelman syndrome: mimicking conditions and phenotypes. Am J Med Genet 2001;101:59–64. 24 Zweier C, Peippo MM, Hoyer J, et al: Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (PittHopkins syndrome). Am J Hum Genet 2007;80: 994–1001.
25 Gilfillan GD, Selmer KK, Roxrud I, et al: SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. Am J Hum Genet 2008;82:1003–1010.
Fiorella Gurrieri, MD Istituto di Genetica Medica Università Cattolica del Sacro Cuore Largo F. Vito, 1, IT–00168 Roma (Italy) Tel. +39 0630 154 927; Fax +39 0635 0031, E-Mail
[email protected]
28
Gurrieri · Accadia
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 29–37
Muscle Involvement and IGF-1 Signaling in Genetic Disorders: New Therapeutic Approaches Laura Barberi ⭈ Gabriella Dobrowolny ⭈ Laura Pelosi ⭈ Cristina Giacinti ⭈ Antonio Musarò Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Histology and Medical Embryology, CE-BEMM, and Interuniversity Institute of Myology, Sapienza University of Rome, Rome, Italy
Abstract In the last decade, dramatic progress has been made in elucidating the molecular defects underlying a number of muscle diseases. With the characterization of mutations responsible for muscle dysfunction in several inherited pathologies, and the identification of novel signaling pathways, subtle alterations in which can lead to significant defects in muscle metabolism, the field is poised to devise successful strategies for treatment of this debilitating and often fatal group of human ailments. Yet progress has been slow in therapeutic applications of our newly gained knowledge. The complexity of muscle types, the intimate relationship between structural integrity and mechanical function, and the sensitivity of skeletal muscle to metabolic perturbations have impeded rapid progress in successful clinical intervention. The relatively poor regenerative properties of striated muscle compound the devastating effects of muscle degeneration. Perhaps the most difficult hurdle is the sheer volume of tissue that must be treated to effect a significant improvement in quality of life. Recent studies on the role of insulin-like growth factor–1 in skeletal muscle growth and homeostasis have excited new interest in this important mediator of anabolic pathways and suggest promising new avenues for intervention in catabolic disease. In this review, we will discuss the potential therapeutic role of local insulin-like growth factor 1 in the treatment of muscle wasting associated with muscle Copyright © 2009 S. Karger AG, Basel diseases.
Although the genetic defects responsible for muscle dysfunction in several inherited pathologies have been well characterized, the molecular basis of muscle wasting remains elusive. It is generally accepted that the primary cause of functional impairment in muscle is a cumulative failure to repair damage related to an overall decrease in anabolic processes. In the last decade, dramatic progress has been made in elucidating the molecular defects underlying a number of muscle diseases. However, the complexity of muscle
types, the intimate relationship between structural integrity and mechanical function, and the sensitivity of skeletal muscle to metabolic perturbations have impeded rapid progress in successful clinical intervention. In addition, the relatively poor regenerative properties of striated muscle compound the devastating effects of muscle degeneration. In this context, where direct therapeutic approaches to redress the primary disease are still suboptimal, it may be more effective to focus on strategies for improving skeletal muscle function. In this review we will discuss the potential therapeutic role of insulin-like growth factor 1 (IGF-1) in the treatment of muscle wasting associated with several muscle diseases.
Molecular Complexities of IGF-1 Transcription
IGF-1 controls growth and metabolism in several organs and tissues during both embryonic and postnatal development [1, 2]. At the structural level, IGF-1 is related to insulin with which it shares a 50% amino acid identity. Unlike the insulin gene, the IGF-1 gene locus encodes multiple proteins with variable N-terminal and C-terminal amino acid sequences. The amino acid sequence of the mature peptide differs from that of insulin by retention of the C peptide, by a short extension of the A chain to include a novel domain D, and by the presence of variable C-terminal E peptides (fig. 1). Although the IGF-1 gene is highly conserved in numerous species, its relatively large size (over 70 kb), combined with complex transcriptional and splicing patterns, has complicated its analysis. The primary structure of IGF-1 is highly conserved in placental mammalian species: canine [3], bovine [4], ovine [5], porcine [6] and human [7] IGF-Is are identical, whereas rat [8] and mouse [9] IGF-1s differ from human by 3 and 4 amino acids, respectively, and there is only one amino acid difference between these rodent IGF-1s. The rodent IGF-1 gene contains six exons, separated by five introns (fig. 1). Exons 1 and 2 encode distinct 5´UTRs, as well as different parts of the signal peptide, and are therefore termed leader exons. Exon 3 encodes 27 amino acids that are part of the signal peptide and common to all isoforms, as well as part of the mature IGF-1 peptide. Exon 4 encodes the rest of the mature peptide and 16 amino acids of the aminoterminal region of the E-peptide, which is also common to all IGF-1 mRNAs. Exons 5 and 6 encode two distinct carboxy-terminal E-peptides and the 3´UTR. Two promoters initiating at alternate 5⬘exons add further complexity. Although IGF-1 transcripts are not exclusively tissue-restricted, those that initiate at exon 2 predominate in the liver, are highly growth hormone responsive and as such are major endocrine effectors of GH [10]. By contrast, transcripts initiating at exon 1 are widely
30
Barberi · Dobrowolny · Pelosi · Giacinti · Musarò
Exon 1
Exon 2
Exon 3 B
Class 2 Class 1
Exon 4 B C
A
Exon 5
Exon 6
D Eb/MGF Ea
Fig. 1. Schematic representation of a rodent IGF-1 gene. The rodent IGF-1 gene contains six exons (filled boxes), separated by five introns (dashes). Both exons 1 and 2 contain multiple transcription start sites (horizontal arrows). Translation initiation codons (AUG) are located at exons 1, 2 and 3 (vertical arrows). These exons code for the signal peptide of precursor IGF-1. Exons 5 and 6 each encode distinct portions of the E peptides.
expressed in all tissues, and are less affected by circulating growth hormone levels, presumably performing autocrine or paracrine functions. The alternate splicing at the 5⬘ ends of these two IGF-1 transcripts generates different signal peptides, which purportedly affects the precise N-terminal pro-peptide cleavage site [10, 11]. The functions of the proteins encoded by these different transcripts are widely debated but a cohesive picture has yet to emerge. Elucidation of isoform function is also complicated by alternate splicing at the 3⬘ end of IGF-1 transcripts. This produces variability in the length and amino acid sequence of the E peptide, and in the length and base sequence of the 3⬘UTR. To date, two different splice patterns have been documented in rodents (fig. 1). Each generates E peptides with a common N-terminal 16 aa sequence, and alternate C-terminal sequences [10–13]. If exon 4 splices to exon 6 (the predominant pattern), the length of the 3⬘UTR is highly variable, but in all cases the Ea peptide is generated with 19 additional amino acids. If exon 4 splices to exons 5 and 6, a variant known as Eb is encoded, which is frameshifted relative to exon 6 and therefore a different 25 aa sequence is added to the common 16 aa encoded by exon 4. Although E peptide choice appears to be independent of promoter use, Eb-containing transcripts are more abundant in liver, whereas Ea-containing transcripts are widespread in extrahepatic tissues. In addition, the analysis of the amino acid structure of both E peptides has revealed the presence of two N-linked glycosylation sites only in the Ea peptide, but not in the Eb peptide, suggesting that this post-translational modification is involved in a biological action of the IGF-1 isoform [14]. The IGF-1Eb isoform is also upregulated in muscles subjected to stretch and has been named mechano growth factor (MGF) [13]. It has been also reported that, unlike mature IGF-1, the distinct E domain of MGF inhibits terminal differentiation whilst increasing myoblast proliferation [15]. The determination of E peptide function and fate awaits the availability of epitope-specific antibodies, since it is unclear when or whether E peptides are cleaved from the mature IGF-1 protein. Notably, E peptide
IGF-1 Counteracts Muscle Wasting
31
splicing patterns are different in the human gene [16], an anomaly that will need to be considered in the future when translating the results of animal research into clinical applications. In humans, three mRNA variants with alternatively spliced 3’-end have been identified [17]. Similarly to rat, splicing of human exon 4 to exon 6 yields an mRNA sequence which encodes the 35 amino acid Ea peptide [18], which shares 91% homology with the mouse Ea peptide [9]. The second mRNA splice variant identified in human liver is an exon 4–5 splice variant, which encodes an extension peptide termed Eb peptide [19, 20]. Human Eb peptide contains additional 61 amino acids encoded by exon 5 [20], giving rise to an E peptide with the total length of 77 amino acids. The third mRNA splice variant identified in human liver contains exon 4, 49 bp of exon 5 and then exon 6 (exons 4–5–6) and yields an extension peptide with a total predicted length of 41 amino acids, termed Ec peptide [21]. This human Ec peptide shares 73% homology with rat Eb peptide (MGF) and is considered to be its counterpart [21]. Possible existence of the exon 4–5 splice variant, which codes for Eb peptide in humans, was also predicted in rats [8].
Importance of IGF-1 Isoforms
Analyses of transgenic mice expressing different IGF-1 isoforms have provided insight into the role of local IGF-1 signaling in the physiology of striated muscle [22]. By controlling the transcription of IGF-1 transgenes with different promoters, it has been possible to characterize the role of the local and/or circulating form of IGF-1 on muscle cell and tissue function [22]. The fact that IGF-1 can act either as a circulating hormone or as a local growth factor has confounded previous analyses of animal models in which transgenic IGF-1 synthesized in extrahepatic tissues was released into the circulation [23, 24]. Overexpression of one IGF-1 isoform in the heart prevented activation of cell death in the viable myocardium after infarction, limiting ventricular dilation, myocardial loading, cardiac hypertrophy, and diabetic cardiomyopathy, supporting the notion that constitutive over-expression of IGF-1 in cardiomyocytes protects them from apoptosis and hypertrophy in the normal and pathological heart [23]. In another study, overexpression of a different IGF-1transgene in the heart induced physiological cardiac hypertrophy that progressed to maladaptive hypertrophy [25]. The transgenic IGF-1 model generated in this study demonstrated that short-term systolic performance benefit of increased IGF-1, but ultimately it diminishes systolic performance raising doubt about the therapeutic value of chronic IGF-1 administration. The discrepancies in these phenotypes underscore the normal physiological difference between IGF-1 isoform function. Promising a survival factor as IGF-1 might be, substantial evidence supports its involvement in mitogenesis and neoplastic transformation [26], suggesting that this signaling pathway plays an important role in the
32
Barberi · Dobrowolny · Pelosi · Giacinti · Musarò
process of tumor promotion. The neoplastic potential of at least certain IGF-1 isoforms is an obvious concern to be taken into account when designing IGF-therapeutic strategies for human pathologies, where the specific role of each IGF-1 isoform must be viewed in the appropriate tissue context.
Effects of the Local Isoform of IGF-1 on Muscle Homeostasis and Regeneration
The prolongation of skeletal muscle strength in aging and neuromuscular disease has been the objective of numerous studies employing a variety of approaches. IGF-1, involved in muscle growth and hypertrophy, decline during postnatal life, raising the prospect that this decline contributes to the progress of muscle atrophy in senescence, and limits the ability of skeletal muscle tissue to effect repair or to regenerate. To test this possibility we generated a transgenic mouse in which the local isoform of IGF-1 (mIGF-1) is driven by MLC promoter (MLC/mIGF-1) [27]. The MLC regulatory elements included in this construct activate linked gene expression as early as E9.5 days in embryonic mouse development, and expression continues to be high in the fastest type IIb fibers. Transgenic animals exhibits marked skeletal muscle hypertrophy and no undesirable side effects such as tumor formation, as revealed in transgenic mice over-expressing the circulating IGF-1 isoform. The importance of appropriate IGF-1 isoform selection is further underscored by preliminary analysis of mouse lines generated with a second IGF-1 transgene. The IGF-1 isoform used (cIGF-1) differed from the mIGF-1 transgene only in a variant C-terminal peptide, which was presumably responsible for the dramatic phenotypic differences of cIGF-1 mice. These animals did not display pronounced muscle hypertrophy but had increased levels of circulating IGF-1, mild cardiac hypertrophy, an increased incidence of late onset neoplasia [unpubl. obs.]. Thus, the choice of isoform is critical to the design of gene therapeutic strategies employing IGF-1. The increased muscle mass in mIGF-1 transgenic mice was associated with augmented force generation compared to age-matched wild-type littermates. Overexpression of the mIGF-1 transgene also promoted and preserved the regenerative capacity of muscle tissues and the ability to repair of damaged muscle during aging [27]. The anabolic effects of IGF-1 may be due in part to stimulation of activation of satellite cells [22]. It is not known whether in MLC/mIGF-1 transgenic animals, the satellite cells have an increased ability for self-renewal or whether there is an increased recruitment of nonsatellite cells. Our recent experimental evidence indicates that mIGF-1 promotes the two suggested pathways, which can be considered two temporally separated events of the same biological process.
IGF-1 Counteracts Muscle Wasting
33
We demonstrated that upon muscle injury, stem cells expressing c-Kit, Sca-1, and CD45 antigens increased locally and the percentage of the recruited cells were conspicuously enhanced by mIGF-1 expression [28]. FACS profiles of tissues from wild-type and MLC/mIGF-1 transgenic mice, whose muscles were injured with cardiotoxin, revealed a consistent increase of side population (SP) cells in the bone marrow, compared to noninjured controls whose percentages increase in MLC/mIGF-1 transgenic mice [28]. Thus, humoral signals emanating from the injured muscles were sufficient to induce stem cell proliferation in the bone marrow, but not in other tissues. One of the crucial parameters of tissue regeneration is the microenvironment in which the stem cell population should operate. Stem cell microenvironment, or niche, provides essential cues that regulate stem cell proliferation and that direct cell fate decisions and survival. Moreover, loss of control over these cell fate decisions might lead to cellular transformation and cancer. More recently, we investigated whether accelerating the course of muscle repair through mIGF-1 expression involves modulation of the inflammatory response, which represents one of the critical stages of tissue regeneration [29]. We show that local expression of mIGF-1 transgene accelerates the regenerative process of injured skeletal muscle, modulating the inflammatory response, and limiting fibrosis [29]. At the molecular level, mIGF-1 expression significantly downregulated proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, and modulated the expression of CC chemokines involved in the recruitment of monocytes/macrophages [29]. Analysis of the underlying molecular mechanisms revealed that mIGF-1 expression modulated key players of inflammatory response, such as macrophage migration inhibitory factor (MIF), high mobility group protein-1 (HMGB1), and transcription NF-κB [29]. The rapid restoration of injured mIGF-1 transgenic muscle was also associated with connective tissue remodeling and a rapid recovery of functional properties [29]. By modulating the inflammatory response and reducing fibrosis, supplemental mIGF-1 creates a qualitatively different environment for sustaining more efficient muscle regeneration and repair. Thus, mIGF-1 can overcome the normal inability of skeletal muscle to sustain regeneration and repair and as such represents a potentially effective gene therapeutic strategy to combat muscle wasting.
Effects of mIGF-1 on Muscular Dystrophy and Muscle Wasting
Because it is clear that mIGF-1 can prevent aging- related loss of muscle function [28, 22], it is possible that mIGF-1 can prevent or diminish muscle loss associated with disease.
34
Barberi · Dobrowolny · Pelosi · Giacinti · Musarò
To prove this hypothesis, we introduced mIGF-1 into the mdx dystrophic animals (mdx/mIGF-1) [30]. This approach allowed for the assessment of the maximum potential benefit that could be derived from IGF-I expression for dystrophic muscle, as well as examination of both the diaphragm and the extensor digitorum longus (EDL), which display a spectrum of dystrophic pathologies. By analyzing both muscle morphology and function in transgenic mdx/mIGF-1, we observed a significant improvement in muscle mass and strength, a decrease in myonecrosis, and a reduction in fibrosis in aged diaphragms [30]. In particular, even though IGF-1 has been shown to stimulate fibroblasts, there was a net decrease in fibrosis in diaphragms of the mdx/mIGF-1 mice [30]. In fact, age-related fibrosis in the mdx diaphragm was effectively eliminated by mIGF-1 expression. It may be that the efficient and rapid repair of the mdx/mIGF-1 muscles prevents the establishment of an environment into which the fibroblasts migrate. This is of particular relevance to the human dystrophic condition where virtually all skeletal muscles succumb to fibrosis. Thus, the results found in the mouse diaphragm suggest that mIGF-1 might be effective not only in increasing muscle mass and strength, but also in reducing fibrosis associated with the disease. Finally, signaling pathways associated with muscle regeneration and protection against apoptosis were significantly elevated. These results suggest that a combination of promoting muscle regenerative capacity and preventing muscle necrosis could be an effective treatment for the secondary symptoms caused by the primary loss of dystrophin. More recently, Abmayr et al. [31] demonstrated that co-injection of the rAAVmicrodystrophin and rAAV-mIGF-1 vectors resulted in increased muscle mass and strength, reduced myofiber degeneration, and increased protection against contraction-induced injury. These results suggest that a dual-gene, combinatorial strategy could enhance the efficacy of gene therapy of DMD and underscored the importance of rAAV vectors due to their relative lack of immunologic and toxic side effect combined with their potential for body-wide systemic gene delivery to muscle [31]. Recent studies on the role of mIGF-1 in skeletal muscle growth and homeostasis have excited new interest in this important mediator of anabolic pathways and suggest promising new avenues for intervention in different catabolic diseases. Indeed, it has been recently reported that transgenic overexpression of mIGF-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction (CLVD) [32] and counteracts the symptoms of amyotrophic lateral sclerosis (ALS) [33, 34], a progressive, lethal neuromuscular disease associated with the degeneration of motor neurons, leading to muscle atrophy and paralysis [34]. In particular, we demonstrated that mIGF-1 induces satellite cell activity, stabilizes neuromuscular junctions and leads to a reduction in astrocytosis in the spinal cord of ALS mouse model [33, 34].
IGF-1 Counteracts Muscle Wasting
35
Conclusions
Although the evidence to date for growth factor supplementation is encouraging, it remains to be determined which IGF-1 isoforms or combination of growth factors elicit the most effective response. These preliminary studies provide exciting avenues for future discovery, however true innovation in this field will undoubtedly derive from the integration of our insights with other key advances in regenerative research, to achieve precise modulation of the regenerative response, and to form a cohesive and coherent strategy that addresses the short-term, medium and long-term aspects of the therapeutic process.
Acknowledgments Work in the authors’ laboratories has been supported by Italian Telethon, MDA, AIRC, ASI, AFM and Progetti Ricerca Università.
References 1
2
3
4
5
6
7
8
36
Stewart CE, Rotwein P: Growth, differentiation, and survival: multiple physiological functions for insulinlike growth factors. Physiol Rev 1996;76:1005–1026. Butler AA, LeRoith D: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001;142:1685–1688. Delafontaine P, Lou H, Harrison DG, Bernstein KE: Sequence of a cDNA encoding dog insulin-like growth factor I. Gene 1993;130:305–306. Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC: Insulin-like growth factors I and II in bovine colostrums: sequences and biological activities compared with those of a potent truncated form. Biochem J 1988;251:95–103. Francis GL, McNeil KA, Wallace JC, Ballard FJ, Owens PC: Sheep insulin-like growth factors I and II: sequences, activities and assays. Endocrinology 1989;124:1173–1183. Francis GL, Owens PC, McNeil KA, Wallace JC, Ballard FJ: Purification, amino acid sequences and assay crossreactivities of porcine insulin-like growth factor-I and –II. J Endocrinol 1989;122:681–687. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769–2776. Shimatsu A, Rotwein P: Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene. J Biol Chem 1987;262:7894–7900.
9 Bell GI, Stempien MM, Fong NM, Rall LB: Sequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursors. Nucleic Acid Res 1986;14:7873–7882. 10 LeRoith D, Roberts CT Jr: Insulin-like growth factor I (IGF-I): a molecular basis for endocrine versus local action? Mol Cell Endocrinol 1991;77:C57–61. 11 Adamo ML, Ben-Hur H, Roberts CT Jr, LeRoith D: Regulation of start site usage in the leader exons of the rat insulin-like growth factor-I gene by development, fasting, and diabetes. Mol Endocrinol 1991;5: 1677–1686. 12 LeRoith D, Roberts, CT Jr: Insulin-like growth factors. Ann NY Acad Sci 1993;692:1–9. 13 McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G: Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 1999;516:583–592. 14 Bach MA, Roberts CT Jr, Smith EP, LeRoith D: Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol Endocrinol 1990;4:899–904. 15 Yang SY, Goldspink G: Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett 2002; 522:156–160. 16 Adamo ML, Neuenschwander S, LeRoith D, Roberts CT Jr: Structure, expression, and regulation of the IGF-I gene. Adv Exp Med Biol 1993;343:1–11.
Barberi · Dobrowolny · Pelosi · Giacinti · Musarò
17 Shavlakadze T, Winn N, Rosenthal N, Grounds MD: Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 2005;15:4–18. 18 Jansen M, van Schaik FM, Ricker AT, Bullock B, Woods DE, Gabbay KH, Nussbaum AL, Sussenbach JS, Van den Brande JL: Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature 1983;306:609–611. 19 Rotwein P, Pollock KM, Didier DK, Krivi GG: Organization and sequence of the human insulinlike growth factor I gene. J Biol Chem 1986;261: 4828–4832. 20 Rotwein P: Two insulin-like growth factor I messenger RNAs are expressed in human liver, Proc Natl Acad Sci USA 1986;83:77–81. 21 Chew SL, Lavender P, Clark AJ, Ross RJ: An alternatively spliced human insulin-like growth factor-I transcript with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide. Endocrinology 1995;136:1939–1944. 22 Musarò A, Rosenthal N: The critical role of insulinlike growth factor-1 isoforms in the physiopathology of skeletal muscle. Curr Genomics 2006;3: 19–32. 23 Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J 1999;13:1923–1929. 24 Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P: J Clin Invest 1997;100: 1991–1999. 25 Leri A, Liu Y, Wang X, Kajstura J, Malhotra A, Meggs LG, Anversa P: Overexpression of insulinlike growth factor-1 attenuates the myocyte reninangiotensin system in transgenic mice. Circ Res 1999;84:752–762. 26 Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505–18.
27 Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N: Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195– 200. 28 Musarò A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, Ottolenghi S, Bernardi G, Cossu G, Battistini L, Molinaro M, Rosenthal N: Muscle restricted expression of mIGF-1 enhances the recruitment of stem cells during muscle regeneration. Proc Natl Acad Sci USA 2004;101:1206–1210. 29 Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musarò A: Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J 2007;21:1393–1402. 30 Barton ER, Morris L, Musaro A, Rosenthal N, and Sweeney HL: Muscle specific expression of Insulinlike Growth Factor I counters muscle decline in mdx mice. J Cell Biol 2002;157:137–147. 31 Abmayr S, Gregorevic P, Allen JM, Chamberlain JS: Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther 2005;12:441–450. 32 Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, Lee RT, Rosenthal N: Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005;97:418–426. 33 Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, Molinaro M, Rosenthal N, Musarò A: Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005;168:193–199. 34 Musarò A, Dobrowolny G, Rosenthal N: The neuroprotective effects of a locally acting IGF-1 isoform. Exp Gerontol 2007;42:76–80.
Antonio Musarò; MD Department of Histology and Medical Embryology Via A. Scarpa14 IT–00161 Rome (Italy) Tel. +39 0649 766 956, Fax +39 06 44 62 854, E-Mail
[email protected]
IGF-1 Counteracts Muscle Wasting
37
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 38–52
Mitochondrial Encephalomyopathies and Related Syndromes: Brief Review Enrico Bertini ⭈ Adele D’Amico Bambino Gesu’ Children’s Research Hospital, Unit of Molecular Medicine for Neuromuscular and Neurodegenerative Disorders, Department of Laboratory Medicine, Rome, Italy
Abstract A brief and comprehensive review on mitochondrial cytopathies is reported showing the extreme clinical and genetic heterogeneity of these disorders. Syndromes of mitochondrial cytopathies encompass most of the medical specialties and diagnosis of mitochondrial cytopathies is complicated, needing the combination of multiple expertise: muscle morphology, neuroradiology, bioCopyright © 2009 S. Karger AG, Basel chemistry (enzymology, chemical analysis), and genetics.
Mitochondria have their own distinct DNA. Each mitochondrion contains several circular double-stranded DNA copies that are normally 16,569 bp in length. Each copy contains 37 genes that code for several respiratory chain structural proteins and for mitochondrial DNA transcription and translation (22 tRNAs) factors. Mitochondrial DNA abnormalities were first linked to human disease in 1988. In that year, Leber’s hereditary optic neuropathy and several progressive muscle disorders were found to be caused by mutations in mitochondrial DNA [1, 2]. Aerobic metabolism depends on the hundreds of mitochondria that every cell in the body contains. Cellular dysfunction results when the proportion of mutated mitochondrial DNA strands exceeds a threshold level. Because sperm do not contribute with mitochondria to the zygote, mutations in mitochondrial DNA are classically inherited only from the mother (maternal inheritance). Mitochondria have their own distinct DNA. The proportion of mutated mitochondria can differ widely from one oocyte to the other. Consequently, siblings can have widely varying symptoms and severity of disease. Similarly, the proportion of mutant mitochondrial DNA differs from cell to cell in an embryo, so different daughter cell lines can have widely varying levels of cell dysfunction. Slightly later it became evident that also defects in chromosomal DNA can also cause mitochondrial disease, because chromosomal DNA supplies most of the proteins necessary for mitochondrial DNA replication and expression. These conditions
were inherited by a Mendelian trait in an autosomal-dominant or autosomal-recessive fashion [3]. Describing an overview of mitochondrial encepahlomyopathies, we will keep with the concept that the term ‘mitochondrial encephalomyopathy’ or mitochondrial cytopathy (MC) refers to defects of oxidative phosphorylation of the mitochondrial respiratory chain, excluding other mitochondrial disorders related to other mitochondrial functions such as iron homeostasis, β-oxidation, etc. The clinical presentation in these disorders is extraordinarily heterogeneous, because any tissue can be affected, isolatedly or multisystemically. First of all, symptoms may begin at any age but the first symptoms are observed before 1 month of age in more than one third of the cases and before the age of 2 years in 80% of the cases [4]. Tissues that are highly energy dependent are more frequently affected, such as brain, skeletal muscle, heart and kidney. Skeletal muscle is the most often affected tissue, suggesting that these are somatic mutations, that is, spontaneous events that arose in myoblasts or in myoblast precursors after germ-layer differentiation. Pure myopathy, dominated by exercise intolerance with or without myoglobinuria, is generally highly evocative for a mitochondrial encephalomyopathy. Exercise intolerance is a common complaint, which, if the patient has no objective weakness, increased serum creatine kinase (CK) levels or abnormal electromyography (EMG), is often dismissed as ‘psychogenic’ or mislabeled as ‘chronic fatigue syndrome’ or ‘fibromyalgia rheumatica’. Many patients with mutations in mtDNA protein-coding genes fall into this group, and the lack of maternal inheritance further deflects the physician from thinking about a mitochondrial cytopathy. When faced with these puzzling patients, it is important to consider the possibility of a mitochondrial disease and to obtain, at least, a resting lactate value. Myoglobinuria, and especially recurrent myoglobinuria, is commonly associated with blocks in the utilization of the two major sources of energy for muscle contraction, glycogen or fatty acids [5]. Another special symptom that may occur in a mitochondrial encephalomyopathy is sideroblastic anemia or megaloblastic anemia generally associated with complex I deficiency. The fact that tissues other than muscle can be affected selectively suggests that we should keep an open mind about the possibility that somatic mutations of mtDNA protein-coding genes may be involved in other tissue-specific disorders such as cardiopathy or encephalopathy. A multisystemic presentation affecting multiple tissues is highly evocative of a mitochondrial encephalomyopathy; however, it is important that the clinician confirms the clinical suspect searching for persistent or fluctuating increased lactate in blood, urine and CSF or by MR spectroscopy. If lactate is not increased further work for molecular genetic confirmation is not recommended. The diagnostic approach of mitochondrial encephalomyopathies is complicated, and needs the combination of multiple expertise: muscle morphology, neuroradiology, biochemistry (enzymology, chemical analysis), and genetics.
Mitochondrial Encephalomyopathies
39
In muscle morphology, ragged-red fibers (RRF), the histochemical hallmark of massive mitochondrial proliferation in muscle, are typically seen in patients with mtDNA mutations that impair overall mitochondrial protein synthesis, such as mutations in tRNA or rRNA genes, single or multiple deletions, or mtDNA depletion (most frequent and known phenotypes are MELAS, MERFF, Pearson syndrome, KearnSayre syndrome (KSS), PEO). Conversely, RRF are absent in muscle biopsies from patients with mutations in mtDNA protein-coding genes, such as the NARP/MILS mutations in the ATPase 6 gene, or the various mutations in genes encoding complex 1 subunits (ND genes) associated with Leber’s hereditary optic neuropathy (LHON).
Genetics
Mitochondrial diseases can be due to mitochondrial DNA (mtDNA) mutations or mutations in nuclear genes. Mitochondrial DNA is more subjected to mutations because mtDNA is more susceptible to damage by ROS resulting from low efficiency of mtDNA repair systems, lack of protection by histones, and unique structural characteristics favoring mutations [6]. Point mutations in mitochondrial DNA (mtDNA) are generally transmitted by maternal inheritance; however, point mutations in protein-coding genes may arise de novo and cause sporadic disorders. Moreover, severe large-scale deletions of mtDNA rearrangements are rarely segregated through generations and frequently arise sporadically. With time, nuclear DNA mutations have been identified as being responsible for respiratory chain defects [6]. Two of the four most common causes of Leigh syndrome, a devastating neurodegenerative disease of infancy or childhood, are due to specific respiratory chain defects: complex I deficiency, and COX deficiency due to SURF-I deficiency [7, 8]. Both conditions are inherited as autosomal-recessive traits. The product of SURF-I is indeed a mítochondrial protein, which appears to act at the third stage in the four-step process of COX assembly. The other two common causes of Leigh syndrome are pyruvate dehydrogenase complex (PDHC) deficiency and the T8993G mutation in the mtDNA ATPase 6 gene. PDHC deficiency is usually inherited as an X-Iinked dominant trait while the T8993G mutation is the most common cause of maternally inherited Leigh syndrome (MILS). In addition to SURFI, other COX assembly genes were studied, and pathogenic mutations were found in the SC02 gene in 3 infants with fatal infantile cardiomyopathy and encephalopathy, but without the typical neuropathological features of Leigh syndrome [7]. The SC02 gene encodes a copper-binding protein that must play a crucial role in the assembly of COX, which contains two copper atoms. This essential function coupled with Northern blot provides evidence that the SC02 protein is expressed predominantly in heart and muscle and explains both the clinical phenotype and the extremely low levels of COX activity found in heart and muscle.
40
Bertini · D’Amico
A special group of Mendelian mitochondrial diseases reflects the gradual loss of autonomy of the mitochondrial genome, which now depends heavily on factors encoded by nuclear genes for some of its essential functions, including transcription, translation, and replication. Disorders of intergenomic signaling are due to mutations in nuclear genes that, directly or indirectly, control mtDNA number, function, or integrity. The first examples of such faulty ‘dialogue’ between the two genomes was offered by patients with autosomal-dominant progressive external ophthalmoplegia (PEO) and multiple mtDNA deletions in muscle (instead of the single type of mtDNA rearrangement that characterizes each patient with KSS or sporadic PEO) [7]. Another disorder of intergenomic communication, resulting in tissue-specific paucity of mtDNA copies (‘mtDNA depletion’), was described in infants with severe congenital myopathy or hepatopathy [3]. There are milder myopathic forms of mtDNA depletion and the clinical spectrum may involve both central and peripheral nervous systems. Several genetic defects have been characterized for conditions related to mtDNA depletion and others still remain elusive. A defect of polymerase-γ (POLG) has been reported in children with Alpers syndrome and mtDNA depletion, and in adults affected by neuropathy and ataxia inherited as an autosomal-recessive trait [9], and dominant polymerase-γ deficiency has also been found in adult patients with autosomal-dominant PEO. Another example of disorder of intergenomic signaling is an autosomal-recessive form of PEO known with the acronym of MNGIE, for mitochondrial neurogastrointestinal encephalomyopathy dominated by gastrointestinal problems (chronic diarrhea, intestinal pseudoobstruction) leading to cachexia and early death. The gene was characterized by Nishino et al. [10] in 1999 as thymidine phosphorylase (TP). TP is widely expressed in human tissues, including some that are selectively involved in MNGIE, such as the gastrointestinal system, brain, and peripheral nerves. Additional symptoms and signs include ptosis and ophthalmoplegia, peripheral neuropathy, and leukoencephalopathy. In contrast to the autosomal-dominant forms of PEO, which are largely confined to muscle, autosomal recessive PEO syndromes with multiple mtDNA deletions tend to be multisystemic [7]. Muscle biopsy shows COX-negative RRF, biochemical evidence of COX deficiency, and molecular evidence of mtDNA multiple deletions, sometimes associated with mtDNA depletion [7]. We will now summarize below the main clinical presentations of mitochondrial cytopathies (MC) dividing them systematically by the different tissues predominantly involved (table 1).
Syndromes in Mitochondrial Cytopathies
Myopathy Myopathy is a frequent feature in MC. It is responsible for muscle weakness with myalgia and exercise intolerance [7]. Sometimes rabdomyolysis can be the leading symptom.
Mitochondrial Encephalomyopathies
41
Table 1. Main symptoms of mitochondrial cytopathies Affected organ
Symptoms
Central nervous system
apnea, lethargy, hypotonia, coma in the neonatal period, hypotonia, psychomotor regression, cerebellar ataxia, stroke-like episodes, myoclonus, seizures, dementia, spasticity, headache, hemiparesis in infants and children, leukodystrophy, myoclonus
Muscle
myopathy, poor head control, limb weakness, myalgia, exercise intolerance, rhabdomyolysis
Liver
liver enlargement, hepatocellular dysfunction
Heart
cardiomyopathy, heart block
Kidney
proximal tubulopathy, nephrotic syndrome, renal failure, tubulointerstitial nephritis
Gut
vomiting, diarrhea, villous atrophy, colonic pseudo-obstruction, exocrine pancreas dysfunction
Endocrine
diabetes mellitus, growth hormone deficiency, hypoparathyroidism, hypothyroidism
Bone marrow
sideroblastic anemia, neutropenia, thrombocytopenia
Ear
hearing loss
Eye
progressive external ophthalmoplegia, pigment retinal degeneration, ptosis, diplopia, cataract
Skin
mottled pigmentation, discoloration, acrocyanosis, vitiligo, cutis marmorata, anhydrosis and jaundice; trichothiodystrophy, hirsutism alopecia, alopecia with brittle hair; symmetric cervical lipomas
Limb weakness may be associated with chronic progressive external ophthalmoplegia (PEO). The main features of PEO are ptosis, limitation of eye movements and diplopia. While PEO may be isolated, it is often part of KSS characterized by the association of PEO, pigment retinopathy, ataxia and heart block occurring before the age of 20 [11].
Central Nervous System A number of patients show symptoms involving predominantly or exclusively the central nervous system. These symptoms are variably associated and consist of psychomotor retardation, seizures, stroke, sensorineural hearing loss, optic atrophy, ataxia, myoclonus, peripheral neuropathy, dementia. Several clinicopathological entities such as KSS, MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), MERRF (myoclonus epilepsy and ragged red fibers), Leigh syndrome [12] and Alpers syndrome [13] have been described according to clinical
42
Bertini · D’Amico
presentations. There are several reports of patients with overlap syndromes such as KSS and MELAS, KSS and MERRF, PEO and MERRF or MERRF and MELAS. Recently, new neurological syndromes have been related to mutations in autosomalrecessive genes which affect the mRNA translation machinery and in which biochemical assessment of muscle biopsy for the mitochondrial respiratory chain enzymes is frequently normal or not helpful to address genetic confirmation. Mutations affecting elongation factors are responsible for agenesis of the corpus callosum and dysmorphism and fatal neonatal lactic acidosis [14], encephalomyopathy and hypertrophic cardiomyopathy [15], lactic acidosis, diffuse cystic leukoencephalopathy, polymicrogyria, liver involvement and early death [16]. In addition, mutations affecting mitochondrial amino-acyl-tRNA synthetase give rise to autosomal-recessive leukoencephalopathy with brain stem and spinal cord involvement and elevated lactate (aspartyl-tRNA synthetase) [17] or autosomal-recessive pontocerebellar atrophy with lactic acidosis [18].
Kidney Renal disease is more frequently reported in children than adults. The most frequent renal manifestation is proximal tubulopathy with a de Toni-Debré-Fanconi syndrome. Other renal presentations have been reported, including glomerular disease with a nephrotic syndrome and chronic tubulointerstitial nephropathy [19]. The de Toni-Debré-Fanconi syndrome is characterized by impairment of proximal tubular reabsorption leading to urinary losses of amino acids, glucose, proteins, phosphate, uric acid, bicarbonate, potassium and water. Renal Fanconi syndrome has been reported as the most frequent renal disorder in MC [19]. Proximal tubular losses are often moderate as seen in a few patients presenting hyperaminoaciduria only. Other patients present with plasma acidosis, impaired tubular phosphate reabsorption, moderate glycosuria, hypercalciuria and tubular proteinuria. The first symptoms may develop in the neonatal period and before the age of 2 years in most patients. When reported, the renal biopsy shows more or less severe unspecific anomalies of tubular epithelium with dilations or obliterations by casts, dedifferentiation or atrophy. Some tubular cells show cytoplasmic vacuolization. Giant mitochondria are frequently observed ultrastructurally. Extrarenal symptoms are generally present in all patients with mitochondrial encephalomyopathies: myopathy or other neurological symptoms, hepatic dysfunction, Pearson syndrome, cardiac involvement or diabetes mellitus, hearing loss, growth retardation. Some patients may have signs of proximal tubular acidosis with hypercalciuria. The Bartter-like phenotype has rarely been reported [20]. Glomerular disease has been observed in a few patients with MC. Patients in whom renal biopsy had shown focal and segmental glomerular sclerosis were affected by a nephrotic syndrome [19]. One of them had a decrease in the glomerular filtration rate at 9 years of age. In addition, patients had myopathy, ophthalmoplegia,
Mitochondrial Encephalomyopathies
43
pigmentary retinopathy, hearing loss, and hypoparathyroidism. More recently, nephrotic syndrome and segmental glomerular sclerosis has been related to disorders of Coenzyme Q10 biogenetic genes [21–23]. Renal disease in patients with mitochondrial cytopathies may also consist of tubulointerstitial nephritis. Six patients with chronic renal insufficiency without proximal tubular losses have been reported [19]. Renal biopsy in patients showed diffuse interstitial fibrosis with tubular atrophy and sclerosed glomeruli within the area of interstitial fibrosis. All patients developed extrarenal symptoms including hearing loss, cardiomyopathy, myopathy, ataxia, developmental delay, ophthalmoplegia and diabetes mellitus.
Gut Gastrointestinal symptoms include recurrent vomiting, colonic pseudo-obstruction or untreatable diarrhea. Gastrointestinal symptoms are particularly frequent in a condition called mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) or POLIP (polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudoobstruction), an autosomal-recessive disease clinically defined by gastrointestinal dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral neuropathy, white-matter changes in brain magnetic resonance imaging, and mitochondrial abnormalities. Lossof-function mutations in thymidine phosphorylase gene induce pathologic accumulations of thymidine and deoxyuridine that in turn cause mitochondrial DNA (mtDNA) defects (depletion, multiple deletions, and point mutations). Another condition where gastrointestinal symptoms are prominent is ethylmalonic encephalopathy, a rare metabolic disorder with an autosomal-recessive mode of inheritance that is clinically characterized by neuromotor delay, hyperlactic acidemia, recurrent petechiae, orthostatic acrocyanosis, and chronic diarrhea. Increased urinary levels of ethylmalonic acid and methylsuccinic acid are the main biochemical features of the disorder [24, 25]. Villous atrophy syndrome has been recognized as an mtDNA rearrangement defect. A complex III deficiency was found in the muscle of affected patients. Southern blot analysis showed evidence of heteroplasmic mtDNA rearrangements that involved deletion and deletion duplication. Two different mutations were described in the 2 children reported. In 1 patient, a deletion spanning 3,380 bp encompassed 3 genes for complex I and 3 transfer ribonuclease genes. The deletion in the second patient was larger [26].
Heart Hypertrophic cardiomyopathy is the most commonly reported type of cardiomyopathy associated with MRC disorders [27]. Cardiac hypertrophy in these disorders
44
Bertini · D’Amico
is thought to result from an increased oxidative stress, and its pathogenetic mechanism is thought to involve a cross-talk mechanism between several cell-signaling pathways as well as several transcription factors. Supraventricular tachycardia (WolfParkinson-White syndrome) have rarely been reported in association with hypertrophic cardiomyopathy. Dilated cardiomyopathy was essentially as common as hypertrophic cardiomyopathy and a change in pattern (an ‘undulating cardiomyopathy type’) can be observed [27]. Dilated cardiomyopathy is thought to result from an acute oxidative stress as a result of a high surge in reactive oxygen species, inducing damage to the mitochondrial DNA, as shown in a mouse model. Cardiac conduction disturbances have been reported in KSS with large mitochondrial DNA deletions [28]. Repeat cardiac assessment as part of monitoring disease progression is warranted in patients with confirmed OXPHOS disorders, even in the absence of clinical cardiac symptoms. Patients with OXPHOS defects who present with primary cardiac manifestations have a poorer outcome.
Endocrine System Besides common syndromes of MELAS, patients have endocrine disorders such as dysfunction with growth hormone deficiency, hypothalamopituitary hypothyroidism, hypogonadotropic hypogonadism, hypoparathyroidism, diabetes and short stature [29]. The KSS, a form of mitochondrial myopathy, is also associated with a variety of endocrine and metabolic abnormalities, in particular growth hormone deficiency (short stature), hypogonadism, diabetes mellitus, thyroid disease, hyperaldosteronism, hypomagnesemia, as well as calcification abnormalities. These patients can also show features of Pearson’s syndrome, a rare, often fatal, disorder of infancy characterized by impaired bone marrow, exocrine pancreatic, hepatic and renal function and adrenal insufficiency [30]. Finally, a few patients with diabetes mellitus have mitochondrial disorders. Patients with KSS, MELAS syndrome and Wolfram syndrome may develop diabetes mellitus [6]. The MELAS mtDNA, involving the substitution of guanine for arginine at position 3243 of tRNA leu(UUR), have been described in several families with maternally transmitted diabetes as well as in sporadic cases with insulin-dependent diabetes mellitus or with non-insulin-dependent diabetes mellitus [31]. This mutation was also reported in a family with maternally inherited cardiomyopathy, diabetes mellitus, sensorineural deafness and renal failure that was not related to diabetes mellitus [6]. It may be postulated that mutations of mtDNA in pancreatic β cells contribute to the development of diabetes mellitus.
Mitochondrial Encephalomyopathies
45
Liver Hepatic manifestations of mitochondrial disorders range from hepatic steatosis, cholestasis, and chronic liver disease with insidious onset to neonatal liver failure, which is frequently associated with neuromuscular symptoms multisystem involvement, and lactic acidemia. The liver disease is usually progressive and eventually fatal. Current medical therapy of mitochondrial hepatopathies is largely ineffective, and the prognosis is usually poor. These disorders include primary disorders, in which the mitochondrial defect is the primary cause of the liver disorder, and secondary disorders, in which a secondary insult to mitochondria is caused either by a genetic defect that affects non-mitochondrial proteins or by an acquired (exogenous) injury to mitochondria. Examples of secondary mitochondrial hepatopathies include Reye syndrome, Wilson’s disease, valproic acid hepatotocixity [32]. Further divided primary mitochondrial diseases into those caused by mutations affecting mtDNA genes and those caused by mutations in nuclear genes that encode mitochondrial respiratory chain proteins or cofactors. Several specific molecular defects in nuclear genes (SCO1, BCS1L, POLG, DGUOK, and MPV17 and deletion or rearrangement of mitochondrial DNA) have been identified in recent years. Four male siblings with mitochondrial cytochrome c oxidase deficiency due to compound heterozygosity for mutations in the SCO1 gene have been reported. They were affected with predominantly hepatic failure in infancy, lactic acidosis, and neurodevelopmental delays. One patient died at age 2 months and a second at the age of 5 days. Histopathologic studies of the liver showed swollen hepatocytes with microvesicular lipid vacuoles and panlobular steatosis. A muscle biopsy sample showed an accumulation of lipid droplets. SCO1 mutations are associated with COX deficiency and SCO1 is a COX assembly nuclear gene. The SCO1 gene, located at chromosome 17p13.1, is believed to encode a protein functioning as a copper chaperone that transfers copper from Cox17p, a copper-binding protein of the cytosol and mitochondrial intermembrane space, to the mitochondrial COX subunit II. A mutation in BCS1L has been found to be associated with mitochondrial neonatal liver failure. A deficient activity of complex III of the respiratory chain in the liver was reported [32], fibroblasts, or muscle in affected infants with hepatic failure, lactic acidosis, renal tubulopathy, and variable degrees of encephalopathy. Three mutations in BCS1L were demonstrated in 3 affected families. Subsequently, it was confirmed that mutations in BCS1L were associated with fatal complex III deficiency and liver failure in 2 siblings. BCS1L is a nuclear gene encoding proteins involved in the assembly of respiratory complex III [32]. The mitochondrial deoxynucleoside salvage pathway is regulated by nuclear encoded enzymes, including dGK and TK2 [32]. Human dGK phosphorylates deoxyguanosine and deoxyadenosine, whereas TK2 phosphorylates deoxythymidine,
46
Bertini · D’Amico
deoxycytidine, and deoxyuridine. An imbalance of this mitochondrial dNTP pool has been proposed to be responsible for both the hepatocerebral and myopathic forms of MC.40 In 2001, mutations in 2 genes involved in this pathway were identified in patients with MC:deoxyguanosine kinase (DGUOK) in the hepatocerebral form and TK2 in the myopathic form [32]. Mandel et al. [33] using homozygosity mapping in 3 consanguineous kindreds affected with hepatocerebral MC, mapped this disease to chromosome 2p13, which encompasses the gene DGUOK encoding dGK. A single-nucleotide deletion (204delA) within the coding region of DGUOK was identified. The reduction of enzymatic activities of mitochondrial respiratory chain complexes containing mtDNA encoded subunits (complexes I, III and IV but not complex II, which is solely encoded by nuclear genes) was demonstrated in the liver but not in muscle, showing the tissuespecific nature of this disorder. However, Salviati et al. [34] screened the frequency of DGUOK mutations in 21 patients with hepatocerebral MC and noted that DGUOK mutations were present in only 14%, suggesting this was not the only gene responsible for MC in the liver. Patients with DGUOK mutations present with lactic acidosis, hepatomegaly, hypoglycemia, jaundice, and encephalopathy with hypotonia, hyperreflexia, and nystagmus, and oculogyric crises. Two other nuclear genes have recently been linked to the hepatocerebral form of MC [9, 35], POLG and MPV17. Mutations in DNA POLG, which is confined to mitochondria but encoded by a nuclear gene, have now been described in infants with MC and in older children with Alpers-Huttenlocher disease. Most of the cases with MC in early childhood are associated with at least 1 mutation in the linker region of POLG and 1 in the polymerase domain. More recently, Spinazzola et al. [35] used a novel integrative genomics approach to discover mutations in the nuclear gene MPV17 in 3 families affected by the hepatocerebral form of MC. This gene encodes an inner mitochondrial membrane protein of uncertain function. Mutations in POLG have recently been shown to be common in patients with Alpers-Huttenlocher syndrome. The mtDNA polymerase g (POLG) is essential for mtDNA replication and repair. Pol g is composed of a 140-kDa catalytic (α) subunit that contains DNA polymerase, 3–5 exonuclease, and dRP (deoxyribose phosphate) lyase activity and a 55-kDa accessory (β) subunit that functions as a progressive and DNA-binding factor. In Alpers-Huttenlocher syndrome, children are usually normal at birth with some developmental delay in infancy and often present with hypotonia and bouts of vomiting. The seizure disorder usually has an abrupt onset and although clinical signs of liver disease often appear later, biochemical evidence of liver disease is sometimes present before the onset of seizures. EEG and visual-evoked potentials are abnormal. Most patients die before the age of 3 years. Less frequently, late presentation occurs, even up to 25 years of age. Some patients also have visual disturbances. Pathologic liver findings, including fatty changes, abnormal bile duct architecture and fibrosis,
Mitochondrial Encephalomyopathies
47
are unrelated to anticonvulsant therapy. Neuropathology shows severe cortical neurodegeneration and astrocytosis. A deficiency in mitochondrial POLG activity and mtDNA depletion was first reported in a patient with Alpers-Huttenlocher syndrome in 1999 [9]. Naviaux and Nguyen [9] reported that in 2 unrelated pedigrees with Alpers-Huttenlocher syndrome, each affected child was found to harbor a homozygous mutations in exon 17 of POLG that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein. In addition, each affected child was heterozygous for the G1681A mutation in exon 7, which led to an Ala467Thr substitution in POLG, within the linker region of the protein. Vu et al. [36] first demonstrated mtDNA depletion in liver biopsies from 2 patients with NNH (Navajo neurohepatopathy), which was consistent with the hypothesis that a nuclear gene might be responsible for this autosomal-recessive disease. Navajo neurohepatopathy is an autosomal-recessive multisystem disorder prevalent in the Navajo population of the southwestern United States. Patients with NNH present with liver disease, severe sensory and motor neuropathy, corneal anesthesia and scarring, cerebral leukoencephalopathy, failure to thrive, and recurrent metabolic acidosis with intercurrent illness. A genomewide scan, performed with 400 DNA microsatellite markers, demonstrated mapping of the disease to chromosome 2p24.1. The gene was MPV17 [37], involved in mtDNA maintenance and in the regulation of OXPHOS and is localized to the inner mitochondrial membrane. The sequencing of MPV17 in 6 NNH patients from 5 families in 2006 demonstrated the same homozygous diseasecausing R50Q mutations in exon 2 in all patients, confirming a founder effect in this disease. Thus, it is now clear that NNH is indeed a form of mtDNA depletion with a unique clinical presentation in Navajos. Prospective, longitudinal multicenter studies will be needed to address the gaps in our knowledge in these rare liver diseases. The role of liver transplantation in patients with liver failure remains poorly defined because of the systemic nature of the disease that does not respond to transplantation.
Blood Hematological manifestations of mitochondrial cytopathies include aplastic, megaloblastic or sideroblastic anemia, leukopenia, neutropenia, thrombocytopenia, or pancytopenia. In single cases, either permanent or recurrent eosinophilia has been observed. Hematological abnormalities may occur together with syndromic or nonsyndromic mitochondrial cytopathies. Syndromic mitochondrial cytopathies in which hematological manifestations predominate are Pearson syndrome (pancytopenia), KSS (anemia), Barth syndrome (neutropenia), and autosomal-recessive mitochondrial myopathy, lactic acidosis and sideroblastic anemia syndrome (MLASA) [38]. The association of Pearson syndrome and a specific deletion in mtDNA was
48
Bertini · D’Amico
first reported in 1990 by Rotig’s group. It is now established that mtDNA rearrangements are present in all patients with Pearson syndrome, with large (4,000–5,000 bp) deletions predominating in three quarters of the reported cases. The most common deletion is located between nt 8488 and nt 13,460. The proteins affected by this deletion include respiratory chain enzymes (complex I is the most severely affected), 2 subunits of complex V, 1 subunit of complex IV, and 5 transfer RNA genes. Other mtDNA deletions of differing lengths are associated with clusters of the characteristic clinical manifestations. Another rare condition of mitochondrial cytopathy is X-linked sideroblastic anemia with ataxia (XLSA/A), a rare syndromic form of inherited sideroblastic anemia associated with spinocerebellar ataxia, due to mutations in the mitochondrial ATPbinding cassette transporter Abcb7 [39]. Anemia has been described in single cases with Leigh syndrome, MERRF (myoclonic epilepsy and ragged-red fiber) syndrome, or Leber’s hereditary optic neuropathy. Anemia, leukopenia, thrombocytopenia, eosinophilia, or pancytopenia can also be found frequently in nonsyndromic mitochondrial cytopathies with or without involvement of other tissues. Therapy of blood cell involvement in MID comprises application of antioxidants, vitamins, iron, bone marrow-stimulating factors, or substitution of cells.
Skin Reviewing the literature of skin disorders associated with mitochondrial encephalomyopathies, the most recurring sign is lipomas. Symmetric cervical lipomas are a presenting feature of Ekbom’s syndrome of cervical lipomas associated with myoclonic epilepsy and ragged red muscle fibers (MERRF) and mutations in mtDNA tRNA LysUUR 8344A-G [40]. Excluding lipomas, skin findings such as discoloration, hirsutism, and anhidrosis have been reported in several other patients. Pigment alterations consistent with poikiloderma, i.e. acrocyanosis and vitiligo, have been reported in some patients. Acrocyanosis has been reported together with Pearson syndrome, and the presence of episodic acrocyanosis is part of the syndromic association of ethylmalonic encephalopathy (EE), a devastating infantile metabolic disorder affecting the brain, gastrointestinal tract, and peripheral vessels. The gene responsible for EE is ETHE1 [24] and the principal signs of the syndrome are recurrent petechiae, orthostatic acrocyanosis, and chronic diarrhea. Other discolorations of the skin have been reported such as periorbital darkening, generalized hyperpigmentation associated with adrenal insufficiency, cutis marmorata and jaundice in patients with the hepatocerebral form of mitochondrial DNA depletion syndrome (MDDS) due to mutations in the nuclear-encoded mitochondrial deoxyguanosine kinase gene DGUOK [33] or in the MPV17 gene [35].
Mitochondrial Encephalomyopathies
49
Another characteristic finding of mitochondrial encephalomyopathies is hirsutism or hypertrichosis that has been reported in patients with Pearson syndrome and quite frequently in severe Leigh syndrome with encephalomayopathy, citochome-coxidase deficiency and mutations in the SURF-1 gene. In addition alopecia, alopecia with brittle hair, or trichothiodystrophy have also been reported [40].
References 1 Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988; 242:1427–1430. 2 Holt IJ, Harding AE, Morgan Hughes JA: Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717– 719. 3 Moraes CT, Shanske S, Tritschler H-J, Aprille JR, Andreetta F, Bonilla E: MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991; 48:492–501. 4 Munnich A, Rustin P, Rotig A, Chretien D, Bonnefond JP, Nuttin C, Cormier V, Vassault A, Parvy P, Bardet J, Chrapentier C, Rabier D, Saudaubray JM: Clinical aspects of mitochondrial disorders. J Inher Metab Dis 1992;15:448—455. 5 DiMauro S, Haller RG: Metabolic myopathies: substrate use defects; in Schapira AHV, Griggs RC (eds): Muscle Diseases. Boston, Butterworth-Heinernann, 1999, pp 225–249. 6 DiMauro S: Mitochondrial encephalomyopathies: back to Mendelian genetics. Ann Neurol 1999;45: 693–694. 7 Rahman S, Blok RB, Dahl HHM, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thurber DR: Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996;39:343– 351. 8 Tiranti V, Jaksch M, Hofmann S, Galimberti C, Hoertnagel K, Lulli L, Freisinger P, Bindoff L, Gerbitz KD, Comi GP, Uziel G, Zeviani M, Meitinger T: Loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome c oxidase deficiency. Ann Neurol 1999;46: 161–166. 9 Naviaux RK, Nguyen KV: POLG mutations associated with Alpers’ syndrome and mitochondrialDNA depletion. Ann Neurol 2004;55:706–712. 10 Nishino I, Spinazzola A, Hirano M: Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689–692.
50
11 Berenberg RA, Pellock JM, DiMauro S, Schotland DL, Bonilla E, Eastwood A, Hays A, Vicale CT, Behrens M, Chutorian A, Rowland LP: Lumping or splitting? ‘Ophthalmoplegia-plus’ or Kearns-Sayre syndrome? Ann Neurol 1977;1:37–54. 12 Huntsman RJ, Sinclair DB, Bhargava R, Chan A: Atypical presentations of Leigh syndrome: a case series and review. Pediatr Neurol 2005;32:334–340. 13 Horvath R, Hudson G, Ferrari G, Fütterer N, Ahola S, Lamantea E, Prokisch H, Lochmüller H, McFarland R, Ramesh V, Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, Udd B, Taylor RW, Turnbull D, Hanna M, Fialho D, Suomalainen A, Zeviani M, Chinnery PF: Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006;129:1674–1684. 14 Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, Hershkovitz E, Elpeleg O: Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann Neurol 2004;56:734–738. 15 Smeitink JA, Elpeleg O, Antonicka H, Diepstra H, Saada A, Smits P, Sasarman F, Vriend G, JacobHirsch J, Shaag A, Rechavi G, Welling B, Horst J, Rodenburg RJ, van den Heuvel B, Shoubridge EA: Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am J Hum Genet 2006;79:869–877. 16 Valente L, Tiranti V, Marsano RM, Malfatti E, Fernandez-Vizarra E, Donnini C, Mereghetti P, De Gioia L, Burlina A, Castellan C, Comi GP, Savasta S, Ferrero I, Zeviani M: Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am J Hum Genet 2007;80:44–58. 17 Scheper GC, van der Klok T, van Andel RJ, van Berkel CG, Sissler M, Smet J, Muravina TI, Serkov SV, Uziel G, Bugiani M, Schiffmann R, KrägelohMann I, Smeitink JA, Florentz C, Van Coster R, Pronk JC, van der Knaap MS: Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007; 39:534–539.
Bertini · D’Amico
18 Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, Saada A, Elpeleg O: Deleterious mutation in the mitochondrial arginyltransfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet. 2007; 81:857–862. 19 Nialdet P, Rotig A: The kidney in mitochondrial cytopathies. Kidney Int 1997;51:1000–1007. 20 Emma F, Pizzini C, Tessa A, Di Giandomenico S, Onetti-Muda A, Santorelli FM, Bertini E, Rizzoni G: ‘Bartter-like’ phenotype in Kearns-Sayre syndrome. Pediatr Nephrol 2006;21:355–360. 21 DiMauro S, Quinzii CM, Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest. 2007;117:587–589. 22 López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, Dimauro S, Hirano M: Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79:1125–1129. 23 Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F: COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007;18:2773–2780. 24 Tiranti V, Briem E, Lamantea E, Mineri R, Papaleo E, De Gioia L, Forlani F, Rinaldo P, Dickson P, AbuLibdeh B, Cindro-Heberle L, Owaidha M, Jack RM, Christensen E, Burlina A, Zeviani M: ETHE1 mutations are specific to ethylmalonic encephalopathy. J Med Genet 2006;43:340–346. 25 Hirano M, Nishino I, Nishigaki Y, Martí R: Thymidine phosphorylase gene mutations cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern Med 2006;45:1103. 26 Cormier-Daire V, Bonnefont JP, Rustin P, Maurage C, Ogier H, Schmitz J, Ricour C, Saudubray JM, Munnich A, Rötig A: Mitochondrial DNA rearrangement with onset as chronic diarrhea with villous atrophy. J Pediatr 1994;124:63–70. 27 Yaplito-Lee J, Weintraub R,. Jamsen K, Chow C W, ThorburnD R, Boneh A: Cardiac manifestations in oxidative phosphorylation disorders of childhood. J Pediatr 2007;150:407–411. 28 Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, Osame M, Tanaka H: Cardiac involvement in mitochondrial diseases: a study on 17 patients with documented mitochondrial DNA defects. Circulation 1995;91:955–961. 29 Stark R and Roden M. Mitochondrial function and endocrine diseases. Eur J Clin Invest 2007;37:236– 248.
Mitochondrial Encephalomyopathies
30 Bruno C, Minetti C, Tang Y, Magalhães PJ, Santorelli FM, Shanske S, Bado M, Cordone G, Gatti R, DiMauro S: Primary adrenal insufficiency in a child with a mitochondrial DNA deletion. J Inherit Metab Dis 1998;21:155–161. 31 Kadowaki T, Kadowaki H, Mori Y, Tobe K, Sakuta R, Suzuki Y, Tanabe Y, Sakura H, Awata T, Goto Y, Hayakawa T, Matsuoka K, Kamada RKT, Horai S, Ikuya Nonaka I, Hagura R, Akanuma Y, Yazaki Y: A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 1994;330: 962–968. 32 Lee WS, Sokol RJ: Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007;45:1555–1565. 33 Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M, Eriksson S, Cohen N: The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001;29:337–340. 34 Salviati L, Sacconi S, Mancuso M, Otaegui D, Camaño P, Marina A, Rabinowitz S, Shiffman R, Thompson K, Wilson CM, Feigenbaum A, Naini AB, Hirano M, Bonilla E, DiMauro S, Vu TH: Mitochondrial DNA depletion and dGK gene mutations. Ann Neurol 2002;52:311–317. 35 Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D’Adamo P, Calvo S, Marsano RM, Donnini C, Weiher H, Strisciuglio P, Parini R, Sarzi E, Chan A, DiMauro S, Rötig A, Gasparini P, Ferrero I, Mootha VK, Tiranti V, Zeviani M: MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006;38:570–575. 36 Vu TH, Tanji K, Holve SA, Bonilla E, Sokol RJ, Snyder RD, Fiore S, Deutsch GH, Dimauro S, De Vivo D: Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 2001;34:116– 120. 37 Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, Kurth J, Eggers E, Palenzuela L, Tanji K, Bonilla E, De Vivo DC, DiMauro S, Hirano M. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet 2006;79:544–548. 38 Fernandez-Vizarra E, Berardinelli A, Valente L, Tiranti V, Zeviani M: Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA). J Med Genet 2007;44:173– 180.
51
39 Pondarre C, Campagna DR, Antiochos B, Sikorski L, Mulhern H, Fleming MD: Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007; 109:3567–3569.
40 Bodemer C, Rötig A, Rustin P, Cormier V, Niaudet P, Saudubray JM, Rabier D, Munnich A, de Prost Y: Hair and skin disorders as signs of mitochondrial disease. Pediatrics 1999;103:428–433.
Enrico Bertini, MD Bambino Gesu’ Children’s Research Hospital Unit of Molecular Medicine for Neuromuscular and Neurodegenerative Disorders Department of Laboratory Medicine, IT–00165 Rome (Italy) Tel. +39 06 6859 2105, Fax +39 06 6859 2024, E-Mail
[email protected]
52
Bertini · D’Amico
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 53–60
Overgrowth Syndromes: A Classification Giovanni Neri ⭈ Marco Moscarda Institute of Medical Genetics, Catholic University, Rome, Italy
Abstract Overgrowth syndromes are characterized by macrosomia, congenital anomalies, mental retardation and an increased risk of tumors. In this article we will analyze what we define ‘classical’ overgrowth syndromes (Beckwith-Wiedemann, Simpson-Golabi-Behmel, Sotos, Weaver and Perlman syndromes) and will trace a brief overview of other conditions with excessive growth. Copyright © 2009 S. Karger AG, Basel
Congenital ‘overgrowth’ is defined by a neonatal weight above the 97th centile, while in childhood and adulthood overgrowth is defined by height (above the 97th centile) rather than by weight. Secondary causes of high birth weight, like maternal diabetes mellitus or obesity, should be ruled out before considering the diagnosis of constitutional infant macrosomia. Due to the frequently overlapping findings, a diagnostic strategy may be in order, as proposed by Boccuto et al. [1]. Familial history and some specific clinical characteristics may be relevant in selecting molecular tests to confirm the diagnosis. In particular, we shall describe conditions with overgrowth as the main finding of the clinical presentation, like Beckwith-Wiedemann, SimpsonGolabi-Behmel, Sotos, Weaver and Perlman syndromes. We shall also describe some other conditions that have macrosomia as an accessory finding and for which a laboratory test is available. These are the Bannayan-Riley-Ruvalcaba, the Pallister Killian, and the 22q13 deletion syndromes.
Beckwith-Wiedemann Syndrome
Beckwith-Wiedemann syndrome (BWS) (OMIM #130650) is the most common overgrowth syndrome with an estimated incidence of 1/13,700 liveborns. Major clinical findings are omphalocele, macrosomia and macroglossia that can be accompanied by other manifestations, delineating a broader phenotypic spectrum.
Table 1. Relative frequency and associated recurrence and tumor risk for molecular defects involved in BWS Defect (frequency)
Recurrence in sibs
Tumor risk
Loss of methylation of LIT1 (40–50%)
sporadic
lower
Paternal UPD (20%)
sporadic
higher
CDKN1C mutation (5%, 40% of familial BWS)
up to 50%
lower
Gain of methylation of H19 (5–10%)
sporadic
higher
Paternal duplication or maternal rearrangement of 11p15.5 (2%)
up to 50% if parent is a carrier
IC1 or IC2 deletion (1%) Unknown defect (15–25%)
Hemihyperplasia (asymmetric overgrowth of one or more regions of the body) occurs in about 25% of cases and is thought to result from somatic mosaicism. In most cases, hemihyperplasia is not manifest at birth. Adult height is generally normal, indicating a deceleration of the initial excess of growth. The face may be coarse with prominent metopic suture, large anterior fontanelle, prominent occiput, midfacial hypoplasia and infraorbital creases. Other important characteristics can be the presence of anterior ear lobe creases/posterior helical ear pits, cleft palate, visceromegaly (i.e. hepatomegaly, also detectable prenatally), renal abnormalities. Polyhydramnios and prematurity, neonatal hypoglycemia, facial nevus flammeus, capillary dysplasias, cardiac anomalies (9–34% of patients), diastasis recti, advanced bone age (especially in the first 4 years of life), monozygotic twinning are less frequent findings. There is a 20% incidence of perinatal death due to complications of prematurity, macroglossia or, rarely, cardiomyopathy. IQ is generally normal, unless there is a concomitant chromosomal imbalance extending beyond the 11p15 region, which contains the genes responsible for BWS. For a comprehensive review of diagnostic criteria, see Weksberg et al. [2]. BWS constitutes a risk factor for developing infantile malignancies (7.5–12.5%). The most common occurrences are Wilms’ tumor, hepatoblastoma, and neuroblastoma, although rhabdomyosarcoma and many other malignant and benign tumors have also been reported. Hemihyperplasia confers an increased cancer risk, even on the side not affected by overgrowth. Nephromegaly and nephrogenic rests or nephroblastomatosis are considered precursors of Wilms’ tumor. After mid-childhood (age 8), BWS patients are no longer considered to be at increased risk of malignancies. BWS is caused by altered expression of growth regulatory genes on the imprinted regions of chromosome 11p15. IGF2 (insulin-like growth factor 2) and LIT1 are expressed only in the paternal allele and promote cell growth. On the other hand, H19 and CDKN1C, which negatively regulate cell proliferation, and KvLQT1, are expressed
54
Neri · Moscarda
in the maternal allele. These genes are controlled by 2 different imprinting centers: the telomeric IC1, regulating H19 and IGF2, and the centromeric IC2, controlling LIT1 and CDKN1C. Gene dosage imbalance leading to BWS may be caused by chromosomal rearrangements, paternal uniparental disomy, loss of methylation in the maternal allele of LIT1, gain of methylation in the maternal allele of H19, mutations in CDKN1C, deletions of the IC1 or IC2. For a review about molecular mechanisms involved in BWS, see Cytrynbaum et al. [3]. Defects involving IC1 are associated with higher tumor risk, in particular Wilms tumor, while IC2 alterations are correlated with a lower cancer risk (table 1). A diagnosis of BWS in infancy should follow up with a detailed tumor surveillance protocol, including abdominal ultrasound screening every three months until age 8 years [4]. Assisted reproductive technology (ART) has been investigated as a possible risk factor for BWS. However, a molecular mechanism still has to be defined and further studies are needed [5].
Simpson-Golabi-Behmel Syndrome
Simpson-Golabi-Behmel syndrome (SGBS) (OMIM #312870) is an X-linked semidominant condition characterized by a wide phenotypic spectrum, from mildly affected female carriers to severely affected males, with a high risk of neonatal death. The main clinical findings are pre- and postnatal overgrowth, congenital hypotonia and multiple malformations, including heart defects, polydactyly, supernumerary nipples [6]. Prenatal overgrowth in affected males persists postnatally, with final height usually above the 97th centile. The face is typical, with hypertelorism, downslanting palpebral fissures, epicanthic folds, low-set, posteriorly angulated ears, macrostomia with macroglossia and dental malocclusion, midline groove of lower lip, short nose with anteverted nares, short or webbed neck. Other common findings are macrocephaly, rib and vertebral anomalies, advanced bone age, hepatosplenomegaly, neonatal hypoglycemia. Hands and feet are usually broad with polydactyly, cutaneous syndactyly, clino-/camptodactyly, and fingernail hypoplasia, especially of the 2nd finger. Multicystic dysplastic kidneys, hyperplastic islets of Langherans, cryptorchidism, diaphragmatic defects, diastasis recti, umbilical and inguinal hernias and early death are less common. SGBS has an increased risk of embryonal and childhood tumors, like Wilms’ tumor and neuroblastoma, but also hepatocellular carcinoma and testicular gonadoblastoma. The syndrome is caused by mutations in the GPC3 gene, mapped to Xq26 [7]. GPC3 is probably a negative regulator of cell proliferation and apoptosis, through modulation of cellular responses to growth factors, possibly involving the IGF-II pathway. The gene is highly expressed during fetal development, especially in those tissues that are most affected by overgrowth. The genetic test is indicated in all cases with a clinical diagnosis of SGBS, although a confirmatory results is usually seen in no more than about half of the tested cases.
Overgrowth Syndromes
55
Sotos Syndrome
Sotos syndrome (SoS) (OMIM #117550) is characterized by overgrowth of prenatal onset persisting during the first years of life, advanced bone age and characteristic facial features [8]. Birth weight averages 4,200 g in males and 4,000 g in females, while mean birth length is 55.6 cm in males and 57.3 cm in females Occipitofrontal head circumference (OFC) tends to exceed the 97th centile by the age of 1 year. However, final height is usually within normal range, due to the advanced bone age, present in 84% of SoS patients. Advanced bone age is common to many overgrowth syndromes, including Weaver, BWS and SGBS. However, SoS can be distinguished for the presence of a peculiar (disharmonic) metacarpophalangeal profile. Hand and foot length is often above the 97th centile; dental eruption can occur early; puberty can be precocious. Facial characteristics are marked frontal bossing (in 97.5% of patients), high frontal hairline (97.5%), frontoparietal balding, downslanting palpebral fissures (90%), narrow bitemporal diameter, full cheeks, high palate (70%). The face gradually lengthens with age and the jaw becomes more prominent, with a pointed chin. Congenital hypotonia and poor feeding affect the neonatal period, while in childhood there is delay in expressive language. IQ is borderline (mean of 78, ranging from 40 to 129). Autistic behavior may also be noted. Pes planus is frequent, strabismus is found in nearly 40% of patients, and seizures in 50%. MRI can show a typical pattern characterized by prominence of the trigonus (90%) and of the occipital horns (75%) and ventriculomegaly (63%). The supratentorial extracerebral fluid spaces and those of the posterior fossa are increased for age in 70% of patients. Heart defects (i.e. septal defects and patent ductus arteriosus) are observed in 8% of SoS patients, but seem to be as frequent as 35–41% in patients of Japanese ethnicity. Gastrointestinal and urogenital anomalies have also been reported. Upper respiratory tract infections, especially otitis media, are frequent and may lead to conductive hearing loss. Cohen [9] critically reviewed neoplasms reported to occur with SoS. One third of patients with neoplasia, all males, developed lympho-hematological malignancies (lymphoma or leukemia), which seem to represent the most frequent neoplasias in SoS. Many cases occurred after the age of 5 (10/22; 45%) or 10 years (4/22; 18%). Thus, it is not easy to give an overall recommendation for cancer surveillance in SoS. The NSD1 gene (nuclear-receptor- binding SET-domain-containing protein 1) was first identified as causing agent of SoS in patients with a chromosomal translocation, encompassing chromosomal band 5q35. Haploinsufficiency of NSD1 has been confirmed as the major cause of SoS [10]. A recurrent 2.2-Mb microdeletion at 5q35, including NSD1 and adjacent genes, is the primary cause of SoS in Japan, accounting for over 50% of cases. In Europe and USA intragenic mutations cause 60–80% of SoS cases, whereas microdeletions are responsible for no more than 10% of cases. Partial NSD1 deletions, encompassing one or more exons, were detected in SoS cases without NSD1 mutation or 5q35 microdeletion [11].
56
Neri · Moscarda
Weaver Syndrome
Weaver syndrome (WS) (OMIM #277590) is characterized by persistent overgrowth of prenatal onset, accelerated bone maturation, distinctive craniofacial appearance, developmental delay, a hoarse and low-pitched cry, congenital hypotonia, widened distal long bones and camptodactyly. Mean birth weight is 4,785 g in males and 3,883 g in females, length 56 and 53 cm, and OFC 36.6 and 35.2 cm, respectively. Average final height is 194.2 cm in males and 176.3 cm in females, with an average weight of 102.2 kg in males and 87.6 kg in females, OFC averages 61 cm in males and 59.5 cm in females. Skeletal growth is more accelerated than skeletal maturation, resulting in excessive height in adults. There may also be large low-set ears, a large bifrontal diameter, flat occiput, hypertelorism, long upper lip with prominent philtrum, micrognathia, postnatal persistence of fingerpads, clinodactyly of fifth finger, broad thumbs, transverse palmar crease(s), thin hyperconvex and deep-set nails, and finger camptodactyly [12]. Limited extension at elbows and knees may be secondary to reduced prenatal movements. Clubfoot may be unilateral or bilateral. Brain MRI findings include cavum septi pellucidi and dilated ventricles. Skeletal X-rays may show short fourth metatarsals, wide distal metaphyses of femora (and somewhat mottled epiphyses), and low, broad iliac wings. Loose skin and inverted nipples may result from resorption of congenital lymphedema. Hair may be sparse. Umbilical and inguinal hernias are common. Mild hypertonicity or hypotonia are common, with mild-to-moderate psychomotor delay that improves with age, so that IQ is usually normal or ‘borderline’. Young children may have breathing and swallowing difficulties. Douglas et al. [13] analyzed 7 WS patients and identified a NSD1 mutation in 3 (42%). However, these WS cases were later re-diagnosed as SoS. Therefore, the cause of WS remains unidentified.
Perlman Syndrome
Perlman syndrome (PS) (OMIM #267000) is a rare, autosomal-recessive condition characterized by nephromegaly, macrosomia, hypotonia, cryptorchidism and a typical facial appearance, with a full round face, prominent forehead, deep-set eyes with epicanthic folds, broad depressed nasal bridge, everted upper lip, micrognathia and highly arched palate [14]. The chest may be broad with pectus excavatum, the abdomen distended due to visceromegaly. Hyperplasia of the islets of Langerhans is frequent and can be related to congenital macrosomia and hypoglycaemia, leading to infant death. Sex ratio is reported as 2 M:1 F. There may be a history of polyhydramnios and fetal ascites. PS is a severe condition and most children die neonatally. In the few survivors growth pattern quickly falls within or below normal range. Wilms’ tumor is the only neoplasia whose risk is increased in PS, due to the high prevalence of nephroblastomatosis and nephrogenic rests. Autosomal-recessive inheritance has
Overgrowth Syndromes
57
been assumed since the observation of multiple affected siblings in consanguineous as well as nonconsanguineous families.
Bannayan-Riley-Ruvalcaba Syndrome
Bannayan-Riley-Ruvalcaba syndrome (BRRS) (OMIM #153480) is an autosomaldominant disorder consisting of macrocephaly, vascular malformations, lipomas (75% of patients), hamartomatous polyps of the distal ileum and colon (45% of patients), pigmented macules on the shaft of the penis and Hashimoto thyroiditis [15]. Birth weight usually exceeds 4,000 g and birth length is above the 97th centile. Postnatal growth decelerates, so older children and adults fall within the normal height range. Head circumference is at least 4.5 SD above the mean. Hypotonia, gross motor delay, mild-to-severe mental retardation and cognitive speech delay may be present in approximately 70% of patients, while seizures in about 25%. Asymmetric motor development has been reported, as well as a lipid storage myopathy involving neutral fat accumulation, predominantly in enlarged type I muscle fibers, and reduced muscle-free carnitine levels. This myopathic process affects the proximal muscles in at least 60% of BRRS patients. Pigmented macules on the penile shaft are a peculiar finding of the syndrome and may develop in late childhood. Ocular abnormalities have occasionally been reported, such as hypertelorism, downslanting palpebral fissures, strabismus, amblyopia, prominent Schwalbe lines, visible corneal nerves and pseudopapilledema. Joint hyperextensibility, pectus excavatum, scoliosis have been recorded in about 50% of patients. Facial acanthosis-like lesions and accessory nipples may also be present. BRRS is caused by mutations in the PTEN gene (phosphatase and tensin homologue deleted on chromosome 10). PTEN is considered a tumor suppressor gene with an important role in two critical pathways for proliferation and differentiation: the PI3/AKT and the mitogen-activated kinase (MAPK) pathways. PTEN haploinsufficiency was detected in the wide majority of cases of both familial and sporadic BRRS and was found to be correlated with the presence of breast tumors, breast fibroadenomas and lipomatosis [16].
22q13 Deletion Syndrome
The 22q13 deletion syndrome (OMIM #606232) is characterized by normal or accelerated growth in 95% of patients, hypotonia in 97%, absent or delayed speech, global developmental delay and minor anomalies, including dolichocephaly, abnormal ears, pointed chin, palpebral ptosis, epicanthic folds, saddle nose with bulbous tip, fleshy hands, dysplastic toenails, increased tolerance to pain, stereotypic movements (chewing) and tendency to overheating due to poor perspiration [17]. Autism and other behavioral disorders have been frequently described in these patients. Differential
58
Neri · Moscarda
diagnosis of a case with generalized hypotonia in a newborn with no recognizable cause should take into consideration either the del 22q13 syndrome or the PraderWilli syndrome. In older infants and children, overgrowth, hypotonia and developmental delay, associated with absent or severely delayed speech, autistic-like behavior, and minor craniofacial anomalies, should suggest del 22q13 as a possible diagnosis. The 22q13 deletion interval includes the SHANK3 gene, whose haploinsufficiency is responsible for at least some cases of autism. [18]. Interestingly, autism in males is often accompanied by macrocephaly.
Pallister-Killian Syndrome
Pallister-Killian syndrome (PKS) (OMIM #60183) is a rare, sporadic multiple congenital anomaly/mental retardation syndrome, caused by tissue-limited mosaicism of a supernumerary 12p isochromosome [i(12)(p10)]. Typical clinical findings are abnormal pigmentary streaks of the skin, mental retardation, congenital hypotonia, seizures and facial anomalies, such as hypertelorism, epicanthal folds, cataracts, sparse eyebrows and eyelashes, abnormal ears, macrostomia with ‘cupid-bow’ shape of upper lip and pouting lower lip, a broad high forehead, short nose with anteverted nostrils, broad nasal bridge, full cheeks, sparseness of scalp hair, short neck. Hearing deficit, congenital heart defects, accessory nipples, distal digital hypoplasia, diaphragmatic hernia, anal and genito-urinary abnormalities are also present [19]. Growth pattern is characterized by normal to increased birth length with postnatal deceleration of length, normal to increased birth weight with postnatal obesity, and normal to increased OFC at birth, with postnatal deceleration of its growth. In PKS, the average birth weight adjusted for term is about 3,600 g, with individual patients varying from the 75th to the 90th centile. PKS doesn’t seem to be associated with increased risk of neoplasia. Prenatal diagnosis of PKS can be performed by chorionic villus sampling (CVS) from the end of the first trimester of pregnancy, or by amniocentesis or fetal blood sampling. In all cases, FISH analysis is indicated to confirm the diagnosis. In PKS patients, peripheral blood lymphocytes usually show normal chromosomes; isochromosome 12p may be found in skin fibroblasts or bone marrow cells. Zollino et al. [20] reported mitotic instability of the i(12p) clones that may may create a problem with respect to prenatal cytogenetic diagnosis.
References 1
2
Boccuto L, Lapunzina P, Gurrieri F, Neri G. Diagnostic strategies in overgrowth syndromes. Ital J Pediatr 2006;32:81–100. Weksberg R, Shuman C, Smith A: BeckwithWiedemann syndrome. Am J Hum Gen 2005;137C: 12–23.
Overgrowth Syndromes
3
Cytrynbaum CS, Smith AC, Rubin T, Weksberg R: Advances in overgrowth syndromes: clinical classification to molecular delineation in Sotos syndrome and Beckwith-Wiedemann syndrome. Curr Opin Pediatr 2005;17:740–706.
59
4 Rao A, Rothman J, Nichols KE: Genetic testing and tumor surveillance for children with cancer predisposition syndromes. Curr Opin Pediatr 2008;20: 1–7. 5 Lawrence LT, Moley KH: Epigenetics and assisted reproductive technologies: human imprinting syndromes. Semin Reprod Med. 2008;26:143–152. 6 Neri G, Gurrieri F, Zanni G, Lin A: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279–283. 7 DeBaun MR, Ess J, Saunders S: Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab 2001; 72:279–286. 8 Baujat G, Cormier-Daire V: Sotos syndrome. Orphanet J Rare Dis 2007;2:36. 9 Cohen MM Jr: Mental deficiency, alterations in performance, and CNS abnormalities in overgrowth syndromes. Am J Med Genet [C] 2003;117:49–56. 10 Niikawa N: Molecular basis of Sotos syndrome. Horm Res 2004;62(suppl 3):60–65. 11 Douglas J, Tatton-Brown K, Coleman K, Guerrero S, Berg J, Cole TR, Fitzpatrick D, Gillerot Y, Hughes HE, Pilz D, Raymond FL, Temple IK, Irrthum A, Schouten JP, Rahman N: Partial NSD1 deletions cause 5% of Sotos syndrome and are readily identifiable by multiplex ligation dependent probe amplification. J Med Genet 2005;42:e5. 12 Opitz JM, Weaver DW, Reynolds JF Jr: The syndromes of Sotos and Weaver: reports and review. Am J Med Genet 1998;79:294–304. 13 Douglas J, Hanks S, Temple IK, Davies S, Murray A, Upadhyaya M, Tomkins S, Hughes HE, Cole TR, Rahman N: NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet 2003;72:132–143.
14 Henneveld HT, van Lingen RA, Hamel BC, StolteDijkstra I, van Essen AJ: Perlman syndrome: four additional cases and review. Am J Med Genet 1999; 86:439–446. 15 Nowak CB: The phakomatoses: dermatologic clues to neurologic anomalies. Semin Pediatr Neurol 2007;14:140–149. 16 Marsh DJ, Kum JB, Lunetta KL, et al: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8:1461–1472. 17 Cusmano-Ozog K, Manning MA, Hoyme HE: 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet [C] 2007;145: 393–398. 18 Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, GoubranBotros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007;39:25–27. 19 Bielanska MM, Khalifa MM, Duncan AM: PallisterKillian syndrome: a mild case diagnosed by fluorescence in situ hybridization: review of the literature and expansion of the phenotype. Am J Med Genet 1996;65:104–108. 20 Zollino M, Bajer J, Neri G: Chromosome instability limited to the aneuploid clone in the Pallister-Killian syndrome: a pitfall in prenatal diagnosis. Prenat Diagn 1999;19:184–185.
Giovanni Neri, MD Istituto di Genetica Medica, Università Cattolica Largo F. Vito, 1 IT–168 Roma (Italy) Tel. +39 06 305 4449, Fax +39 06 305 0031, E-Mail
[email protected]
60
Neri · Moscarda
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 61–66
C-Type Natriuretic Peptide and Overgrowth Renata Bocciardia Roberto Ravazzoloa,b a Laboratory of Molecular Genetics, G. Gaslini Institute, and bDepartment of Pediatrics, University of Genova and CEBR, Genova, Italy
Abstract Natriuretic peptides are a family of structurally related peptides with different distinct biological effects. C-type natriuretic peptide (CNP)-mediated signaling is important for endochondral ossification and intervenes in the control of chondrocyte maturation by regulating the balance between proliferation and terminal differentiation. CNP is encoded by the NPPC gene on human chromosome 2 for which, so far, no mutations have been described in humans. Recently, two independent articles reported the description of 3 patients with a similar clinical phenotype characterized by the presence of skeletal anomalies and overgrowth. In all 3 cases, the clinical picture was associated with the presence of a balanced translocation involving chromosome 2 and causing overexpression of the NPPC gene and an increased plasma concentration of its product, CNP. Transcriptional dysregulation of NPPC has been ascribed to the separation of the gene unit from the long-range regulatory element with a transcriptional silencing effect on its expression and CNP overproduction has been corCopyright © 2009 S. Karger AG, Basel related to the skeletal overgrowth phenotype observed.
The formation of a skeleton occurs through two different mechanisms: endochondral and membranous ossification. Endochondral ossification involves sequential steps beginning from the shaping of a cartilaginous anlage and culminating in the formation of bones. Briefly, the proliferating mesenchymal cells condense and start to differentiate into chondrocytes. Commitment to the skeletal lineage progresses through a switch in gene activation and results in the production of a cartilage matrix. As development proceeds, chondrocytes enter a process of maturation, characterized by cellular hypertrophy and the onset of type X collagen expression. Finally, chondrocytes die and, concomitant with blood invasion, cartilage is gradually replaced by bone [1]. This process is responsible for longitudinal bone growth, both during embryonic development and in postnatal life. In this latter case, it occurs at the cartilaginous growth plates located at both ends of the vertebrae and long bones. Chondrocyte maturation must be precisely controlled, with a finely tuned balance between proliferation
Nppc/ mice Increased mortality, jaw malocclusion, small rib cage causing pulmonary restriction Dwarfism due to shortening of long bones and vertebrae. Transgenic mice overexpressing Nppc Skeletal overgrowth; expansion of both proliferative and hypertrophic regions of the long bones growth plates
Targeted deletion of selected domains of NPR-B Dwarfism and female infertility Spontaneous L885R substitution in the kinase domain Dwarsfim with short limbs and tail; decreased number in chondrocytes of the proliferative and hypertrophic regions of the growth plates
NPR-B mutations in humans Homozygous mutations associated with acromesomelic dysplasia, maroteaux type; Heterozygous mutations associated with short stature
ANP
CNP
NPR-C/ mice Increased level of available CNP Skeletal overgrowth
BNP
NPR-A
NPR-B
P
P
P
P
P
P
P
P
GTP
NPR-C
GMP
Enhanced downstream signaling
Fig. 1. Schematic representation of natriuretic peptides and their receptors with a particular focus on the CNP/NPR-B signaling system. CNP binds with high affinity to the NPR-B receptor present at the cell membrane. Thanks to its guanylyl cyclases activity, the activated receptor transduces the signal into the cell through the production of the cyclic GMP second messenger. The NPR-C molecules lack a cytosolic kinase domain and work as clearance receptors. CNP and its receptor are involved in the control of endochondral ossification. The effects of targeted or spontaneous mutations affecting this pathway at different levels both in animal models and in humans, are summarized in the rectangles
and terminal differentiation [1]. This process involves both systemic hormones and local regulators cooperating to allow harmonious and coordinated bone growth throughout the body. In this context, the structural and/or functional perturbation of some of these factors can lead to dysregulation of these pathways and to skeletal malformation syndromes. Natriuretic peptides are a family of structurally related hormones/paracrine factors involved in the modulation of cell/tissue homeostasis (regulation of blood volume and blood pressure, ventricular hypertrophy, pulmonary hypertension, fat metabolism, and long bone growth) (for review, see [2]). In mammals, three members of this family are known: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) [2]. Three single membrane-spanning
62
Bocciardi · Ravazzolo
natriuretic peptide receptors (NPRs) have been identified: NPR-A/GC-A/NPR1 and NPR-B/GC-B/NPR2 receptors show guanylyl cyclases activity, whereas NPR-C/ NPR3, lacking intrinsic enzymatic activity, is involved in controlling local concentrations of natriuretic peptides through constitutive receptor-mediated internalization and degradation (for review, see [2]) (fig. 1). The CNP is encoded by the NPPC gene located on chromosome 2q37.1. CNP signaling is mediated by interaction with the NPR2 receptor. Receptor dimerization and activation upon CNP binding trigger the intracellular signaling through generation of the cyclic GMP second messenger. The intensity and duration of the signal is modulated at different levels. One of the most important silencing mechanisms is realized through the binding of CNP to NPR3 that works as clearance receptor [3] (fig. 1). CNP and its cognate receptor are well expressed in cartilage (for review, see [4]) and several data obtained from both cultured cells and animal models have confirmed the role of CNP as regulator of cartilage homeostasis, proliferation and differentiation of osteoblasts and osteoclasts, and endochondral bone growth [4–7]. Knock-out mice for CNP or NPR-B coding genes show a marked dwarfism, with a significant reduction in the thickness of both proliferative and hypertrophic zones of the cartilage growth plates [3, 8, 9]. A similar phenotype is also observed in a spontaneous mouse model harboring the substitution of a conserved residue in the kinase domain of NPRB [8, 9]. These mice are dwarfed with short limbs and tails, due to a decreased number of both proliferative and hypertrophic chondrocytes in growth plates. Conversely, transgenic mice overexpressing the NPPC gene under the control of the Col2A1 promoter are characterized by skeletal overgrowth with expansion of both proliferative and hypertrophic zones of the cartilage growth plates [10] (fig. 1). In humans, homozygous mutations of the NPR2 gene have been found in patients affected with the acromesomelic dysplasia, Maroteaux type [11], whereas heterozygous mutations in the NPR2 gene associated with short stature have been described [12] (fig.1). So far, no mutations in the NPPC gene have been found in humans. However, recently, two independent works have described a relationship between overexpression of the NPPC gene and its product and a particular phenotype characterized by skeletal overgrowth [13, 14]. Both reports moved from the molecular characterization of different chromosomal translocations involving chromosome 2, where the NPPC gene maps, and other unrelated chromosomes. The study of balanced chromosomal rearrangements is often a powerful tool to identify genes involved in human diseases. The first work carried out by our group [13] started with the clinical observation of a girl with a marfanoid habitus, arachnodactyly of the hands and feet, very long allux, scoliosis and marked overgrowth of the long bones. The patient’s karyotype showed the presence of a de novo balanced translocation between chromosomes 2 and 7, t(2;7)(q37.1;q21.3). The molecular characterization of the translocation breakpoints has allowed focussing on NPPC on chromosome 2 and the COL1A2 gene on chromosome 7. Actually, the breakpoint on chromosome 2 caused the truncation of a
CNP and Skeletal Overgrowth
63
gene, called DIS3L2, thus predicting the presence of a single functional copy of it. No functional data were available about the role of this gene. The DIS3L2 locus shows a wide and apparently nonspecific expression profile, and even though it was not possible to exclude its involvement in the genesis of the patient’s phenotype, the search for candidate genes was extended also to the adjacent genomic regions. The breakpoint was around 147 kb telomeric to the 5 end of the NPPC gene, which, given the role of the latter in the modulation of endochondral ossification, strongly attracted our attention. On the other hand, the breakpoint on chromosome 7 resulted to be located 75 kb upstream of the COL1A2 gene, which is well expressed in chondrocytes [15] and is mutated in osteogenesis imperfecta [16]. As the rearrangement was not affecting the coding sequences of these genes, we focused on a possible ‘position effect’ of the translocation influencing gene expression. The expression of COL1A2 from the translocated allele was found to be reduced without significant effect on the total collagen level. Very interestingly, the NPPC gene was overexpressed in patient’s cells compared to what observed in controls and this transcriptional upregulation correlated with a CNP plasma concentration significantly higher than in normal individuals. In the same article we described the generation of transgenic mice overexpressing NPPC in bone. These mice showed a peculiar skeletal phenotype highly reminiscent of the patient’s clinical picture. All these data allowed us to suggest that CNP overproduction was responsible for the patient’s clinical picture. Shortly after publication of our article, a second work supporting our findings was published by Moncla et al. [14]. In their article, the authors described 2 patients with a clinical phenotype very similar to that of our case and featured by postnatal overgrowth, marfanoid habitus, and arachnodactyly with abnormally long allux. Both patients were carriers of a balanced translocation involving chromosome 2 and chromosomes 8 and 13, respectively. The breakpoints on chromosome 2 were clustered around the DIS3L2 locus, as in the translocation reported in our work (fig. 2, vertical arrows). Again, a significant increased amount of NPPC transcripts was present in cells from these patients compared to control cells, supporting the hypothesis that this over-expression could be related to the observed skeletal phenotype. Also in this article, the DIS3L2 gene has not been considered a good candidate for the observed clinical phenotype because, in 1 of the 2 cases the breakpoint was outside of the coding sequence and no expression alteration was observed. On the contrary, the NPPC overexpression was common to all 3 patients [13, 14]. Concerning the molecular mechanisms leading to the enhanced NPPC expression, the hypothesis that can be drawn from these works is that the translocations separate the gene from a cis-acting long-range controlling region, with silencing activity on the NPPC transcription. Balanced chromosomal rearrangements are only rarely associated with a clinical phenotype. When it occurs, they become powerful tools in discovering potential disease genes. A chromosomal rearrangement may affect gene function in different
64
Bocciardi · Ravazzolo
A NPPC
B
C *
DIS3L2
100% 1 50% 100% 2 50% 100% 3 50% 232.543 k
232.593 k
232.643 k
232.693 k
232.743 k
232.793 k
232.843 k
232.893 k
232.943 k
Fig. 2. Comparative analysis of a 460-kb genomic region spanning the NPPC and DIS3L2 genes on chromosomes 2. The panel shows the output of the comparative genomic analysis obtained with a dedicated software available at the VISTA Genome Browser (http://genome.lbl.gov/vista/index. shtml). Conserved sequences with a percentage of identity (vertical axis) higher than 70% are represented as red peaks (noncoding sequences) and blue peaks (coding sequences) and are shown relative to their position in the human genome (horizontal axis) compared to that of the mouse (1), of the chicken (2) and of the pufferfish (3). Two significantly conserved blocks downstream the DIS3L2 gene were found (rectangle and asterisk). Vertical arrows indicate the position of the breakpoints: A and B correspond to the breakpoints found in the 2 patients described by Moncla et al. [14], and C indicates the breakpoint described in the work from our group [13].
ways, by disrupting the coding sequences thus causing a defect in gene dosage or by affecting the expression of the gene even when the latter is not located in the immediate vicinity of the breakpoint. This mechanism, also described as ‘position effect’, can be due to the separation of a gene unit from other cis-acting controlling regions that can be located even several kilobases away from the gene and that can have an important role in the modulation of its expression, with both transcriptional enhancing or silencing activity [17]. These long-range control elements can be critical for proper spatiotemporal expression of a gene or for the level of this expression and are often identifiable as highly conserved noncoding sequences through a comparative genome analysis across species [18]. However, their presence is frequently only suspected or inferred and their actual identification and localization are often due to the observation of unique cases, like the ones carrying chromosomal rearrangements that provide a good starting point for research. Regarding the attractive hypothesis that NPPC overexpression is due to separation of the gene from long-range silencing elements, this is also supported by the presence of two highly conserved noncoding sequences downstream the breakpoints of the described translocations, for which functional characterization should be performed [14] (fig. 2). In conclusion, CNP overproduction can very likely be associated with a clinical phenotype in which the predominant feature is the skeletal picture characterized by
CNP and Skeletal Overgrowth
65
overgrowth and bone anomalies. CNP could also have a causative role in patients with a similar phenotype showing no gross chromosomal abnormalities. In these cases, it would be of interest to evaluate the expression of the NPPC gene (or serum concentration of CNP) and eventually look for the presence of mutations or small rearrangements affecting the functional activity of both proximal and long range control elements.
References 1
2
3
4
5
6
7
8
9
Gilbert S: Paraxial and intermediate mesoderm; in: Developmental Biology. Osteogenesis: The Development of Bones. Sunderland, Sinauer Associates, 2003, pp 474–477. Potter LR, Abbey-Hosch S, Dickey DM: Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47–72. Matsukawa N, Grzesik WJ, Takahashi N, et al: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 1999;96: 7403–7408. Pejchalova K, Krejci P, Wilcox WR: C-natriuretic peptide: an important regulator of cartilage. Mol Genet Metab 2007;92:210–215. Yasoda A, Ogawa Y, Suda M, et al: Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 1998;273:11695–11700. Yasoda A, Komatsu Y, Nakao K, Ogawa Y: C-type natriuretic peptide(CNP)–a novel stimulator of bone growth formed through endochondral ossification. Nippon Rinsho 2004;62(suppl 2):77–81. Yasoda A, Komatsu Y, Nakao K, Ogawa Y: Growth promoting effect of natriuretic peptides on bones formed through endochondral ossification. Nippon Rinsho 2004;62(suppl 9):60–64. Chusho H, Tamura N, Ogawa Y, et al: Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001;98:4016–4021. Tsuji T, Kunieda T: A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem 2005;280:14288–14292.
10 Yasoda A, Komatsu Y, Chusho H, et al: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004;10:80–86. 11 Bartels CF, Bukulmez H, Padayatti P, et al: Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004;75:27–34. 12 Olney RC, Bukulmez H, Bartels CF, et al: Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab 2006;91:1229–32. 13 Bocciardi R, Giorda R, Buttgereit J, et al: Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat 2007;28:724–31. 14 Moncla A, Missirian C, Cacciagli P, et al: A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. Hum Mutat 2007;28: 1183–1188. 15 Karsenty G, Park RW: Regulation of type I collagen genes expression. Int Rev Immunol 1995;12:177– 185. 16 Marini JC, Forlino A, Cabral WA, et al: Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007;28:209–221. 17 Kleinjan DA, van Heyningen V: Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet 2005;76:8–32. 18 Frazer KA, Elnitski L, Church DM, Dubchak I, Hardison RC: Cross-species sequence comparisons: a review of methods and available resources. Genome Res 2003;13:1–12.
Renata Bocciardi, PhD Laboratory of Molecular Genetics G. Gaslini Institute, Largo G. Gaslini, 5 IT–16148 Genova (Italy) Tel. +39 010 563 6797, Fax +39 010 377 9797, E-Mail
[email protected]
66
Bocciardi · Ravazzolo
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 67–82
Role of Transcription Factors in Midline Central Nervous System and Pituitary Defects Daniel Kelberman ⭈ Mehul Tulsidas Dattani Developmental Endocrine Research Group, Institute of Child Health, London, UK
Abstract The anterior pituitary gland is a central regulator of growth, reproduction and homeostasis, and is the end-product of a carefully orchestrated pattern of expression of signalling molecules and transcription factors leading to the development of this complex organ secreting six hormones from five different cell types. Naturally-occurring and transgenic murine models have demonstrated a role for many of these molecules in the aetiology of combined pituitary hormone deficiency (CPHD). These include the transcription factors HESX1, PROP1, POU1F1, LHX3, LHX4, SOX2 and SOX3. The expression pattern of these transcription factors dictates the phenotype that results when the gene encoding the relevant transcription factor is mutated. The highly variable phenotype may consist of isolated hypopituitarism, or more complex disorders such as septo-optic dysplasia. Since mutations in any one transcription factor are uncommon, and since the overall incidence of mutations in known transcription factors is low in patients with CPHD, it is clear that many genes remain to be identified, and characterization of these will further elucidate the pathogenesis of these complex conditions, Copyright © 2009 S. Karger AG, Basel and also shed light on normal pituitary development
Several transcription factors involved in the embryological development of the murine pituitary appear to also be involved in human pituitary organogenesis [1–4]. Spontaneous or artificially induced mutations and gene knockouts in the mouse have led to significant insights into human pituitary disease, with the identification of human mutations in a number of genes which give rise to hypopituitary phenotypes in their respective murine orthologues. Many have been implicated in the aetiology of both murine and human hypopituitarism including Hesx1, Lhx3, Lhx4, Prophet of Pit1 (Prop1), Pou1f1 (previously called Pit-1), Sox2 and Sox3. This review will deal primarily with transcription factors implicated in the aetiology of hypopituitarism in humans as a result of the identification and characterization of mutations within these genes in patients and their respective murine orthologues.
HESX1
Given the closely linked development of the pituitary gland and forebrain during normal embryogenesis, it is not surprising that abnormalities of the two structures can be linked in human disease. One example of this is septo-optic dysplasia (SOD), often referred to as de Morsier syndrome [5], a rare, highly heterogeneous condition initially described by Reeves [6] in a 7-month-old baby with absence of the septum pellucidum and optic nerve abnormalities. The condition is defined loosely by any combination of the triad of optic nerve hypoplasia, midline neuroradiological abnormalities (such as agenesis of the corpus callosum and absence of the septum pellucidum) and pituitary hypoplasia with consequent panhypopituitarism [5–9]. Homeobox gene expressed in embryonic stem cells (Hesx1) is one of the earliest markers of the pituitary primordium, suggesting that it has a critical role in early determination and differentiation of the pituitary gland. It is also called Rpx (Rathke’s pouch homeobox) and is a member of the paired-like class of homeobox genes. The gene is first expressed during mouse embryogenesis in a small patch of cells in the anterior midline visceral endoderm as gastrulation commences. Hesx1 continues to be expressed in the developing anterior pituitary until E12, when it disappears in a spatiotemporal sequence that corresponds to progressive pituitary cell differentiation. Extinction of Hesx1 is important for activation of other downstream genes such as Prop1. Targeted disruption of Hesx1 in the mouse revealed a reduction in the prospective forebrain tissue, absence of developing optic vesicles, markedly decreased head size and severe microphthalmia reminiscent of the syndrome of SOD in humans. Other abnormalities included absence of the optic cups, the olfactory placodes and Rathke’s pouch, reduced telencephalic vesicles, hypothalamic abnormalities and aberrant morphogenesis of Rathke’s pouch. In 5% of null mutants, the phenotype was characterized by complete lack of the pituitary gland. In the majority of mutant mice, they were characterized by formation of multiple oral ectodermal invaginations and hence multiple pituitary glands. HESX1 therefore appeared to be a candidate for SOD in humans. Screening of human hypopituitary patients for mutations in HESX1 led to the identification of mutations in two siblings with SOD and subsequently other mutations have been shown to present with varying phenotypes characterized by IGHD, CPHD and SOD [10–12]. MRI revealed anterior pituitary hypoplasia, an infundibulum that is either normal or absent, and a posterior pituitary that is either eutopic or ectopic. Mutations can be dominant (n = 8) or recessive (n = 5) in humans. The former demonstrate variable penetrance. We have now screened over 800 patients with SOD and hypopituitarism, and identified mutations in less than 1% of individuals confirming the rarity of HESX1 mutations [13]. As a result of this screening we have identified a number of sequence variants, including a change of unknown functional importance in a highly conserved base in a known cis-regulatory region upstream of HESX1. Whether these variants
68
Kelberman · Dattani
contribute to the pathogenesis remains to be proven. The overall frequency of HESX1 mutations is low suggesting that mutations in other known or unknown genes contribute to this complex disorder, together with a likely contribution from environmental factors [14, 15].
SOX3
The identification of a chromosomal abnormality (46, X, inv[X][p21q27]) in a patient with mental retardation led to the identification of SOX3 as a candidate gene for X-linked mental retardation (XLMR). SOX3 lay 100kb from the Xq breakpoint, and given its expression in neuroepithelial progenitor and stem cells from an early age, was thought to be a good candidate for XLMR [16]. SOX3 (OMIM 313430) is a member of the SOX (SRY-related HMG box) family of transcription factors, which were initially identified based on homology to the conserved binding motif of the high mobility group (HMG) class, present in the mammalian sex-determining gene, SRY [17]. Approximately 20 different SOX genes have been identified in mammals and variation in homology exhibited within the HMG box between different members allows them to be grouped into different subfamilies [18]. SOX3 was among the first of the SOX genes to be cloned, and together with SOX1 and SOX2, belongs to the SOXB1 subfamily exhibiting the highest degree of similarity to SRY [17]. SOX3 is encoded by a single exon producing a transcript with a coding region of approximately 1.3 kb, mapping to chromosome Xq27. The SOX3 protein consists of a short 66 amino acid N-terminal domain of unknown function, the 79 amino acid DNA binding HMG domain and a longer C-terminal domain, containing four polyalanine stretches, shown to be involved in transcriptional activation [17, 19]. Members of the SOXB1 subfamily of genes are expressed throughout the developing central nervous system (CNS) and are some of the earliest neural markers that are believed to play a role in neuronal determination [20]. High levels of expression have also been noted in the ventral diencephalon, including the infundibulum and presumptive hypothalamus [21]. Targeted disruption of Sox3 in mice results in mutants that have a variable and complex phenotype including craniofacial abnormalities, midline CNS defects, and a reduction in size and fertility [21, 22]. Sox3 mutant mice of both sexes are born with expected frequency showing no evidence for embryonic lethality, and approximately one third of mutant mice are viable and fertile with no gross abnormalities. Heterozygous females are mosaic with respect to the mutation due to X inactivation and generally appear normal, although some display a mild craniofacial phenotype. However, approximately 43% of Sox3 null mice do not survive to weaning, and the most severely affected mice exhibit profound growth insufficiency and general weakness with craniofacial defects including overgrowth and misalignment of the front teeth and abnormality of the shape of the pinna which was completely absent in some animals [21].
Transcription Factors and Hypopituitarism
69
The mutants had a variable endocrine deficit, the extent of which was correlated with body weight. Pituitary levels of growth hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) were all lower in mutant compared to wild-type mice at 2 months of age [21]. Histological analysis of the pituitary gland at this stage revealed a hypoplasic anterior lobe with the presence of an additional abnormal cleft disrupting the boundary between the anterior and intermediate lobes. Further examination of Sox3 mutant embryos revealed that Rathke’s pouch displayed an abnormally expanded and bifurcated appearance in mutant embryos which possibly results in the additional cleft observed at later stages of development and in the adult pituitary. Sox3 is not expressed in Rathke’s pouch; however, it is expressed at high levels in the ventral diencephalon including the infundibulum which provides necessary inductive signals for the formation of the anterior pituitary [4]. In Sox3 mutants, the evagination of the infundibulum was less pronounced than observed in wild-type mice and the presumptive hypothalamus thinner and shorter [21]. This suggests that the hypopituitary phenotype observed in mutant mice arises as a secondary consequence of the absence of Sox3 in the ventral diencephalon. In humans, tandem duplications involving chromosome Xq26–27 have also been identified in several pedigrees with mental retardation and hypopituitarism [23–26]. By using array comparative genomic hybridisation, Solomon et al. [26] defined a critical duplication region of 3.9 Mb between Xq26.1 and Xq27.3 containing 18 annotated transcripts including SOX3. The phenotypes of affected males with X linked hypopituitarism involving duplications within this region are variable. All affected males manifest GH deficiency and varying degrees of developmental delay or mental retardation. Some individuals have been reported to have varying combinations of deficiencies of other hormones including ACTH, TSH or gonadotrophins, and complete panhypopituitarism has been documented in some cases. Woods et al. [27] described a pedigree with two half brothers manifesting evidence of X linked hypopituitarism, in the absence of developmental delay, and harbouring a submicroscopic duplication on chromosome Xq27.1, further refining the critical interval to approximately 690 kb. The first child manifested GHD and borderline low FT4 concentrations, with hypoplasia of the lower half of the infundibulum and an abnormal corpus callosum which contained a cyst within the splenium. The second sibling manifested a more severe phenotype of combined pituitary hormone deficiency, with complete absence of the infundibulum and hypoplastic genitalia; however his corpus callosum appeared normal. Both patients had anterior pituitary hypoplasia and an undescended posterior pituitary as revealed by MRI. The duplication identified in this family is the smallest described to date encompassing SOX3 and two additional transcripts of unknown function, neither of which is expressed in the developing infundibulum [27] suggesting that the phenotype in these patients is due to the presence of an additional copy of SOX3. Further implication of SOX3 in X linked hypopituitarism comes from the identification of patients harbouring an expansion of one of the polyalanine tracts within the
70
Kelberman · Dattani
gene [16,27]. Laumonnier et al. [16] identified an in frame duplication of 33 bp occurring between nucleotides 711 to 743 and co-segregating in affected males in a large family with X linked mental retardation and GH deficiency. This mutation encodes an additional 11 alanine residues and is predicted to cause expansion of the normal polyalanine tract from 15 to 26 residues. Additionally, a second novel expansion of seven alanine residues within the same tract has been identified in three siblings of a consanguineous pedigree presenting with profound and complete panhypopituitarism in association with anterior pituitary hypoplasia, an absent or hypoplastic infundibulum and an undescended posterior pituitary. There was no evidence of mental retardation or craniofacial dysmorphism in these individuals. In vitro analysis of the SOX3 +7 alanine expansion identified by Woods et al. [27], revealed that the expansion leads to partial loss of function possibly due to impairment of nuclear localization as the mutant protein was largely excluded from the nucleus, compared to wild-type SOX3 which is predominantly localized within the nucleus of the cell [27]. Similar findings have also been shown for the mutant SOX3 protein containing the +11 alanine expansion which forms aggregates within the cytoplasm [28]. In summary, both duplications of Xq27 encompassing SOX3 and loss-of-function polyalanine expansion mutations are essentially associated with similar phenotypes, predominantly infundibular hypoplasia, suggesting that gene dosage of SOX3 is critical for normal development of the diencephalon and infundibulum and, consequently, the anterior pituitary.
SOX2
SOX2 (OMIM 184429) is also a member of the same SOXB1 subfamily as SOX3 and SOX1 (OMIM 602148). In the mouse, initial expression of Sox2 is detected at 2.5 dpc at the morula stage, and then in the inner cell mass of the blastocyst at 3.5 dpc. Later expression of Sox2, following gastrulation, is restricted to the presumptive neuroectoderm and by 9.5 dpc it is expressed throughout the brain, CNS, sensory placodes, branchial arches, gut endoderm and the esophagus and trachea [29, 30]. Homozygous loss of Sox2 results in peri-implantation lethality, whereas Sox2 heterozygous mice appear relatively normal but show a reduction in size and male fertility [31]. Further studies that have resulted in the reduction of Sox2 expression levels below 40% compared to normal levels result in anophthalmia in the affected mutants [32]. Given the observation of growth retardation and reduced fertility, we investigated the role of Sox2 in murine pituitary development, showing that a proportion of heterozygous animals manifested a variable hypopituitary phenotype, with hypoplasia and abnormal morphology of the anterior pituitary gland with concomitant reduction in levels of GH, LH, ACTH and TSH [33]. Like its murine counterpart, the human SOX2 gene is composed of a single exon encoding a 317 amino acid protein
Transcription Factors and Hypopituitarism
71
containing an N-terminal domain of unknown function, a DNA binding HMG domain and a C-terminal transcriptional activation domain. To date, 24 de novo intragenic heterozygous mutations have been reported [30, 33–40], in addition to 8 de novo heterozygous deletions of the entire gene and 1 case of a partial deletion [30, 34, 40, 41], as well as 3 heterozygous non-synonymous sequence changes identified in individuals who inherited the variant from a clinically unaffected parent [33, 42]. The phenotypes include bilateral anophthalmia or severe microphthalmia with additional abnormalities including developmental delay, learning difficulties, oesophageal atresia and genital abnormalities [30, 34–37]. SOX2 mutations were also associated with anterior pituitary hypoplasia on MRI and hypogonadotrophic hypogonadism, which resulted in the absence of puberty in 9/10 patients studied by our group, and genital abnormalities in males [33, 43]. All affected individuals exhibited learning difficulties with other variable manifestations including hippocampal abnormalities and defects of the corpus callosum on MRI, esophageal atresia, hypothalamic hamartoma and sensorineural hearing loss [33]. The mutations were associated with significant loss of function that included loss of DNA binding, nuclear localization, and transcriptional activation, suggesting that these phenotypes arise as a result of haploinsufficency of SOX2 in development. More recently, Sato et al. [38] have reported an additional patient with a missense mutation in the HMG domain (L75Q) resulting in decreased DNA binding affinity of the mutant protein. The affected individual manifested unilateral right sided anophthalmia and isolated hypogonadotrophic hypogonadism, with a normal anterior pituitary and normal mental development, further supporting a critical role for SOX2 in the regulation of correct gonadotrophin production in addition to eye development. We have also shown that human SOX2 can inhibit β-catenin-driven reporter gene expression in vitro, whereas mutant SOX2 proteins are unable to efficiently repress this activity [43]. Given the critical role of Wnt signalling in the development of most of these tissues, our data suggest that a failure to repress the WNT-β-catenin pathway could be one of the underlying pathogenic mechanisms associated with loss-offunction mutations in SOX2. Furthermore, we have shown that SOX2 is expressed throughout the human brain including the developing hypothalamus as well as Rathke’s pouch, the developing anterior pituitary, the trachea and oesophagus, the inner ear, and the eye. SOX2 expression patterns in human embryonic development therefore support a direct involvement of the protein during development of tissues affected in individuals harbouring heterozygous SOX2 mutations [43].
LHX3/LHX4
Lhx3 is a member of the LIM family of homeobox genes which are characterized by the presence of a unique cysteine/histidine-rich zinc-binding LIM domain. The protein contains two such tandemly repeated LIM motifs between the N-terminus and
72
Kelberman · Dattani
the homeodomain, which are likely to be involved in protein-protein interactions [44, 45]. Lhx3 is one of the earliest transcription factors expressed within the developing pituitary, initially detectable with strong uniform expression in Rathke’s pouch. Expression is maintained in the pouch and is subsequently restricted to fields fated to form the anterior and intermediate lobes. By 16.5 dpc, the gene is expressed in all regions of the developing anterior and intermediate pituitary, but not the posterior gland, and continued expression is essential for the establishment of hormone producing cell types. Expression persists throughout development and is also detected in the adult pituitary suggesting a role in maintenance of one or more of the mature anterior pituitary cell types [44, 46]. In addition to the pituitary, Lhx3 is also detected transiently in regions of the developing spinal cord, prior to neural tube closure, and later within restricted regions of the hindbrain, in addition to cells in immediate proximity to the otic vesicles. Mice with a targeted homozygous disruption of Lhx3 die shortly after birth, although the cause of death is unknown, and exhibit pituitary aplasia, suggesting an essential role of Lhx3 in differentiation and proliferation of anterior pituitary cell lineages. Although Rathke’s pouch is initially formed in Lhx3 null mice, a failure of proliferation and growth results in a lack of the anterior and intermediate lobes of the pituitary with depletion of all hormone-producing cell types except corticotrophs, which differentiate and express pro-opiomelanocortin (POMC), but fail to proliferate [47, 48]. Homozygous mutations in LHX3 (OMIM 600577) have currently been identified in twelve patients from seven unrelated consanguineous families, all of which result in loss of LHX3 function [49–53]. The patients presented with an endocrine phenotype similar to that observed in individuals with PROP1 mutations with a deficit in all anterior pituitary hormones except ACTH. This was additionally associated in 9/12 patients with a short rigid cervical spine with limited head rotation and trunk movement. As with PROP1-deficient patients, pituitary morphology is variable between patients with LHX3 mutations, with two patients from one family exhibiting small anterior pituitaries with a normal posterior pituitary and midline structures on MRI. However, an additional individual from an unrelated family demonstrated a markedly enlarged anterior pituitary that was not evident in a previous MR scan performed ten years previously [49]. Additionally, Bhangoo et al. [51] recently reported a further patient with a hypointense lesion in the anterior pituitary consistent with a microadenoma. Lhx4 is closely related to Lhx3 and is expressed in specific fields of the developing brain and spinal cord. Similar to Lhx3, Lhx4 is initially expressed throughout the invaginating Rathke’s pouch, however subsequent expression is transient and restricted to the future anterior lobe, whereas Lhx3 expression is maintained throughout the whole pouch. A similar pattern of transient expression of LHX4 (OMIM 602146) in the developing pituitary and spinal cord, with continuous expression of LHX3, has also been observed in human development [52]. Null mutations of Lhx4 do not prevent pouch formation; however the pouch is defective with reduced numbers of the
Transcription Factors and Hypopituitarism
73
various anterior pituitary cell types. Lhx3–/–, Lhx4–/– double mutant mice show a more severe phenotype than either single mutant with an early arrest of pituitary development; additionally a single normal copy of either Lhx3 or Lhx4 in murine development is sufficient for formation of a definitive pouch, thereby suggesting that these two genes may act in a redundant manner during early pituitary development [54]. Mutational analysis of the first reported patient, with CPHD (GH, TSH and ACTH deficiency), revealed a heterozygous intronic mutation in LHX4 [55]. MR imaging revealed anterior pituitary hypoplasia, an undescended posterior pituitary, an absent pituitary stalk, a poorly formed sella and pointed cerebellar tonsils. The second patient presented with a similar phenotype but also had additional prolactin, LH and FSH deficiencies, Chiari malformation and respiratory distress syndrome and was found to have a heterozygous missense mutation (P366T) in exon 6, which was present in the LIM4 specific domain. [56]. More recently, Pfaeffle et al. [53] have reported three novel heterozygous mutations (A120P, L190R, R84C) in 3 unrelated families. All patients had evidence of variable hypopituitarism between and within families and a hypoplastic anterior pituitary on neuroimaging. However, an undescended posterior pituitary was not observed in patients of the first family, two of whom demonstrated pituitary cysts. Mutations in LHX4 are rare and the resultant phenotype in patients with mutations suggests that LHX4 tightly coordinates brain development and skull shape in qddition to pituitary development.
PROP1
Prop1 is a paired-like homeodomain transcription factor, expressed exclusively within the embryonic pituitary. Expression is first detected in the dorsal portion of the murine Rathke’s pouch in a region overlapping the expression domain of Hesx1. Maximal expression of Prop1 is achieved at 12 dpc in the full caudomedial area of the developing anterior pituitary followed by a marked decrease, becoming undetectable by 15.5 dpc [57]. The Ames dwarf (df) mouse harbours a naturally occurring serine to proline (S83P) substitution within the homeodomain of Prop1, resulting in a mutant protein with an 8-fold lower DNA binding affinity than wild-type Prop1 [57]. Homozygous Ames dwarf mice exhibit severe proportional dwarfism, hypothyroidism and infertility and although early pituitary development is similar to wild-type mice, the emerging anterior pituitary gland is reduced by about 50%, displaying an abnormal looping appearance [58]. The adult Ames dwarf mouse exhibits GH, TSH and prolactin deficiency resulting from a severe reduction of somatotroph, lactotroph and caudomedial thyrotroph lineages with approximately 1% of the normal complement of each cell type. Additionally, these mice have reduced gonadotrophin expression correlating with low LH and FSH plasma levels [57–59]. Following the identification of Prop1 as the gene underlying the Ames dwarf phenotype in mice, Wu et al. [60] reported the first mutations in PROP1 (OMIM 601538)
74
Kelberman · Dattani
in human patients with GH, TSH and PRL deficiency in addition to reduced gonadotrophins and a failure to enter puberty spontaneously. To date, 22 distinct mutations have been identified in more than 170 patients, suggesting that PROP1 mutations are the most common cause of CPHD reported, accounting for approximately 50% of familial cases [61, 62], although the incidence in sporadic cases is much lower [63]. All affected individuals exhibit recessive inheritance, and, with one exception, all mutations identified to date involve the DNA binding homeodomain, which is highly conserved between mouse and human sharing 91% identity at the nucleotide level [64]. The majority of these mutations are predicted to result in complete loss of function of the protein by ablating DNA binding and transcriptional activation. However, in vitro analysis has shown that some missense mutations retain partial activity [60, 65, 66]. By far the most common mutation (50–72% of all familial PROP1 mutations) [61, 62, 67], detected in multiple unrelated families from several different countries, is a 2-bp deletion among three tandem GA repeats (296-GAGAGAG-302) within exon 2 resulting in a frameshift at codon 101 and the introduction of a termination codon at position 109 (often referred to as S109X), and probably represents a mutational hot spot within the gene, rather than a single common founder mutation [62]. Recently, Reynaud et al. [68] reported the first PROP1 mutation downstream of the homeodomain involving a substitution of a tryptophan residue for a stop codon at position 194 (W194X) in the transactivation domain, with the resultant mutant protein showing only 34% activity compared with wild type PROP1. Recessive inheritance of mutations in PROP1 is typically associated with GH, TSH, PRL and gonadotrophin deficiencies, although the time of initiation and severity of pituitary hormone deficiencies is highly variable. Most patients present with early onset GH deficiency and growth retardation; however normal growth in early childhood has been reported in a patient who attained a normal final height without GH replacement therapy [69]. TSH deficiency is also highly variable and has been reported as the first presenting symptom in some cases, while others show delayed TSH deficiency which may not be present at birth [61, 70–72]. Individuals with PROP1 mutations exhibit normal ACTH/cortisol levels in early life but often demonstrate an evolving cortisol deficiency that is strongly and significantly correlated with increasing age [72–76]. However, patients as young as 6–7 years have also been described with cortisol deficiency [76, 77]. Although Prop1 is essential for the differentiation of gonadotrophs in fetal life, the spectrum of gonadotrophin deficiency is again extremely variable in patients with PROP1 mutations. Clinical variability can range from hypogonadism with complete lack of pubertal development to reports of spontaneous, albeit often delayed, onset of puberty with subsequent development of gonadotrophin deficiency requiring hormone replacement [61, 70, 71, 74]. The pituitary morphology in patients with PROP1 mutations is also highly variable; most individual reports have documented a normal pituitary stalk and posterior lobe, with a small or normal size anterior pituitary gland on MRI. However, in some
Transcription Factors and Hypopituitarism
75
cases, an enlarged anterior pituitary gland has been reported [60, 72, 78]. Longitudinal analyses of anterior pituitary size over time have revealed that a significant number of patients demonstrated pituitary enlargement in early childhood with subsequent regression and involution; thus ensuing MRI in older patients usually demonstrates anterior pituitary hypoplasia [75, 79]. The pituitary enlargement consists of a mass lesion interposed between the anterior and posterior lobes, possibly originating from the intermediate lobe [79]. Turton et al. [63] recently demonstrated that the mass can wax and wane in size prior to eventual involution. To date, the underlying mechanism for the mass remains unknown. There has been only one report of a biopsy of the ‘tumour’, and the histology was non-specific with the presence of amorphous material with no signs of apoptosis, and no recognisable cell types [80]. Consequent to the highly variable phenotype associated with PROP1 mutations, no genotypephenotype correlation has been identified; furthermore phenotypic differences have been reported in siblings with identical mutations [70]. The evolving nature of hormone insufficiencies in patients with PROP1 mutations suggests a progressive decline in the anterior pituitary axis, indicating a need for continual monitoring of patients for the development of hormone insufficiencies that may not be apparent at initial presentation.
POU1F1
POU1F1 (OMIM 173110; previously known as PIT1) is a pituitary-specific transcription factor belonging to the POU homeodomain family of transcription factors (named after the genes PIT1, OCT1 and unc-86) characterized by a highly conserved DNA binding domain consisting of a POU-specific domain and a POU homeodomain. In the mouse, Pou1f1 is expressed relatively late during pituitary development (14.5 dpc), and expression persists throughout post-natal life and adulthood, restricted to the anterior pituitary lobe [81]. Pou1f1 is essential for the development of somatotroph, lactotroph and thyrotroph cell lineages in the anterior pituitary [82], and for the subsequent expression of the GH-1 (OMIM 139250), prolactin (PRL; OMIM 176760) and TSH-β (OMIM 188540) genes between 15.5 and 17 dpc [83]. Two naturally occurring murine models have shed light on the role of Pou1f1 in normal pituitary development. In the Snell dwarf (dw) mouse, a recessive point mutation (W261C) results in the absence of somatotrophs, lactotrophs and thyrotrophs [84]. A similar phenotype results in the Jackson dwarf mouse (dwJ) that harbours a recessive null mutation due to rearrangement of Pou1f1. Pou1f1-binding sites have also been found in the GHRHR (OMIM 139191) and the Pou1f1 gene itself [82, 85], and autoregulation is required to sustain gene expression once the Pou1f1 protein has reached a critical threshold [86]. The first mutation within POUIFI was identified by Tatsumi et al. [87] in a child with GH, prolactin and profound TSH deficiency caused by homozygosity for a
76
Kelberman · Dattani
Table 1. Human mutations causing abnormal hypothalamo-pituitary development and function Gene
Phenotype
Inheritance
Combined pituitary hormone deficiency POU1F1 GH, TSH, prolactin deficiencies; usually severe; small or recessive, normal AP dominant PROP1 GH, TSH, LH, FSH, prolactin deficiencies; evolving recessive ACTH deficiency; small, normal or enlarged AP Specific syndrome HESX1 LHX3
LHX4
SOX3 SOX2
IGHD, CPHD, SOD; AP(H), EPP, absent infundibulum, ACC CPHD (GH, TSH, LH, FSH, prolactin deficiencies), short neck, limited rotation; small, normal or enlarged AP, microadenoma of pituitary, short cervical spine CPHD (GH, TSH, ACTH, LH, FSH deficiencies); small AP, normal PP or EPP, pituitary cysts, cerebellar abnormalities IGHD and mental retardation, panhypopituitarism; AP(H), infundibular hypoplasia, EPP hypogonadotrophic hypogonadism; AP(H), bilateral anophthalmia/microphthalmia, abnormal corpus callosum, learning difficulties, oesophageal atresia, sensorineural hearing loss
recessive, dominant recessive
dominant
X-linked de novo
AP(H) = Anterior pituitary (hypoplasia); EPP = ectopic posterior pituitary; ACC = agenesis of corpus callosum.
nonsense mutation within the gene. The majority of mutations identified in POU1F1 to date are recessive; however, in addition a number of heterozygous point mutations have been reported [88]. Of these, the amino acid substitution R271W appears to be a ‘hotspot’ for POU1F1 mutations [88], and has been identified in several unrelated patients of different ethnic backgrounds. When co-transfected with wild-type POU1F1, this mutant protein prevented transcriptional activation by the wild-type protein acting as a dominant negative [89], although this has been recently disputed [90]. The spectrum of hormone deficiency can vary in patients with POU1F1 mutations; GH and prolactin deficiencies generally present early in life, however TSH deficiency can be highly variable with presentation later in childhood [91, 92]. We have recently described a POU1F1 mutation in a 21-year-old with GH and prolactin deficiency who has normal thyroid function to date [93]. Magnetic resonance imaging demonstrates a small or normal anterior pituitary with a normal posterior pituitary and infundibulum, and no midline abnormalities. Since the first report, a total of 27 POU1F1 mutations have been described including 22 recessive and 5 dominant mutations in over
Transcription Factors and Hypopituitarism
77
60 patients originating from 19 different countries, all of which have been associated with a broadly similar phenotype of GH, TSH and prolactin deficiency [94].
Conclusions
Several transcription factors and signalling molecules are critical for cell differentiation and proliferation in the pituitary gland at a very early stage of gestation. The mouse has served as an excellent model for understanding the genetic basis of congenital hypopituitarism in humans, although the correlation between mouse and human disease phenotypes is variable. This candidate gene approach, based on mouse studies, had led to the identification of several human mutations that disrupt hypothalamopituitary development resulting in specific patterns of hormone dysfunction. Establishing the genotype can aid in the management of individual patients with hypopituitarism. For example, a patient with an identified PROP1 mutation exhibiting an enlarged anterior pituitary may be at risk of visual impairment due to anterior pituitary hyperplasia; however a number of reports in individuals with PROP1 mutations have shown the enlarged anterior pituitary to undergo spontaneous involution. Careful monitoring of the anterior pituitary in such cases may prevent the patient undergoing further invasive procedures. Additionally, identification of a mutation within POU1F1 predicts that cortisol and gonadotrophin secretion will remain normal in the patient. Identification of the genotype can also aid in genetic counselling and early diagnosis, particularly in autosomal dominant POU1F1 mutations. However, no genetic aetiology has been established to date in most patients with hypopituitarism. Given that a number of these patients may represent familial cases, it is clear that many genes implicated in hypopituitarism remain to be identified. Mapping and identification of the underlying causative mutations in these rare familial cases will help to identify novel genes for mutational screening in the more common sporadic forms of the condition.
References 1
2
3
78
Takuma N, Sheng HZ, FurutaY, Ward JM, Sharma K, Hogan BL, Pfaff SL, Westphal H, Kimura S, Mahon KA: Formation of Rathke’s pouch requires dual induction from the diencephalon. Development 1998;125:4835–4840. Dasen JS, Rosenfeld MG: Signaling mechanisms in pituitary morphogenesis and cell fate determination. Curr Opin Cell Biol 1999;11:669–677. Dasen JS, Rosenfeld MG: Signaling and transcriptional mechanisms in pituitary development. Annu Rev Neurosci 2001;24:327–355.
4
5
6
Rizzoti K, Lovell-Badge R: Early development of the pituitary gland: induction and shaping of Rathke’s pouch. Rev Endocr Metab Disord 2005;6:161–172. de Morsier G: Studies in cranio-encephalic dysraphia. I: Agenesis of the olfactory lobe (lateral telencephaloschisis) and of the callous and anterior commissures (median telencephaloschisis); olfactogenital dysplasia. Schweiz Arch Neurol Psychiatr 1954;74:309–361. Reeves DL: Congenital absence of the septum pellucidum. Bull Johns Hopkins Hosp 1941;69:61–71.
Kelberman · Dattani
7 Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS: Septo-optic dysplasia and pituitary dwarfism. Lancet 1970;i:893–894. 8 Arslanian SA, Rothfus WE, Foley TP Jr, Becker DJ: Hormonal, metabolic, and neuroradiologic abnormalities associated with septo-optic dysplasia. Acta Endocrinol (Copenh) 1984;107:282–288. 9 Stanhope R, Preece MA, Brook CG: Hypoplastic optic nerves and pituitary dysfunction. A spectrum of anatomical and endocrine abnormalities. Arch Dis Child 1984;59:111–114. 10 Dattani MT, Martinez-Barbera JP et al: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125–133. 11 Thomas PQ, Dattani MT, Brickman JM et al: Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septooptic dysplasia. Hum Mol Genet 2001;10:39–45. 12 Sobrier ML, Netchine I, Heinrichs C, Thibaud N, Vie-Luton MP, Van VG, Amselem S: Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Hum Mutat 2005; 25: 503. 13 McNay DE, Turton JP, Kelberman D et al: HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007;92:691–697. 14 Patel L, McNally RJ, Harrison E, Lloyd IC, Clayton PE: Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J Pediatr 2006;148:85–88. 15 Tornqvist K, Ericsson A, Kallen B: Optic nerve hypoplasia: Risk factors and epidemiology. Acta Ophthalmol Scand 2002;80:300–304. 16 Laumonnier F, Ronce N, Hamel BCJ et al: Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet 2002;71:1450–1455. 17 Stevanovic M, Lovellbadge R, Collignon J, Goodfellow PN: Sox3 is an X-linked gene-related to Sry. Hum Mol Genet 1993;2:2013–2018. 18 Pevny LH, Lovell-Badge R: Sox genes find their feet. Curr Opin Genet Dev 1997;7:338–344. 19 Kamachi Y, Uchikawa M, Collignon J, Lovell-Badge R, Kondoh H: Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction. Development 1998;125:2521–2532. 20 Pevny L, Placzek M: SOX genes and neural progenitor identity. Curr Opin Neurobiol 2005;15:7–13. 21 Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, Lovell-Badge R: SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat Genet 2004;36:247–255.
Transcription Factors and Hypopituitarism
22 Weiss J, Meeks JJ, Hurley L, Raverot G, Frassetto A, Jameson JL: Sox3 is required for gonadal function, but not sex determination, in males and females. Mol Cell Biol 2003;23:8084–8091. 23 Hamel BC, Smits AP, Otten BJ, van den HB, Ropers HH, Mariman EC: Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings. Am J Med Genet 1996;64:35–41. 24 Lagerstrom-Fermer M, Sundvall M, Johnsen E, Warne GL, Forrest SM, Zajac JD, Rickards A, Ravine D, Landegren U, Pettersson U: X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. Am J Hum Genet 1997; 60:910–916. 25 Hol FA, Schepens MT, van Beersum SE, Redolfi E, Affer M, Vezzoni P, Hamel BC, Karnes PS, Mariman EC, Zucchi I: Identification and characterization of an Xq26-q27 duplication in a family with spina bifida and panhypopituitarism suggests the involvement of two distinct genes. Genomics 2000;69: 174–181. 26 Solomon NM, Nouri S, Warne GL, LagerstromFermer M, Forrest SM, Thomas PQ: Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarism. Genomics 2002;79:553–559. 27 Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R, Wong J, Chong WK, Al Zyoud M, El Ali M et al: Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005;76:833–849. 28 Albrecht AN, Kornak U, Boddrich A, Suring K, Robinson PN, Stiege AC, Lurz R, Stricker S, Wanker EE, Mundlos S: A molecular pathogenesis for transcription factor associated poly-alanine tract expansions. Hum Mol Genet 2004;13:2351–2359. 29 Wood HB, Episkopou V: Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pregastrulation to early somite stages. Mech Dev 1999; 86:197–201. 30 Williamson KA, Hever AM, et al: Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006;15:1413–1422. 31 Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R: Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003;17:126–140. 32 Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH: SOX2 is a dosedependent regulator of retinal neural progenitor competence. Genes Dev 2006;20:1187–1202. 33 Kelberman D, Rizzoti K, Avilion A et al: Mutations withinSox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 2006;116:2442–2455.
79
34 Fantes J, Ragge NK, Lynch SA, et al: Mutations in SOX2 cause anophthalmia. Nat Genet 2003;33:461– 463. 35 Ragge NK, Lorenz B, Schneider A, et al: SOX2 anophthalmia syndrome. Am J Med Genet 2005; 135A:1–7. 36 Hagstrom SA, Pauer GJT, Reid J, Simpson E, Crowe S, Maumenee IH, Traboulsi EI: SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies. Am J Med Genet 2005;138A:95–98. 37 Zenteno JC, Gascon-Guzman G, Tovilla-Canales JL: Bilateral anophthalmia and brain malformations caused by a 20-bp deletion in the SOX2 gene. Clin Genet 2005;68:564–566. 38 Sato N, Kamachi Y, Kondoh H, Shima Y, Morohashi K, Horikawa R, Ogata T: Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol 2007;156:167–171. 39 Chassaing N, Gilbert-Dussardier B, Nicot F, Fermeaux V, Encha-Razavi F, Fiorenza M, Toutain A, Calvas P: Germinal mosaicism and familial recurrence of a SOX2 mutation with highly variable phenotypic expression extending from AEG syndrome to absence of ocular involvement. Am J Med Genet [A] 2007;143:289–291. 40 Bakrania P, Robinson DO, Bunyan DJ et al: SOX2 anophthalmia syndrome: twelve new cases demonstrating broader phenotype and high frequency of large gene deletions. Br J Ophthalmol 2007;91,1471– 1476 41 Guichet A, Triau S, Lepinard C, Esculapavit C, Biquard F, Descamps P, Encha-Razavi F, Bonneau D: Prenatal diagnosis of primary anophthalmia with a 3q27 interstitial deletion involving SOX2. Prenat Diagn 2004;24:828–832. 42 Faivre L, Williamson KA, Faber V et al: Recurrence of SOX2 anophthalmia syndrome with gonosomal mosaicism in a phenotypically normal mother. Am J Med Genet [A] 2006;140:636–639. 43 Kelberman D, de Castro SC, Huang S et al: SOX2 plays a critical role in the pituitary, forebrain and eye during human embryonic development. J Clin Endocrinol Metab 2008;in press. 44 Bach I, Rhodes SJ, Pearse RV, Heinzel T, Gloss B, Scully KM, Sawchenko PE, Rosenfeld MG: P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. Proc Natl Acad Sci USA 1995;92:2720– 2724. 45 Schmitt S, Biason-Lauber A, Betts D, Schoenle EJ: Genomic structure, chromosomal localization, and expression pattern of the human LIM-Homeobox3 (LHX 3) gene. Biochem Biophys Res Commun 2000;274:49–56.
80
46 Zhadanov AB, Bertuzzi S, Taira M, Dawid IB, Westphal H: Expression pattern of the murine lim class homeobox gene Lhx3 in subsets of neural and neuroendocrine tissues. Dev Dynam 1995;202:354– 364. 47 Sheng HZ, Zhadanov AB, Mosinger B, Fujii T, Bertuzzi S, Grinberg A, Lee EJ, Huang SP, Mahon KA, Westphal H: Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 1996;272:1004–1007. 48 Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA, Westphal H: Pituitary organogenesis controlled by LIM-homeobox genes. Dev Biol 1997; 186, B132. 49 Netchine I, Sobrier ML, Krude H, et al: Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000;25:182–186. 50 Sloop KW, Parker GE, Hanna KR, Wright HA, Rhodes SJ: LHX3 transcription factor mutations associated with combined pituitary hormone deficiency impair the activation of pituitary target genes. Gene 2001;265:61–69. 51 Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, Ten S, Rhodes SJ: A novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab 2006; 91:747–753. 52 Sobrier ML, Attie-Bitach T, Netchine I, EnchaRazavi F, Vekemans M, Amselem S: Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development. Gene Expression Patterns 2004;5:279–284. 53 Pfaeffle RW, Savage JJ, Hunter CS et al: Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab 2007; 92:1909–1919. 54 Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA, Westphal H: Multistep control of pituitary organogenesis. Science 1997;278:1809– 1812. 55 Machinis K, Pantel J, Netchine I et al: Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69:961–968. 56 Tajima T, Hattori T, Nakajima T, Okuhara K, Tsubaki J, Fujieda K: A novel missense mutation (P366T) of the LHX4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocr J 2007;54:637–641.
Kelberman · Dattani
57 Sornson MW, Wu W, Dasen JS et al: Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996;384:327–333. 58 Gage PJ, Roller ML, Saunders TL, Scarlett LM, Camper SA: Anterior pituitary cells defective in the cell-autonomous factor, df, undergo cell lineage specification but not expansion. Development 1996; 122:151–160. 59 Tang K, Bartke A, Gardiner CS, Wagner TE, Yun JS: Gonadotropin secretion, synthesis, and gene expression in human growth hormone transgenic mice and in Ames dwarf mice. Endocrinology 1993;132: 2518–2524. 60 Wu W, Cogan JD, Pfaffle RW et al: Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998;18:147–149. 61 Deladoey J, Fluck C, Buyukgebiz A, Kuhlmann BV, Eble A, Hindmarsh PC, Wu W, Mullis PE: ‘Hot spot’ in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1999;84:1645–1650. 62 Cogan JD, Wu W, Phillips JA III, Arnhold IJ, Agapito A, Fofanova OV, Osorio MG, Bircan I, Moreno A, Mendonca BB: The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998;83:3346– 3349. 63 Turton JPG, Mehta A, Raza J et al: Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). Clin Endocrinol 2005;63: 10–18. 64 Duquesnoy P, Roy A, Dastot F, et al: Human Prop1:cloning, mapping, genomic structure: mutations in familial combined pituitary hormone deficiency. FEBS Lett 1998;437:216–220. 65 Reynaud R, Chadli-Chaieb M, Vallette-Kasic S, Barlier A, Sarles J, Pellegrini-Bouiller I, Enjalbert A, Chaieb L, Brue T: A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies. J Clin Endocrinol Metab 2004;89:5779–5786. 66 Osorio MG, Kopp P, Marui S, Latronico AC, Mendonca BB, Arnhold IJ: Combined pituitary hormone deficiency caused by a novel mutation of a highly conserved residue (F88S) in the homeodomain of PROP-1. J Clin Endocrinol Metab 2000;85: 2779–2785. 67 Lebl J, Vosahlo J, Pfaeffle RW et al: Auxological and endocrine phenotype in a population-based cohort of patients with PROP1 gene defects. Eur J Endocrinol 2005;153:389–396.
Transcription Factors and Hypopituitarism
68 Reynaud R, Barlier A, Vallette-Kasic S, Saveanu A, Guillet MP, Simonin G, Enjalbert A, Valensi P, Brue T: An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. J Clin Endocrinol Metab 2005;90:4880–4887. 69 Arroyo A, Pernasetti F, Vasilyev VV, Amato P, Yen SS, Mellon PL: A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty. Clin Endocrinol (Oxf) 2002;57:283– 291. 70 Fluck C, Deladoey J, Rutishauser K, Eble A, Marti U, Wu W, Mullis PE: Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg–>Cys at codon 120 (R120C). J Clin Endocrinol Metab 1998;83:3727–3734. 71 Vallette-Kasic S, Barlier A, Teinturier C et al: PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab 2001;86: 4529– 4535. 72 Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS, Arnhold IJ: Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab 1999;84:942–945. 73 Asteria C, Oliveira JH, Abucham J, Beck-Peccoz P: Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 gene. Eur J Endocrinol 2000;143:347–352. 74 Pernasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, Lourenco DM, Mellon PL: Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301–302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000;85:390–397. 75 Riepe FG, Partsch CJ, Blankenstein O, Monig H, Pfaffle RW, Sippell WG: Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J Clin Endocrinol Metab 2001;86:4353–4357. 76 Bottner A, Keller E, Kratzsch J, Stobbe H, Weigel JF, Keller A, Hirsch W, Kiess W, Blum WF, Pfaffle RW: PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab 2004;89:5256–5265.
81
77 Agarwal G, Bhatia V, Cook S, Thomas PQ: Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. J Clin Endocrinol Metab 2000;85:4556–4561. 78 Fofanova O, Takamura N, Kinoshita E, Vorontsov A, Vladimirova V, Dedov I, Peterkova V, Yamashita S: MR imaging of the pituitary gland in children and young adults with congenital combined pituitary hormone deficiency associated with PROP1 mutations. AJR Am J Roentgenol 2000;174:555– 559. 79 Voutetakis A, Argyropoulou M, Sertedaki A, Livadas S, Xekouki P, Maniati-Christidi M, Bossis I, Thalassinos N, Patronas N, Dacou-Voutetakis C: Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. J Clin Endocrinol Metab 2004;89:2200–2206. 80 Parks JS, Brown MR, Baumbach L, et al: Natural history and molecular mechanisms of hypopituitarism with large sella turcica. Am Endocrine Soc Meet, New Orleans, 1998, abstr P3–409, p 470. 81 Bodner M, Castrillo JL, Theill LE, Deerinck T, Ellisman M, Karin M: The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 1988;55:505–518. 82 Andersen B, Rosenfeld MG: POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 2001;22:2–35. 83 Rhodes SJ, DiMattia GE, Rosenfeld MG: Transcriptional mechanisms in anterior pituitary cell differentiation. Curr Opin Genet Dev 1994;4:709–717. 84 Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG: Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990; 347:528–533. 85 Andersen B, Rosenfeld MG: Pit-1 determines cell types during development of the anterior pituitary gland: a model for transcriptional regulation of cell phenotypes in mammalian organogenesis. J Biol Chem 1994;269:29335–29338.
86 Rhodes SJ, Chen R, DiMattia GE, Scully KM, Kalla KA, Lin SC, Yu VC, Rosenfeld MG: A tissue-specific enhancer confers Pit-1-dependent morphogen inducibility and autoregulation on the pit-1 gene. Genes Dev 1993;7:913–932. 87 Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, Kohno H: Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nat Genet 1992;1:56–58. 88 Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD, Radovick S: A ‘hot spot’ in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. J Clin Endocrinol Metab 1995;80:679– 684. 89 Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE: A mutation in the POUhomeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992;257: 1115–1118. 90 Kishimoto M, Okimura Y, Fumoto M, Iguchi G, Iida K, Kaji H, Chihara K: The R271W mutant form of Pit-1 does not act as a dominant inhibitor of Pit-1 action to activate the promoters of GH and prolactin genes. Eur J Endocrinol 2003;148:619–625. 91 Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van-der-Nat H, Van-den-Brande JL, Rosenfeld MG, Ingraham HA: Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992;257:1118– 1121. 92 Pfaffle RW, Martinez R, Kim C, Frisch H, Lebl J, Otten B, Heimann,G: GH and TSH deficiency. Exp Clin Endocrinol Diabetes 1997;105(suppl 4):1–5. 93 Turton JPG, Reynaud R, Mehta A et al: Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab 2005;90:4762–4770. 94 Cohen LE, Radovick S: Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002; 23:431–442.
Mehul Tulsidas Dattani, MD Developmental Endocrine Research Group Institute of Child Health, 30 Guilford Street London WC1N 1EH (UK) Tel. +44 0207 905 2657, Fax +44 0207 404 6191, E-Mail
[email protected]
82
Kelberman · Dattani
Cappa M, Maghnie M, Loche S, Bottazzo GF (eds): Endocrine Involvement in Developmental Syndromes. Endocr Dev. Basel, Karger, 2009, vol 14, pp 83–94
Developmental Abnormalities of the Posterior Pituitary Gland Natascia di Iorgi ⭈ Andrea Secco ⭈ Flavia Napoli ⭈ Erika Calandra ⭈ Andrea Rossi ⭈ Mohamad Maghnie Departments of Pediatrics and Neuroradiology (A.R.), IRCCS G, Gaslini Institute, University of Genova, Genova, Italy
Abstract While the molecular mechanisms of anterior pituitary development are now better understood than in the past, both in animals and in humans, little is known about the mechanisms regulating posterior pituitary development. The posterior pituitary gland is formed by the evagination of neural tissue from the floor of the third ventricle. It consists of the distal axons of the hypothalamic magnocellular neurones that shape the neurohypophysis. After its downward migration, it is encapsulated together with the ascending ectodermal cells of Rathke’s pouch which form the anterior pituitary. By the end of the first trimester, this development is completed and vasopressin and oxytocin can be detected in neurohypophyseal tissue. Abnormal posterior pituitary migration such as the ectopic posterior pituitary lobe appearing at the level of median eminence or along the pituitary stalk have been reported in idiopathic GH deficiency or in subjects with HESX1, LHX4 and SOX3 gene mutations. Another intriguing feature of abnormal posterior pituitary development involves genetic forms of posterior pituitary neurodegeneration that have been reported in autosomal-dominant central diabetes insipidus and Wolfram disease. Defining the phenotype of the posterior pituitary gland can have significant clinical implications for management and counseling, as well as providing considerable insight into normal and abnormal mechanisms of posterior pituitary development in Copyright © 2009 S. Karger AG, Basel humans.
The molecular mechanisms and roles of transcription factors in anterior pituitary development are now much better understood than in the past, both in animals and in humans, but little is known about the mechanisms that regulate posterior pituitary development. The anterior, intermediate and posterior lobes of the pituitary gland develop from separate embryonic cell lineages: the oral ectoderm and neural ectoderm, respectively. Pituitary organogenesis begins when an area of oral ectoderm at the roof of the presumptive oral cavity invaginates upwards to form the Rathke’s pouch, which
Timeline Prenatal time scale (months)
Lateral ventricles
SIM1 ARNT2
OTP
Blastocyst
Ventricular layer
BRN2 1 SS
PVN
Embryo
Third Movement path ventricle of cellular migration
TRH
CRH
AVP
OT
Differentiation of neurones involves cascades of transcription factors which progressively define their phenotype
2
PVN
Lateral ventricles
SON Caudate nuclei Thalamus
3 Fetus
4
SON Third Hypothalamus ventricle Indicates direction of migration of cells from the ventricular layer, through the PVN to their resting place in the SON
9 Birth
Optic chiasm
Anterior pituitary
Mamillary body Posterior pituitary
Completion of the formation of the posterior pituitary involves the development of axonal projections from the PVN and SON through the neural stalk, terminating in the posterior pituitary lobe
Fig. 1. Timeline of the development of the posterior pituitary neurone. SIM1, ARNT2, OTP and BRN2 are genes involved in the cascade of transcription factors. PVN = Paraventricular nuclei; SON = supraoptic nuclei: SS = synthesizing somatostatin; TRH = thyrotropin-releasing hormone; CRH = corticotrophin-releasing hormone; AVP = arginine vasopressin; OT = oxytocin. With permission.
eventually becomes the anterior and intermediate lobes of the gland. The posterior pituitary evolves from an infundibulum that develops by downward evagination of the dorsal presumptive diencephalon soon after Rathke’s pouch begins to extend upward. The two structures maintain close contact while cells migrate from the mesoderm and neural crest into the space between the presumptive brain and oral cavities. The ventral wall of Rathke’s pouch becomes the anterior lobe whereas the posterior wall of the pouch develops into the pars intermedia [1]. The following sections of this article will focus on the most important aspects of diseases involving abnormal posterior pituitary gland development.
Abnormal Development of the Posterior Pituitary Lobe
The hypothalamo-neurohypophysis consists of magnocellular neurons that produce the peptide hormones vasopressin and oxytocin. The cell bodies are located in the
84
di Iorgi · Secco · Napoli · Calandra · Rossi · Maghnie
paraventricular nucleus (PVN) and supraoptic nucleus (SON) in the hypothalamus, and axons project to the neurohypophysis where the hormones are secreted into the bloodstream. During embryogenesis, neuroepithelial cells from the lining of the third ventricle migrate to the walls of the third ventricle where they mature into PVN. Some cells continue to migrate laterally towards and above the optic chiasm to form the SON. Their unmyelinated axons traverse the basal hypothalamus, form the neural stalk and terminate at the floor of the third ventricle and in the median eminence. The early differentiation of these cell lineages has recently been made clearer through an understanding of the role of transcription factors in hypothalamic development [2]. The SIm1, ARNt2, OTP, and BRN2 genes appear to be involved in the cascade of transcription factors implicated in the development of the neuroendocrine hypothalamus leading to the completion of posterior pituitary development by the end of the first trimester (fig. 1), when vasopressin and oxytocin can be detected in neurohypophyseal tissue [3]. Null mutation of UNcx4.1 showed a phenotype consisting of an ectopic localization that extends vasopressinergic axons from PVN and SON; these axons do not halt at the proper position in the neurohypophysis, but instead grow into the anterior pituitary lobe [4]. In humans, a similar picture has been reported in association with cerebral malformations [5]. In a recent study, a Hes1-null pituitary gland was revealed to be reduced in size but was otherwise morphologically normal compared with the control. Indeed, in Hes1-Hes5 double-mutant mice, the evagination of the infundibulum was affected and the neurohypophysis was lost compared to both the wild-type and Hes1-null mice, suggesting that both Hes genes are essential for the formation of the neurohypophysis [6]. In the nervous system, both Hes1 and Hes5 are essential for the regulation of neural stem cells, while in the endocrine system, Hes1 controls pancreatic cell differentiation: indeed, an analysis of mice deficient for Prop1 has indirectly implicated involvement of the Notch pathway in pituitary development [7].
Relationship between Posterior Pituitary Development and Pituitary Diseases
Abnormal posterior pituitary development can be subdivided into two main categories (fig. 3). The first is associated with a migration defect and the second with neurodegeneration of the hypothalamic PVN and SON nuclei. Developmental abnormality of the posterior pituitary will lead to an ectopic posterior pituitary (EPP) at the median eminence or along the pituitary stalk with partial or complete pituitary stalk agenesis with or without additional central nervous system malformations where the genetic and the idiopathic forms are closely linked and might have a common origin [8]. On the other hand, the neurodegeneration of the hypothalamic nuclei will lead to posterior pituitary dysfunction and central diabetes
Posterior Pituitary Development
85
Posterior pituitary pathologies
Developmental abnormality–migration ectopic posterior pituitary
Neurodegenerative neurones
Wolfram syndrome Autosomal-dominant FNDI
Partial or complete agenesis pituitary stalk CNS malformations
Partial or complete agenesis pituitary stalk
Astrocytoma Choristoma (granular cell tumor)
Genetic syndromes idiopathic
Neurohypophyseal germinoma
Posterior pituitary function
Fig. 2. Tree diagram showing the two main categories of developmental anomalies of the posterior pituitary gland.
insipidus. Whether posterior pituitary function is affected in patients with developmental abnormalities of the posterior pituitary remains uncertain.
Abnormal Posterior Pituitary Development and Phenotype Craniofacial dysmorphisms and eye abnormalities are often manifestations of major developmental syndromes and can give useful clues about possible defects of the brain and/or hypothalamus and pituitary gland [9–10]. Some facial malformation syndromes including septo-optic dysplasia (SOD) and Pallister-Hall are easy to recognize by visual and/or physical examination. Indeed, the diagnosis of hypopituitarism in childhood can sometimes be straightforward when short stature and persistent growth failure are associated with frontal bossing, mid-facial hypoplasia and truncal adiposity; however, this presentation tends to be the exception rather than the rule and thus the clinical phenotype may not be particularly impressive. Recent study shows, however, that patients with an EPP at magnetic resonance imaging (MRI) had significantly higher canthal index CI values (the relative distance between the eyes; hypertelorism is generally defined as CI >42, and hypotelorism as CI <38) compared
86
di Iorgi · Secco · Napoli · Calandra · Rossi · Maghnie
a
b
d
e
c
f
Fig. 3. a Normal pituitary gland appearance on sagittal T1-weighted images. The posterior pituitary hyperintensity (PP, arrowhead), anterior pituitary lobe (AP, thick arrow), pituitary stalk (PS, thin arrow) and median eminence (ME) are clearly visible. b Case with MPHD, small pituitary sella, anterior pituitary hypoplasia (thick arrow), absent pituitary stalk and ectopic posterior lobe at the of the median eminence (arrowhead). c Case with MPHD, small pituitary sella, anterior pituitary hypoplasia (thick arrow), and ectopic posterior lobe at the distal end (arrowhead) of the hypoplastic pituitary stalk (thin arrow). d Case with isolated GHD, small pituitary sella, anterior pituitary hypoplasia and ectopic posterior lobe within the middle third (arrowhead) of pituitary stalk. e Case with isolated GHD, small pituitary sella, anterior pituitary hypoplasia and ectopic posterior lobe at the distal end (arrowhead) of pituitary stalk. f Case 7 with evolving pituitary hormone deficiency, small pituitary sella, anterior pituitary hypoplasia and ectopic posterior lobe extended (arrowhead) within the pituitary stalk.
to patients who had in situ posterior pituitary [11]. Ectopic posterior pituitary has occasionally been reported in several other syndromes as well [12–17] (table 1).
Genes and Ectopic Posterior Pituitary Ectopic posterior pituitary gland associated with anterior pituitary dysfunction has been reported in a variety of naturally occurring mutations of transcription factors involved in pituitary development. In particular, human mutations of HESX1, LHX4 and SOX3 can give rise to abnormal anterior pituitary organogenesis and posterior pituitary migration with or without additional central nervous system and/or extrapituitary abnormalities (table 2).
Posterior Pituitary Development
87
Table 1. Syndromes associated with developmental abnormalities of the posterior pituitary gland Septo-optic-dysplasia [1] Dubowitz syndrome [15] Poland’s syndrome [12] Worster-Drought syndrome [16] Arthrogryposis multiplex congenital [13] Situs inversus totalis [17] Fanconi’s anemia [14]
Table 2. Gene mutations associated with abnormal development of the posterior pituitary Gene inheritance
Hormone deficiencies
HESX1 AR/AD/v.p.
GH
LHX4 AD
GH
SOX3 X-linked R
GH
± PRL
PRL
Pituitary phenotypes
Associated abnormalities
±TSH
± LH/ FSH
± ACTH normal/aplasia/ SOD AP hypoplasia SOD variants EPP/AP hypoplasia
TSH
LH/FSH ACTH (?)
pituitary cysts/ AP hypoplasia/ EPP*
Arnold-Chiari I
TSH
LH/FSH ACTH
AP hypoplasia/ EPP
mental retardation (variable)
AR = Autosomal recessive; AD =autosomal dominant; v.p. = variable penetrance; AP = anterior pituitary; EPP =ectopic posterior pituitary; SOD =septo-optic dysplasia; ONH= optic nerve hypoplasia; CNS = central nervous system. *Posterior pituitary in situ has been recently reported.
HESX1 Various pituitary phenotypes have been reported in association with a HESX1 mutation and, interestingly, HESX1 was the first gene mutation described with EPP (a common finding in idiopathic GHD). However, the majority of a cohort of more than 500 patients with a variety of pituitary gland disorders (of whom approximately 200 were candidates for SOD variants) showed no mutation when screened [1, 18]. The pituitary phenotype in HESX1 mutations has been reported to be associated with agenesis of the corpus callosum, hypoplasia of the optic nerves, pituitary hypoplasia and EPP. In other cases, MRI examination has evidenced unilateral hypoplasia of the optic nerve associated with a normal or hypoplastic pituitary gland in patients with isolated GH deficiency or with panhypopituitarism. Aplasia of the anterior pituitary and optic nerve coloboma, as well as anterior pituitary aplasia in the absence of optic nerve abnormalities, have also been reported recently [8, 18].
88
di Iorgi · Secco · Napoli · Calandra · Rossi · Maghnie
LHX4 Three reports have described patients with LHX4 gene mutations. In the first, analysis of a consanguineous family with members exhibiting multiple pituitary hormone deficiency (MPHD), short stature, small sella turcica, hypoplastic anterior pituitary, and cerebellar defects revealed a heterozygous mutation in an intron of LHX4 [19]. These patients presented with deficiencies in GH, TSH, and ACTH (LH and FSH were not investigated). A second heterozygous mutation (P366T) affecting a residue in the carboxyl terminus of LHX4 was associated with deficiencies of GH, prolactin, TSH, LH, FSH, ACTH, a hypoplastic anterior lobe, an ectopic posterior pituitary, a poorly developed sella turcica, Arnold-Chiari malformation, and respiratory distress syndrome [20]. In a recent study of 5 patients, three types of heterozygous missense mutations in LHX4 were identified. The patients have GH deficiency and some also display reductions in TSH, LH, FSH, or ACTH. Three patients displayed in situ posterior pituitary and two had ectopic posterior pituitary while the anterior pituitary was hypoplastic in 3 and normal in one; pituitary cysts were found in 2 patients [21]. SOX3 Recent studies implicate SOX3, a single exon gene closely related to SRY, in the etiology of X-linked hypopituitarism in both humans and in mice. The phenotype of Sox3 mutant mice is variable and complex, with abnormalities throughout the hypothalamic-pituitary-gonadal axis. Indeed, in humans, mutations of SOX3 and duplications at Xq26–27 are implicated in a syndrome of X-linked hypopituitarism and mental retardation. Both Sox3 overdosage and underdosage cause clinical and endocrine hypopituitarism-related conditions associated with EPP, and abnormality of the infundibulum which suggests that gene dosage of SOX3 is critical for normal development of the diencephalon and infundibulum, and consequently of the anterior pituitary [1].
Idiopathic Forms of Ectopic Posterior Pituitary Patients with idiopathic GH deficiency can present with a variety of pituitary MRI features including: normal pituitary gland size, anterior pituitary hypoplasia or empty sella (these 3 conditions present with normal location of the posterior pituitary gland and normal pituitary stalk connecting the hypothalamus to the pituitary gland); and/ or moderate (pituitary height of 2–3 mm) to severe (pituitary height <2 mm) pituitary hypoplasia and sella turcica associated with EPP at the level of the median eminence or along the stalk projection up to its distal extremity with partial or complete pituitary stalk agenesis. In particular, the classic triad of EPP, pituitary stalk agenesis and anterior pituitary stalk is the most common variant of MRI abnormality in patients with GH deficiency [22]. These features have been reported with or without additional malformations of the central nervous system [23], including malformations
Posterior Pituitary Development
89
a b • • • • • •
Arnold-Chiari type I Tentorial anomaly Septum pellucidum agenesis Septo-optic dysplasia Cortical dysplasia Absence of internal carotid artery
• Arnold-Chiari type II • Vermis dysplasia • Periventricular heterotopia • Corpus callosum dysgenesis • Basilar impression • Arachnoid cyst • Syringomyelia
c
Fig. 4. Small arrows showing ectopic posterior pituitary (EPP) in figures (a) and (b). Long arrow shows Arnold-Chiari I malformation in figure b. Arrows indicate syringomyelia in figure c.
like Arnold-Chiari I, Arnold-Chiari II, agenesis of the septum pellucidum, SOD/SOD variants, vermis dysplasia, syringomyelia, absence of internal carotid artery, dysgenesis of the corpus callosum, arachnoid cysts, and tentorium anomalies with basilar impression (fig. 4). The pathogenetic mechanisms involved in the development of EPP in idiopathic GH deficiency are not yet completely understood. However, a high percentage of birth trauma or breech delivery has been reported in patients with GH deficiency and ectopic posterior pituitary. It is now generally agreed that breech presentation and premature delivery are probably the result, rather than the cause of most congenital hypothalamic-pituitary defects. Two thi